![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
Kol CV for Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Påvirke statistikk
Concept | World rank |
---|---|
sensitive adhd | #1 |
relatives pediatric probands | #1 |
proband child | #1 |
tomoxetine adult adhd | #1 |
overlapping symptoms | #1 |
pdd subjects mania | #1 |
sbrv | #1 |
adhd prs rtv | #1 |
siblings adhd | #1 |
stimulant nonmedical | #1 |
adhd concurrent sud | #1 |
falconer3 | #1 |
adhd conduct disorder | #1 |
1236a | #1 |
rs11568324 | #1 |
volume alterations | #1 |
risk factor psud | #1 |
inattentive symptoms adults | #1 |
severe emotional dysregulation | #1 |
relatives diagnoses | #1 |
taf9bp2 | #1 |
notch4 polymorphisms schizophrenia | #1 |
dat1 vntr | #1 |
oih pain tolerance | #1 |
familial vulnerability schizophrenia | #1 |
adhd candidate | #1 |
genes association studies | #1 |
48basepairrepeat | #1 |
ermph clinical response | #1 |
adhd depressed children | #1 |
behaviors substances | #1 |
ldx expected height | #1 |
17year | #1 |
“forgetfulness | #1 |
15q13 deletions | #1 |
oih fm | #1 |
palauans maps loci | #1 |
adhde | #1 |
studies depressed children | #1 |
predictors persistence | #1 |
schizophrenia fhrs | #1 |
stimulants childhood | #1 |
adhd mdd prss | #1 |
rs2449340 | #1 |
marijuana smoking metaanalysis | #1 |
life adult adhd | #1 |
allele adhd | #1 |
efficacy outcome week | #1 |
htf9c | #1 |
cortical surface adhd | #1 |
comorbid psychopathology childhood | #1 |
relatives multiplex families | #1 |
adhd genetic | #1 |
expected growth children | #1 |
schizotypal relatives | #1 |
adhd somatosensory functioning | #1 |
criteria 14 children | #1 |
starsadhd | #1 |
autistic traits youth | #1 |
affective symptoms dbds | #1 |
biological schizophrenia stress | #1 |
male adolescents adhdct | #1 |
genetic heterogeneity adhd | #1 |
impulsiveness inattention | #1 |
relatives girls | #1 |
onset adult subjects | #1 |
bpi sza | #1 |
concurrent adhd | #1 |
subjects ldx | #1 |
autism‐associated brain regions | #1 |
siblings adolescent | #1 |
adhd fam | #1 |
girls disorder | #1 |
temperamental risk factor | #1 |
pediatric bpi disorder | #1 |
twin adoption studies | #1 |
cbcldesr | #1 |
medications adult adhd | #1 |
adhd scores | #1 |
effects lisdexamfetamine dimesylate | #1 |
2064 trios | #1 |
genetic frontal schizophrenia | #1 |
nplz | #1 |
adhd comorbid dbds | #1 |
adhd smoking risk | #1 |
evidence sud phenotypes | #1 |
adhd serotonin | #1 |
predictors adhd | #1 |
31item | #1 |
adhd clinical obesity | #1 |
ainslbl | #1 |
non‐adhd children | #1 |
sexes bpi disorder | #1 |
children disorder | #1 |
gene interaction comt | #1 |
bpd anx bpd | #1 |
children motor competence | #1 |
sud nicotine dependence | #1 |
adhd youth ld | #1 |
rf041 | #1 |
51 genes | #1 |
c2orf82 | #1 |
“schizotypes | #1 |
abstinence pharmacological treatment | #1 |
expected height weight | #1 |
executive functioning adults | #1 |
osa genetic heterogeneity | #1 |
adhd familial disorder | #1 |
adhd structural abnormalities | #1 |
chronological age age | #1 |
fspds | #1 |
anxious depressed subscales | #1 |
subthreshold adhd subjects | #1 |
motor preference asthma | #1 |
stimulant treatment differences | #1 |
mania clinical interview | #1 |
n55374 | #1 |
anxiety disorders siblings | #1 |
fbxo33 | #1 |
adhd girls adhd | #1 |
htf9c gene | #1 |
cortical networks attention | #1 |
etiology adhd | #1 |
week treatment response | #1 |
clinically diagnosed obesity | #1 |
ldx adult adhd | #1 |
oral nmu nmu | #1 |
adhdassociated alleles | #1 |
ldx bmi | #1 |
biased maternal reporting | #1 |
comorbid odd adhd | #1 |
comorbid problems | #1 |
sud adolescence | #1 |
23 candidate genes | #1 |
risk adhd | #1 |
bpi probands | #1 |
mspi allele | #1 |
depression adhd child | #1 |
adult adhd diagnosis | #1 |
2327ct | #1 |
opd add | #1 |
major depression youth | #1 |
adhd asthma | #1 |
lateandmoderate | #1 |
cdbpd | #1 |
maoa neuropsychological functioning | #1 |
sud phenotypes | #1 |
sud risk offspring | #1 |
alcohol dependence relatives | #1 |
adhd risk alleles | #1 |
dat1 untranslated regions | #1 |
probands comorbidity | #1 |
rs2469758–rs2461489 | #1 |
sample adhd | #1 |
adult samples adhd | #1 |
autism symptoms adhd | #1 |
adhdoddcd | #1 |
loci asd symptoms | #1 |
parental children | #1 |
growth delays weight | #1 |
drd2 disrupts | #1 |
probands rates | #1 |
druggable genome disorder | #1 |
adhd bpi disorder | #1 |
anachronisms | #1 |
motor preference | #1 |
diagnostic continuity | #1 |
desr subjects | #1 |
callingalgorithms | #1 |
siblings adhd children | #1 |
adults life | #1 |
neuropsychological functioning boys | #1 |
trait educational attainment | #1 |
highiq adults adhd | #1 |
mgh studies | #1 |
stimulant treatment adhd | #1 |
rs1633445 | #1 |
gsprss | #1 |
authors adhd | #1 |
childhood genetic background | #1 |
bpi disorder efds | #1 |
lod213 | #1 |
suds neurocognitive functions | #1 |
adhd african children | #1 |
female adhd | #1 |
adolescents sud treatment | #1 |
confusability analyses | #1 |
20183 cases | #1 |
pathways adhd | #1 |
selfreport adhd symptoms | #1 |
add aff | #1 |
onset attention | #1 |
neuropsychological testing individuals | #1 |
adults stimulant sizes | #1 |
adhd desr | #1 |
probands add | #1 |
adhd responders | #1 |
adhd comorbid | #1 |
rs7118422 | #1 |
children behavioral inhibition | #1 |
hamshere | #1 |
snpssnpsa | #1 |
adhd drd4 | #1 |
qelbree | #1 |
adhd module mwq | #1 |
adult adhd differences | #1 |
rels persons | #1 |
drug dependence relatives | #1 |
notch4 polymorphisms | #1 |
nimh genetics initiative | #1 |
adhd educational deficits | #1 |
disorder molecular | #1 |
rs3916970 | #1 |
onset chronological age | #1 |
bpi disorder youth | #1 |
smd higher rates | #1 |
cases adhd | #1 |
135–526 | #1 |
odd disorders follow | #1 |
haplotypes adhd | #1 |
comparison subjects participants | #1 |
dat110 6 | #1 |
adhd brain alterations | #1 |
smoking adhd | #1 |
adolescent patients adhd | #1 |
dat1 adhd | #1 |
efds youth | #1 |
late‐onset adhd | #1 |
aff add | #1 |
nonreferred siblings | #1 |
vivo neuroreceptor imaging | #1 |
motorendophenotype | #1 |
adhd antisocial disorders | #1 |
disorder schizotaxia | #1 |
faraone | #1 |
memory adults | #1 |
inattentive hyperactive | #1 |
hyperactivity comorbidity humans | #1 |
20183 | #1 |
aggregate cutoff score | #1 |
nonreferred sample | #1 |
patients attentional disorders | #1 |
female individuals adhd | #1 |
fiveminutespeechsample | #1 |
deficit hyperactivity | #1 |
prsanalyses | #1 |
adhd control probands | #1 |
desr adults | #1 |
motor skills attention | #1 |
hyperactivity cognition | #1 |
genetic studies sud | #1 |
genetic sexual dimorphism | #1 |
4q28 | #1 |
metabias | #1 |
pinslbl | #1 |
neuroleptic nonresponse | #1 |
gene aggressive behavior | #1 |
lobe mri measures | #1 |
mwq adhd module | #1 |
relatives control | #1 |
referred samples | #1 |
chi25762 | #1 |
subthreshold diagnoses valid | #1 |
95 hrr | #1 |
oral nmu | #1 |
genetic association rorb | #1 |
impulsive symptoms | #1 |
remission definition | #1 |
offspring behavioral disinhibition | #1 |
rs9610449 | #1 |
subjects adhd | #1 |
combination scientific data | #1 |
studies attention | #1 |
adhd familial | #1 |
relatives bipolar | #1 |
genes hallucinations states | #1 |
35191 | #1 |
symptoms versus impairment | #1 |
age groups cohorts | #1 |
disorder hyperactivity | #1 |
adhd pattern | #1 |
genetics adhd | #1 |
conduct disorder aspd | #1 |
chi28783 | #1 |
fidgety philipp | #1 |
nasal nmu nmu | #1 |
genetic risk severity | #1 |
dopamine receptor polymorphism | #1 |
adults neurodevelopmental disorder | #1 |
large controlled study | #1 |
method authors | #1 |
valid diagnosis | #1 |
impact tic disorders | #1 |
comt maoa interaction | #1 |
female gender boys | #1 |
git1 adhd | #1 |
model adult samples | #1 |
arch ger psychiatry | #1 |
adhd adult adhd | #1 |
model ermph | #1 |
asrs | #1 |
risk disorder | #1 |
dysfunctional gene | #1 |
clinical correlates ocd | #1 |
concurrent adhd sud | #1 |
comorbidity major depression | #1 |
onset distributions | #1 |
ldx growth delays | #1 |
greater risk add | #1 |
racial heterogeneity | #1 |
adhdi prenatal exposure | #1 |
illness adolescent | #1 |
lateonset adhd | #1 |
hyperactivity | #1 |
longitudinal outcome boys | #1 |
d10s2327 | #1 |
genes disorder | #1 |
pdi hyperactivity | #1 |
controls rels | #1 |
prs58502974 | #1 |
adhd mini | #1 |
adhd prss | #1 |
relatives bpi probands | #1 |
educational failure | #1 |
genetic variants adhd | #1 |
adhd background | #1 |
mania manic features | #1 |
dbds adhddbds | #1 |
relatives control probands | #1 |
switches bipolar disorder | #1 |
mania pdd | #1 |
nonverbal social–emotional cues | #1 |
hyperactivity cross | #1 |
childhood predictors adhd | #1 |
brain activity flow | #1 |
new diagnoses age | #1 |
repeat allele | #1 |
aisrs asrs | #1 |
neural network correlates | #1 |
p647e07 | #1 |
adhd efds | #1 |
s034 | #1 |
administration marijuana | #1 |
cigarette smoking metaanalysis | #1 |
comorbidity conduct | #1 |
psychiatric conditions adults | #1 |
masir ldx | #1 |
motheronly | #1 |
disorder report | #1 |
disorder | #1 |
features adhd | #1 |
bipolar disorder bpprss | #1 |
shlod | #1 |
rs550818 | #1 |
dao gene schizophrenia | #1 |
anxiety disorders twins | #1 |
gene comt | #1 |
gsprs adhd | #1 |
behavioral inhibition parents | #1 |
siblings adhd probands | #1 |
schizophrenic probands1portions | #1 |
children motor domain | #1 |
bipolars unipolar relatives | #1 |
relatives 1 probands | #1 |
adhd module | #1 |
hyperactivity female | #1 |
familial risk analyses | #1 |
nonreferred subjects | #1 |
disorder versus disability | #1 |
time qualitative review | #1 |
attention deficit | #1 |
adhd sex | #1 |
earlyandmoderate | #1 |
mdd pdag mdd | #1 |
drug frequency variables | #1 |
fm pain tolerance | #1 |
age1542 | #1 |
latrophilin 3 gene | #1 |
productivity adhd | #1 |
genetic variation nr3c1 | #1 |
adhd disorders comorbidity | #1 |
illness child comorbidity | #1 |
rs916455 | #1 |
youth bpi disorder | #1 |
nonreferred | #1 |
adhd phenotypes | #1 |
risk factors opd | #1 |
offspring parental md | #1 |
adhd disorder | #1 |
european treatment guideline | #1 |
adhd reliability | #1 |
subjects lateonset adhd | #1 |
suggestive linkage | #1 |
adhd prs gwas | #1 |
controls adhd probands | #1 |
adhd females | #1 |
adhd seconddegree relatives | #1 |
adhd neuropsychological functioning | #1 |
rs9325032 | #1 |
patients adhdpi | #1 |
inattention items | #1 |
daily parent rating | #1 |
longacting medications | #1 |
stimulant treatment youth | #1 |
adhd baseline assessment | #1 |
trait impulsivity adhdct | #1 |
deletioncarrier | #1 |
boys female gender | #1 |
schizophrenia code | #1 |
77e08 | #1 |
add opd | #1 |
adhd alcohol dependence | #1 |
medications adhd | #1 |
placebo cgsq | #1 |
pdd criteria | #1 |
adhd attention | #1 |
d10s195 | #1 |
trypotphan hydroxylase | #1 |
common genetic risk | #1 |
adhd income loss | #1 |
maoa adhd | #1 |
adhd social disability | #1 |
odd affective symptoms | #1 |
unipolar relatives bipolars | #1 |
persistence childhood adhd | #1 |
depression symptoms aggregation | #1 |
moderating effects patterns | #1 |
diagnoses relatives | #1 |
cigarette smoking siblings | #1 |
hyperactive impulsive | #1 |
adhd genetic studies | #1 |
stimulant treatment alcohol | #1 |
parental sud sud | #1 |
serotonin genetic | #1 |
familiar disease | #1 |
lifetime impairment survey | #1 |
fhrscz | #1 |
quantitative analyses treatment | #1 |
consensus statement combination | #1 |
antisocial families | #1 |
140 adhd probands | #1 |
stimulant nmu | #1 |
hypothesis disorders | #1 |
type attention | #1 |
sud parents | #1 |
gender familial risk | #1 |
children behavioral | #1 |
mania referred children | #1 |
marijuana cocaine crack | #1 |
bpi relatives | #1 |
higher prevalence girls | #1 |
subthreshold adhd | #1 |
ldx sizes | #1 |
pain tolerance oih | #1 |
sodasmph | #1 |
assess adult adhd | #1 |
children ermph | #1 |
twin adoption | #1 |
amses amrs | #1 |
disorders comorbid mania | #1 |
persistent adhd adults | #1 |
multiplex sample | #1 |
adhd dbds | #1 |
adults adhd subjects | #1 |
consensus combination | #1 |
adhd neuropsychological impairments | #1 |
adhd female individuals | #1 |
stimulants abuse potential | #1 |
adhd conclusions | #1 |
drugplacebo response curve | #1 |
severe dysregulation | #1 |
adulthood genetic architecture | #1 |
adolescent psychiatric cohort | #1 |
trypotphan | #1 |
referred juveniles | #1 |
gene studies | #1 |
relatives 3 probands | #1 |
hyperactivity biomarkers | #1 |
scz palau | #1 |
mwq inattention items | #1 |
children mania diagnosis | #1 |
pharmacological treatment adolescents | #1 |
association tph2 | #1 |
stimulants height | #1 |
non‐random error | #1 |
adhd probands relatives | #1 |
autistic traits presence | #1 |
smoking wm microstructure | #1 |
boys social disability | #1 |
maternal inattention anxiety | #1 |
odd relatives | #1 |
palau scz | #1 |
dsmiiir dsmiv adhd | #1 |
morbidity bipolar disorder | #1 |
postmortem brain identifies | #1 |
adolescence longitudinal analysis | #1 |
adhd maoa | #1 |
mp adhd | #1 |
adhd adult disorder | #1 |
dust addictive drug | #1 |
variants aggressive behavior | #1 |
teachers cbt intervention | #1 |
psychopathology reward dysfunction | #1 |
dopamine d4 gene | #1 |
genetic studies adhd | #1 |
adhd switches | #1 |
familial transmission adhd | #1 |
rutters | #1 |
prescription stimulant nmu | #1 |
disorder attention | #1 |
key conceptual issues | #1 |
increasing resource demand | #1 |
proband youth bpd | #1 |
bpd firstdegree relatives | #1 |
d15s1012 | #1 |
dependence controls | #1 |
groups girls | #1 |
dna methylation adhd | #1 |
hyperactivity comorbidity | #1 |
adhd neuroimage study | #1 |
sud adolescent | #1 |
impulsive subtype | #1 |
clinical features adhd | #1 |
adhd methods | #1 |
addictive drugs dust | #1 |
efficacy medications | #1 |
sob adhd | #1 |
schizotaxia negative schizotypy | #1 |
suds crosssectional studies | #1 |
neurocognitive marker | #1 |
drd2 risk gene | #1 |
familybased studies association | #1 |
late onset adhd | #1 |
experts abstinence | #1 |
methylphenidate efficacy | #1 |
candidate genes adhd | #1 |
shared endophenotypes | #1 |
children adolescents cohorts | #1 |
smoking cessation controls | #1 |
motor preference adhd | #1 |
rf025 | #1 |
nr3c1 stress exposure | #1 |
aklt01 tova api | #1 |
type adhd | #1 |
adult samples model | #1 |
affs add | #1 |
bpd hypothesis | #1 |
comorbid oppositional | #1 |
depressed children adhd | #1 |
mania conduct disorder | #1 |
genes adhd | #1 |
parents behavioral disinhibition | #1 |
children antisocial disorders | #1 |
acting medications | #1 |
pilot study adhd | #1 |
persistence adhd | #1 |
adhd smoking | #1 |
neurocognitive dysfunctions | #1 |
matching fallacy | #1 |
age stimulant treatment | #1 |
regions lgi | #1 |
adhd children ld | #1 |
p97e−03 | #1 |
ptsd adhd probands | #1 |
adhd iiv | #1 |
suggestive linkage signals | #1 |
adhd mp | #1 |
outcome adhd | #1 |
ldx amses | #1 |
adhd treatment treatment | #1 |
exposure clinical features | #1 |
biomarkers adhd | #1 |
etiology disorder | #1 |
increased adhd symptoms | #1 |
benefit‐risk ratio | #1 |
cgsq ermph | #1 |
ermph cgsq | #1 |
disorder meta | #1 |
adhd highiq youths | #1 |
based association study | #1 |
new phenotype definition | #1 |
persistent adhd symptoms | #1 |
probands adhd | #1 |
bipolar adhd | #1 |
parental panic depression | #1 |
children idiopathic adhd | #1 |
network‐level assessment | #1 |
adhd cigarette smoking | #1 |
weaknesses comorbidity | #1 |
elaborative verbal encoding | #1 |
adhd rat | #1 |
adult adhd | #1 |
18 items impairment | #1 |
persons rels | #1 |
bipolar disorder switches | #1 |
motor problems adhd | #1 |
subthreshold pediatric | #1 |
tic persistence | #1 |
adhdtd siblings | #1 |
subtype adhd | #1 |
personality traits adults | #1 |
relatives conduct disorder | #1 |
adhd haplotype block | #1 |
longitudinal analysis childhood | #1 |
tourettes syndrome adhd | #1 |
adhd cbcl | #1 |
vall66 | #1 |
manic symptoms disorder | #1 |
bipolar disorders psud | #1 |
mr006 | #1 |
paediatric patients adhd | #1 |
teacher report | #1 |
age onset criterion | #1 |
clinical interview mania | #1 |
adhd dsm | #1 |
schizophrenia current knowledge | #1 |
nonaffected siblings children | #1 |
adhd adverse impact | #1 |
learning disorders adhd | #1 |
efficacy outcome adhd | #1 |
association evidence schizophrenia | #1 |
vntr haplotype | #1 |
adhd screening | #1 |
smoking schizophrenia families | #1 |
mania pdd subjects | #1 |
time reproduction children | #1 |
molecular genetics network | #1 |
psychiatric risk vcfs | #1 |
association attention | #1 |
locus adhd | #1 |
adhd sexes | #1 |
bpprss | #1 |
bpd anx relatives | #1 |
adhd children mania | #1 |
nfspds | #1 |
validity adhd | #1 |
187 children | #1 |
adhd adolescent patients | #1 |
treatment effects values | #1 |
adhd susceptibility genes | #1 |
sexdifferentiated effects traits | #1 |
parental bpd | #1 |
adhd population | #1 |
40basepairrepeat | #1 |
bipolar disorder girls | #1 |
opd add opd | #1 |
familial moderators | #1 |
psud adhd probands | #1 |
adolescent sud | #1 |
relatives multiplex | #1 |
ptsd siblings | #1 |
schizophrenia hrscz | #1 |
interaction adhd | #1 |
adhd siblings | #1 |
youth adhd | #1 |
adhd drug dependence | #1 |
snps drd4 gene | #1 |
chinese outpatient sample | #1 |
relatives bpi | #1 |
youth adhd prss | #1 |
adhd predictors | #1 |
clinical response orosmph | #1 |
schizophrenia european samples | #1 |
nmu nasal nmu | #1 |
17yearold boys | #1 |
stimulants comorbidity | #1 |
relbps | #1 |
p27e05 | #1 |
child psychiatry referrals | #1 |
zmynd17 genes | #1 |
treatment stimulant | #1 |
caregiver strain cgsq | #1 |
association dopamine receptors | #1 |
rs7124601 | #1 |
snp quantitative phenotype | #1 |
5ht1b receptor gene | #1 |
comorbid problems adhd | #1 |
druggable genome adhd | #1 |
adhd genetic variants | #1 |
major depression share | #1 |
adhd outcome | #1 |
potential endophenotypes adhd | #1 |
mddprss | #1 |
regulation desr | #1 |
transmission adhd | #1 |
connectivity executive control | #1 |
depressed children depression | #1 |
iiv hyperactivity behavior | #1 |
adhd obesity overweight | #1 |
symptoms adult | #1 |
anx relatives | #1 |
p81e06 | #1 |
maoa impulsivity | #1 |
pediatric bipolari disorder | #1 |
prss adhd | #1 |
bpd girls | #1 |
hyperactivity child humans | #1 |
hypothesized precursors | #1 |
visual memory deficit | #1 |
add parent report | #1 |
pain tolerance fm | #1 |
tova api aklt01 | #1 |
greater risk adhd | #1 |
efds functional outcomes | #1 |
manic symptoms vcfs | #1 |
emotional problems pmee | #1 |
adhd pdics | #1 |
subsets linkage | #1 |
prevalence attention | #1 |
increased expression methylation | #1 |
compared adhd | #1 |
diagnosis adhd | #1 |
anxiety disorders findings | #1 |
relatives wm performance | #1 |
pdics | #1 |
adults cadhd | #1 |
low attention | #1 |
peer environmental factors | #1 |
paternal overtransmission | #1 |
relatives greater activation | #1 |
desr siblings | #1 |
infas | #1 |
quantitative phenotype snp | #1 |
p44e05 | #1 |
ldx sizes children | #1 |
paternal smoking conception | #1 |
rs11133767 | #1 |
training raters | #1 |
adhd higher | #1 |
familial subtype | #1 |
adhdtd | #1 |
suds relatives | #1 |
tass adhd | #1 |
anx bpd | #1 |
snps quantitative phenotypes | #1 |
p902e−07 | #1 |
adhd aes | #1 |
treatment moderated | #1 |
sud bpdsud | #1 |
pharmacogenetics predictors | #1 |
adhd adoption studies | #1 |
scales risk | #1 |
cognitive endophenotypes adhd | #1 |
genes etiology | #1 |
thermenos | #1 |
aggressive symptoms risk | #1 |
discordant twin study | #1 |
schizophrenia bipolar psychoses | #1 |
add relatives | #1 |
1350t | #1 |
pippi longstocking | #1 |
exposure parental adhd | #1 |
familially | #1 |
pair health | #1 |
followup assessment | #1 |
hyperactivity disorder | #1 |
83097 | #1 |
measurement invariance study | #1 |
bpd probands | #1 |
anxiety disorders families | #1 |
genotype calling procedures | #1 |
growth deficits deficits | #1 |
adult probands siblings | #1 |
antisocial disorders bpd | #1 |
140 adhd | #1 |
diagnoses valid | #1 |
maf⩾1 | #1 |
adhd chinese population | #1 |
md parents | #1 |
hyperactivity pdi | #1 |
disorder relatives | #1 |
adhd follow | #1 |
substantial genetic component | #1 |
normal sexual dimorphisms | #1 |
actual motor performance | #1 |
hyperactivity biomarkers aadhd | #1 |
asd youth adhd | #1 |
intron8 | #1 |
adhddbds adhd | #1 |
21 circadian genes | #1 |
rs1051312 | #1 |
rs2279805 | #1 |
rs12843268 | #1 |
rs2469770 | #1 |
daonrg1 | #1 |
disorder follow | #1 |
standardized manner | #1 |
adhd cognition | #1 |
efficacy adderall | #1 |
deficits time | #1 |
re‐review | #1 |
sex bpi disorder | #1 |
comt odd | #1 |
individuals attention | #1 |
aklt01 adhd | #1 |
healthy cortical development | #1 |
neuropsychological performance adhd | #1 |
nmu oral | #1 |
adhd oxidative stress | #1 |
nonreferred adult | #1 |
hyperactive impulsive symptoms | #1 |
differences medications | #1 |
affective psychosis hraff | #1 |
2276ct | #1 |
paternal over‐transmission | #1 |
comt fsiq | #1 |
risk aggressive symptoms | #1 |
slc9a9 disease associations | #1 |
psud controls | #1 |
adhd community | #1 |
pooleddata | #1 |
adhd hyperactivity automobile | #1 |
cardinal symptom mania | #1 |
schizophrenia notch4 | #1 |
sp067 | #1 |
adhd candidate genes | #1 |
adhd comorbid odd | #1 |
criteria age | #1 |
youth informant source | #1 |
drd5 vntr | #1 |
siblings antisocial families | #1 |
adhd personality traits | #1 |
probands clinical status | #1 |
children bpi disorder | #1 |
motor preference disability | #1 |
nonmental diseases | #1 |
psychiatric comorbidities adhd | #1 |
disorder adhd | #1 |
adhd genetic correlation | #1 |
idir proteins siblings | #1 |
symptom burden adults | #1 |
adhdmethodcurves | #1 |
antisocial disorder relatives | #1 |
drugplacebo | #1 |
school reliability | #1 |
children general psychopathology | #1 |
higher pdi | #1 |
unaffected siblings volumes | #1 |
patients adhdct | #1 |
schizotaxia subjects | #1 |
competitivep | #1 |
rs9627183 | #1 |
cacng2 gene | #1 |
parental sud adhd | #1 |
rs3776512 | #1 |
expressed emotion children | #1 |
neuropsychological impairments relatives | #1 |
nonpsychotic relatives controls | #1 |
specific psychopathology children | #1 |
female humans inhibition | #1 |
adhd alleles | #1 |
stimulant misuse | #1 |
euphoria cardinal symptom | #1 |
phenotype adhd | #1 |
adhd child comorbidity | #1 |
increased methylation genes | #1 |
adhd clinical characteristics | #1 |
lifetime adhd | #1 |
matter volumes volumes | #1 |
adhd vntr | #1 |
adhd maternal | #1 |
elevated rates adhd | #1 |
subcortical volumes adhd | #1 |
anterior insular lobule | #1 |
comt intelligence | #1 |
elevated risk adhd | #1 |
adhd total score | #1 |
future dsm | #1 |
adhd children exposure | #1 |
meaningful anxiety phenotype | #1 |
adherence stimulant treatment | #1 |
adverse impact adhd | #1 |
adherence xr | #1 |
9 nhe9 | #1 |
bmi ldx | #1 |
bpi disorder sexes | #1 |
oih cpt | #1 |
predicted clinical response | #1 |
new psychometric definition | #1 |
mr005 | #1 |
risk tourette spectrum | #1 |
diagnosis bpi disorder | #1 |
impairments adults | #1 |
neurocognitive traits | #1 |
daorasd2 | #1 |
hamiltondepression | #1 |
pdd pdd subjects | #1 |
copy organization | #1 |
antisocial disorders risk | #1 |
gender adhd | #1 |
subcortical structure volume | #1 |
adhd druggable genes | #1 |
adhdfamilies | #1 |
distal genomic region | #1 |
fhraff | #1 |
oral methylphenidate treatment | #1 |
pdd mania | #1 |
mph controls | #1 |
onset distribution | #1 |
asrs‐v11 | #1 |
risk suds | #1 |
affective symptoms children | #1 |
genomesignificance | #1 |
families adhd | #1 |
odd disruptive behavior | #1 |
relatives alcohol dependence | #1 |
rtv adhd prs | #1 |
adhd valid | #1 |
adhd aud | #1 |
kiaa1292 | #1 |
tdt analysis | #1 |
impulsive drive | #1 |
adults ldx sizes | #1 |
mania rates | #1 |
neuropsychologic function schizophrenia | #1 |
adhd antisocial | #1 |
adhd stimulant treatment | #1 |
parental adhd sud | #1 |
emotional symptoms adhd | #1 |
genes sexdifferentiated effects | #1 |
ldx sizes adults | #1 |
neuroanatomic predictors | #1 |
molecular genetic studies | #1 |
adhdrs5 | #1 |
hyperactivity databases | #1 |
risk subsequent substance | #1 |
association syp | #1 |
chronic emotional dysregulation | #1 |
highiq youths | #1 |
adherence stimulant medication | #1 |
adhd risk factors | #1 |
interviews disease humans | #1 |
smaller total brain | #1 |
idir aversion | #1 |
adhd proband | #1 |
orosmph adult adhd | #1 |
drd4 7repeat allele | #1 |
symptoms aggregation | #1 |
larger samples | #1 |
treatment bsd | #1 |
rs41084 | #1 |
relatives default network | #1 |
rs2498799 | #1 |
p0499 | #1 |
ermph placebo groups | #1 |
siblings males | #1 |
adhd gwas | #1 |
5q23q31 | #1 |
p179e06 | #1 |
structured interview pdd | #1 |
interobserver agreement measures | #1 |
cyp2d6 hypothesis | #1 |
structural differences children | #1 |
asds clinical scales | #1 |
unexplored void | #1 |
clinical controls | #1 |
controls adhd children | #1 |
iiv shr | #1 |
cdh13 memory performance | #1 |
aadhd hyperactivity biomarkers | #1 |
analysis adhd | #1 |
rare protective allele | #1 |
rs6000200 | #1 |
age 7repeat allele | #1 |
african‐american pedigrees | #1 |
adhd african | #1 |
adhd gsprs | #1 |
dyscalculia adhd | #1 |
inattention adhd | #1 |
inattention shr | #1 |
adhd subjects controls | #1 |
2 familial factors | #1 |
genetic overlap adhd | #1 |
distribution child | #1 |
valid psychiatric disorder | #1 |
patterns psychiatric comorbidity | #1 |
desr adhd | #1 |
add pdics | #1 |
highiq adults | #1 |
volumes participants | #1 |
cacng2 genes schizophrenia | #1 |
tass adhdrs | #1 |
reproducibility adolescent | #1 |
bpi disorder adhd | #1 |
p446e08 | #1 |
pregnancy adhd | #1 |
psud relatives | #1 |
neurocognitive functions suds | #1 |
unique impairments | #1 |
parental suds | #1 |
self‐reported adhd | #1 |
5‐generation | #1 |
association behavioral inhibition | #1 |
asrs scores | #1 |
bipolar disorder parents | #1 |
adhd asm snps | #1 |
adhd children depression | #1 |
association slc6a3 | #1 |
preschool comorbidity | #1 |
parents md | #1 |
adhd psychoactive substance | #1 |
pepple | #1 |
adhd symptoms crf | #1 |
cbcl clinical scales | #1 |
selfreport adhd | #1 |
motorendophenotypes | #1 |
adhddbds | #1 |
treatment stimulants | #1 |
cbclbp profile children | #1 |
rs1482337–rs2252471 | #1 |
efs girls | #1 |
offspring parental adhd | #1 |
adhd studies | #1 |
adhd clinical | #1 |
downward extension adolescents | #1 |
adhd gene | #1 |
adhd 5 | #1 |
conduct bipolar disorders | #1 |
height ldx | #1 |
hyperactivity child child | #1 |
schizophrenia families smoking | #1 |
rs1076560t | #1 |
sud remittent adhd | #1 |
criteria☆ | #1 |
adhd adhdtd | #1 |
familial evidence | #1 |
hartsough | #1 |
nhe inhibitors adhd | #1 |
mph adult adhd | #1 |
adhd girls | #1 |
anxiety disorders baseline | #1 |
treatment masxr | #1 |
disorders parents | #1 |
onset criterion adhd | #1 |
interaction adhd severity | #1 |
adolescent response inhibition | #1 |
rate symptoms | #1 |
abnormalities adhd | #1 |
population screen | #1 |
intelligence additive effects | #1 |
bipolar mdd | #1 |
rationaleadhd | #1 |
risk anxiety disorders | #1 |
bpd bpd anx | #1 |
slc6a4 gene risk | #1 |
sob sob association | #1 |
adhd desr probands | #1 |
individuals adhd | #1 |
morbidity adhd | #1 |
male individuals adhd | #1 |
noninhibited children | #1 |
braingenie | #1 |
familial association adhd | #1 |
ats siblings | #1 |
diagnostic continuity adhd | #1 |
stimulant treatment | #1 |
diagnoses adhd | #1 |
treatment mts | #1 |
exposure maternal smoking | #1 |
smd greater severity | #1 |
rs2272080 | #1 |
loci adhd | #1 |
np functioning chr | #1 |
hyperactivity child genome | #1 |
teenage parents individuals | #1 |
hyperactivity disorder scores | #1 |
highiq youths adhd | #1 |
add 73 probands | #1 |
offspring sud parents | #1 |
psychiatric disorders adhd | #1 |
adhd prss adhd | #1 |
risk female relatives | #1 |
children teaes | #1 |
disorganized symptom dimensions | #1 |
behavioral disinhibition offspring | #1 |
deficit | #1 |
suds nicotine dependence | #1 |
vulnerability indicators schizophrenia | #1 |
hyperactivity disorder adults | #1 |
adhd clinical trial | #1 |
hyperactivity child | #1 |
vcfsadhd adhd | #1 |
adhd asd youth | #1 |
relatives adhd probands | #1 |
adhd adolescent | #1 |
relatives adhd status | #1 |
putamen volume alterations | #1 |
cadhd aadhd | #1 |
oros methylphenidate orosmph | #1 |
adhd bipolar comorbidity | #1 |
depression offspring variables | #1 |
valid disorder | #1 |
treating adhd | #1 |
n122 | #1 |
stable behavioral inhibition | #1 |
adhd diagnosed | #1 |
ctcata | #1 |
nfspd | #1 |
adhd increased | #1 |
adhd children bpd | #1 |
studies adhd | #1 |
adhd familial risk | #1 |
psychiatric comorbidity md | #1 |
stress exposure connectivity | #1 |
tass internal consistency | #1 |
males overweight obesity | #1 |
cohorts age groups | #1 |
adhd efficacy outcome | #1 |
innovative sms intervention | #1 |
prescription stimulant adults | #1 |
palau early | #1 |
12allele | #1 |
persistence pediatric disorder | #1 |
syp female adhd | #1 |
adhd genetic exome | #1 |
adhdrsivinv | #1 |
tidqam | #1 |
rs6077690 | #1 |
association maoa | #1 |
adhd | #1 |
ldx size children | #1 |
adhd linkage | #1 |
adult persistence adhd | #1 |
alphaglx | #1 |
stimulant treatment adults | #1 |
adhd highly | #1 |
adhd 11 years | #1 |
2327t | #1 |
p758e08 | #1 |
paediatric adhd | #1 |
p20e04 | #1 |
dbds adhd | #1 |
risk opioid dependence | #1 |
adhd stronger connectivity | #1 |
adhd antisocial comorbidity | #1 |
genetic correlation adhd | #1 |
nonreferred siblings probands | #1 |
endophenotypic construct | #1 |
cbt intervention adolescents | #1 |
adhd sample model | #1 |
142 combined subtype | #1 |
adhd neuropsychological | #1 |
“3 | #1 |
adhd probands adhd | #1 |
inattentive subtype adhd | #1 |
manic children pdd | #1 |
siblings control probands | #1 |
sud adolescent patients | #1 |
9r allele | #1 |
relatives add probands | #1 |
cbclbp | #1 |
99item cbs | #1 |
adhd learning | #1 |
transmission parents | #1 |
35191 controls | #1 |
findings adhd | #1 |
adults diagnosis | #1 |
relatives adhd girls | #1 |
placebo ldx treatment | #1 |
masxr treatment | #1 |
distinct subtype | #1 |
neuropsychological probes | #1 |
psychiatric comorbidity girls | #1 |
referred parents | #1 |
levels dysfunction | #1 |
mitigates stimulant | #1 |
qms adult adhd | #1 |
adhd dat1 gene | #1 |
association evidence | #1 |
studies adhd children | #1 |
deficits expected growth | #1 |
childhood adhd adulthood | #1 |
slc9a9 | #1 |
bpd anx | #1 |
bpi disorder relatives | #1 |
odd familial disorders | #1 |
diagnostic criteria adhd | #1 |
adolescents genetic risk | #1 |
shr iiv | #1 |
relatives risk adhd | #1 |
hyperactivity case | #1 |
disorders aa | #1 |
intellectual delays | #1 |
adult adhd treatment | #1 |
stimulant treatment risk | #1 |
impulsive behavioral aggression | #1 |
suds adhd | #1 |
nonreferred adults | #1 |
4‐year follow‐up study | #1 |
nonreferred samples | #1 |
regions age | #1 |
laboratory driving simulation | #1 |
adhd symptom counts | #1 |
relatives children | #1 |
adhd gender | #1 |
robust familiality | #1 |
bpi disorder children | #1 |
juvenile antisocial traits | #1 |
adhd specific | #1 |
rs3792452 | #1 |
alcohol disorders offspring | #1 |
familial risk gender | #1 |
multi‐stage study | #1 |
diagnostic efficiency analysis | #1 |
pediatric panic disorder | #1 |
adhd children | #1 |
akt1 snp markers | #1 |
stimulant therapy youths | #1 |
h2053 | #1 |
impactnl | #1 |
diagnoses probands | #1 |
adhd psychiatric conditions | #1 |
insular lobule | #1 |
adhd community sample | #1 |
control probands | #1 |
clock genes rorb | #1 |
daodisc1 | #1 |
evidence stimulant treatment | #1 |
adhd snps | #1 |
adhd followup | #1 |
childhoodonset mania | #1 |
ptsd familial disorders | #1 |
items 99item cbs | #1 |
adhd psychiatric | #1 |
10repeats | #1 |
disability asthma | #1 |
relatives drug dependence | #1 |
girls learning disabilities | #1 |
mothers fam | #1 |
ld addh children | #1 |
mania criteria | #1 |
anxiety disorders relatives | #1 |
gene attention | #1 |
parental panic disorder | #1 |
learning disabilities girls | #1 |
schizotaxia negative symptoms | #1 |
disorder familial | #1 |
aadhd cadhd | #1 |
adhd long term | #1 |
rs3746544 rs1051312 | #1 |
adhd slc6a3 genotype | #1 |
desipraminestimulants | #1 |
ldx masir | #1 |
molecular psychiatric genetics | #1 |
years adhd | #1 |
genetic correlations schizophrenia | #1 |
lifetime impairment | #1 |
addh dmi | #1 |
or133 | #1 |
ptsd bpi disorder | #1 |
parental md | #1 |
variance oppositional symptoms | #1 |
association adhd | #1 |
family‐based association test | #1 |
persistence disorder | #1 |
parents proband youth | #1 |
112 80 | #1 |
risk comt gene | #1 |
norepinephrine transporter gene | #1 |
mtbi adhd | #1 |
discipline problem | #1 |
df39 | #1 |
a409p | #1 |
adhd dyscalculia | #1 |
asd weaknesses | #1 |
galantamine hydrogen bromide | #1 |
stimulant treatment profiles | #1 |
positive peer affiliation | #1 |
c759t | #1 |
conduct disorder probands | #1 |
1 relatives | #1 |
2455 controls | #1 |
aspd youth | #1 |
dsm bipolar disorder | #1 |
rates relatives | #1 |
high‐risk adolescent offspring | #1 |
firstdegree relatives children | #1 |
n6979 | #1 |
adoption studies | #1 |
rs3027400 | #1 |
–rs2272080 | #1 |
schizophrenia familybased studies | #1 |
metaanalysis controlled study | #1 |
co‐expression modules | #1 |
adhd volumetric reductions | #1 |
expression adhd | #1 |
teacher combined | #1 |
rs1040399 | #1 |
relation stress exposure | #1 |
efds bpi disorder | #1 |
adhd sample | #1 |
ldx growth | #1 |
scqscore | #1 |
overweight obesity males | #1 |
sob association adhd | #1 |
substance disorders relatives | #1 |
add antisocial disorders | #1 |
adhd ads | #1 |
adhd comorbid disorders | #1 |
groundskeeper | #1 |
drd4 association | #1 |
bpi disorder | #1 |
git1 association adhd | #1 |
sbrv adhd | #1 |
versus disability | #1 |
bmi mts | #1 |
adhd oppositional | #1 |
unfamiliar challenges | #1 |
disorder boys | #1 |
slc9a9 adhd | #1 |
familial underpinnings | #1 |
prospective datasets | #1 |
stress adhd severity | #1 |
bpd bpdsud | #1 |
children pdag parents | #1 |
qms adhd | #1 |
risk substance disorders | #1 |
report adhd | #1 |
endosomal genes asds | #1 |
aud adhd | #1 |
prs rtv | #1 |
adolescent follow youth | #1 |
adhd findings | #1 |
higher adhd | #1 |
paliperidone monotherapy | #1 |
rs552655 | #1 |
proband youth bpdsud | #1 |
bpdsud bpd | #1 |
120 normal controls | #1 |
adhd functional | #1 |
familial links | #1 |
13052159 | #1 |
2276tc | #1 |
cortical thickness adhd | #1 |
adult persistence | #1 |
validity diagnosis | #1 |
parental polygenic risk | #1 |
adhd probands | #1 |
prodromal overt psychosis | #1 |
inflation personal satisfaction | #1 |
nonmental diseases adhd | #1 |
foursnp | #1 |
psychopathology implications | #1 |
vcfs manic symptoms | #1 |
hyperactivity body | #1 |
parental probands | #1 |
risk psud | #1 |
timely renewal | #1 |
transient financial stress | #1 |
adhd genetic receptors | #1 |
adhd bipolar studies | #1 |
adolescent attention | #1 |
relszs | #1 |
association snap25 | #1 |
14 children pdd | #1 |
pdd mania mania | #1 |
74±77 | #1 |
adhd baseline | #1 |
european treatment guidelines | #1 |
schizotaxia schizophrenia | #1 |
adolescent outcome adhd | #1 |
bpd relatives | #1 |
dsmiv subtypes adhd | #1 |
rs1799835 | #1 |
adhd maternal smoking | #1 |
24 gm day | #1 |
association psychiatric comorbidity | #1 |
familial disorders adhd | #1 |
desr probands siblings | #1 |
bpi disorder aspd | #1 |
risk childhood onset | #1 |
fam mothers | #1 |
bpd parents | #1 |
adhd medications placebo | #1 |
prss psychiatric disorders | #1 |
onset mania | #1 |
comt maoa | #1 |
229 families | #1 |
growth outcomes adhd | #1 |
shifting sands | #1 |
4q3121 | #1 |
prescription stimulant nonmedical | #1 |
studies method | #1 |
adhd adhd cases | #1 |
criteria mania | #1 |
adhd teenage parents | #1 |
impaired sensorimotor timing | #1 |
adhd france | #1 |
social adjustment inventory | #1 |
cbclbp profile | #1 |
context adhd | #1 |
desr adult probands | #1 |
adhd euphoria | #1 |
asthma motor preference | #1 |
african children adhd | #1 |
psychopharmacologic | #1 |
convergent functional genomic | #1 |
fsiq comt | #1 |
parents sud | #1 |
pediatric bipolar spectrum | #1 |
anxiousdepressed | #1 |
criteria pdd | #1 |
covariates dopamine receptors | #1 |
adolescents concurrent adhd | #1 |
asrs aisrs | #1 |
schizophrenia nonpsychotic relatives | #1 |
dsm5 adult adhd | #1 |
adhd social class | #1 |
comorbid adult adhd | #1 |
masir | #1 |
adhd context | #1 |
aud alcohol disorders | #1 |
pdi impulsiveness | #1 |
linkage wave | #1 |
children growth delays | #1 |
suds genetic studies | #1 |
structured interview mania | #1 |
apol1 schizophrenia | #1 |
adhd degree relatives | #1 |
odd control | #1 |
adhd adhd probands | #1 |
schizophrenia rs1076560t | #1 |
rorb bipolar disorder | #1 |
pdag mdd mdd | #1 |
896 cases | #1 |
adhd single nucleotide | #1 |
disorders hypothesis | #1 |
adhd autism symptoms | #2 |
background attention | #2 |
2q143 | #2 |
subsyndromal manifestations | #2 |
6 17 | #2 |
screening diagnosis treatment | #2 |
work needed | #2 |
actively reducing | #2 |
multigenic inheritance | #2 |
developmental subtype | #2 |
comparative profile analysis | #2 |
levels comorbidity | #2 |
adhd risk factor | #2 |
adhd physical conditions | #2 |
methodological complexities | #2 |
mirsky | #2 |
scz data | #2 |
comorbid oppositional defiant | #2 |
elusive indicators | #2 |
qualitative literature review | #2 |
child behavioral inhibition | #2 |
adverse effects subjects | #2 |
testretest reliability screener | #2 |
function deficits | #2 |
rates odd | #2 |
n17666 | #2 |
617 years | #2 |
stimulants adhd | #2 |
bpd sud | #2 |
140 girls | #2 |
psychotic relatives | #2 |
combinedtype | #2 |
association meta analysis | #2 |
dsm adhd | #2 |
disorder oppositional | #2 |
adhd lower | #2 |
attentional control effects | #2 |
adhd objective | #2 |
adhd icv | #2 |
euphorigenic effects | #2 |
n3199 | #2 |
sex differences adhd | #2 |
regions studies | #2 |
disorders similarities | #2 |
drug abuse dependence | #2 |
personal satisfaction | #2 |
10092 | #2 |
specific haplotype | #2 |
polygenic resilience score | #2 |
disorder girls | #2 |
comorbid conduct disorder | #2 |
adhd conduct | #2 |
factors adhd | #2 |
schizophrenia calcineurin | #2 |
naltrexone adults | #2 |
underlying bipolarity | #2 |
scale asrs | #2 |
psychiatrically | #2 |
deficit hyperactivity disorder | #2 |
versus controls | #2 |
ratio081 | #2 |
enigma adventure | #2 |
probands relatives | #2 |
cbcl desr | #2 |
adhd risk gene | #2 |
consortium neuroscience | #2 |
bipolar disorder relatives | #2 |
investigator ratings | #2 |
prior reports | #2 |
conjfdr005 | #2 |
schizophrenia parahippocampal gyrus | #2 |
adhd neuropsychological tests | #2 |
relatives schizophrenic | #2 |
molecular genetics schizophrenia | #2 |
adhd impact | #2 |
childhoodonset adhd | #2 |
subsequent substance | #2 |
adhd genes | #2 |
comorbidity attention | #2 |
p161e05 | #2 |
youth selfreports | #2 |
disorder conclusions | #2 |
wky nhsd | #2 |
adhd major depression | #2 |
internal distractibility | #2 |
stimulants adults | #2 |
iii attention | #2 |
desr children | #2 |
adhd genetics | #2 |
adhd birth | #2 |
morning behavior | #2 |
youth rates | #2 |
expanded symptom criteria | #2 |
maternal smoking mothers | #2 |
jackknife procedure | #2 |
eye vergence | #2 |
dsmiv adhd | #2 |
bipolar disorder symptomatology | #2 |
reward‐related activation | #2 |
preventing schizophrenia | #2 |
comorbidity disorders comorbidity | #2 |
hypothesis adhd | #2 |
clinically referred | #2 |
parents major depression | #2 |
mood disorders adhd | #2 |
shared genetic background | #2 |
young adult years | #2 |
dsm subtypes | #2 |
relatives adhd | #2 |
role adhd | #2 |
ncrl wky | #2 |
efficacy stimulants | #2 |
consecutively referred children | #2 |
adhd choice | #2 |
adhd adhd children | #2 |
qtl linkage adhd | #2 |
adhd outcomes | #2 |
adhdonly | #2 |
subjects criteria | #2 |
6 17 years | #2 |
parental anxiety disorders | #2 |
disease humans receptors | #2 |
psychoactive substance disorders | #2 |
symptoms neuropsychological | #2 |
galantamine hbr placebo | #2 |
scales adolescent | #2 |
heterogeneity schizophrenia | #2 |
diabetes disorders | #2 |
hypothalamic abnormalities | #2 |
twin studies adhd | #2 |
d2s410 | #2 |
target features | #2 |
efds | #2 |
g72 daao | #2 |
informant source | #2 |
risk factor adhd | #2 |
rs1800955 | #2 |
deficits sustained attention | #2 |
familybased studies | #2 |
adults adhd | #2 |
subjects adults | #2 |
cognition youth | #2 |
childhood adolescent adhd | #2 |
performancemeasures | #2 |
risk add | #2 |
antisocial disorders relatives | #2 |
adhd comparison subjects | #2 |
comorbidity disorder | #2 |
millennium consortium | #2 |
findings children | #2 |
tourette spectrum | #2 |
adhd height | #2 |
d0·18 | #2 |
s038 | #2 |
major depression findings | #2 |
wiatii | #2 |
checklist clinical | #2 |
selfmedicating | #2 |
systematized delusions | #2 |
maoa comt | #2 |
18 dsm | #2 |
subjects desr | #2 |
idiopathic adhd | #2 |
cbsk | #2 |
adolescents substance disorder | #2 |
chromosomes inclusion | #2 |
youth attention | #2 |
d10s1432 | #2 |
adhd bpd | #2 |
adhd growth | #2 |
n328917 | #2 |
psychiatric comorbidity | #2 |
adhd neuropsychological deficits | #2 |
7point | #2 |
factors attention | #2 |
deficit sustained attention | #2 |
eye vergence responses | #2 |
structure adult adhd | #2 |
dsmiiir adhd | #2 |
dsmiv subtypes | #2 |
comorbidity probands | #2 |
suggestive linkage loci | #2 |
risk female cases | #2 |
psychotic mood disorder | #2 |
nicotine substance | #2 |
neuroleptic dose reduction | #2 |
adhd relatives | #2 |
strong heritability | #2 |
hypothetical task | #2 |
asrs health organization | #2 |
default network schizophrenia | #2 |
disorders findings | #2 |
methylphenidate attention | #2 |
adhd major | #2 |
age onset distributions | #2 |
quetiapine monotherapy treatment | #2 |
cigarette smoking suds | #2 |
subthreshold diagnoses | #2 |
adhd acc | #2 |
alleles attention | #2 |
disorder studies | #2 |
activation trigger | #2 |
adhd mph response | #2 |
ppv hyperactivity diagnostic | #2 |
girls adhd | #2 |
items screener | #2 |
correlates adhd | #2 |
comorbid aggression | #2 |
hrscz | #2 |
schizophrenia twin studies | #2 |
concurrent attention | #2 |
adhd combined subtype | #2 |
aggressive symptoms | #2 |
initial stimulant | #2 |
stimulants | #2 |
rates adhd | #2 |
hantac | #2 |
persistent attention | #2 |
disorder background | #2 |
adhd report | #2 |
cbcljbd children | #2 |
youth meaningful | #2 |
variants adhd | #2 |
disorder inattentive | #2 |
separation attention deficit | #2 |
adhd control subjects | #2 |
structured diagnostic | #2 |
dysfunction offspring | #2 |
referred youth | #2 |
neuropsychoanalytic treatment | #2 |
enigma adhd | #2 |
schizophrenia genetic studies | #2 |
boys maoa | #2 |
allele schizophrenia | #2 |
comorbidity adhd | #2 |
pediatrically | #2 |
disorder add | #2 |
cbcl clinical | #2 |
familial adhd | #2 |
5 loci adhd | #2 |
hyperactivity female humans | #2 |
schizotaxia discussion | #2 |
bsfq | #2 |
familial risk analysis | #2 |
juvenile antisocial | #2 |
studies adderall | #2 |
treatment sud patients | #2 |
support genetic factors | #2 |
cacng2 genes | #2 |
patterns comorbidity | #2 |
qualitative review | #2 |
anx bipolar disorder | #2 |
disorder children | #2 |
amses | #2 |
efds adults | #2 |
adhd disability | #2 |
wm deficits | #2 |
status rating scales | #2 |
male psychiatric | #2 |
adherence stimulants | #2 |
adhd adults | #2 |
weaknesses youth | #2 |
adhd subjects | #2 |
adults attention | #2 |
disorders adhd | #2 |
overlap mania | #2 |
genome‐wide association data | #2 |
rs40184 | #2 |
executive function outcome | #2 |
stress adhd | #2 |
viloxazine extendedrelease | #2 |
method subjects | #2 |
adhd adhd patients | #2 |
affective probands | #2 |
emf impairments | #2 |
somatosensory functioning | #2 |
adhd risk icv | #2 |
pdd overlap | #2 |
hyperactivity attention deficit | #2 |
genetic transmission | #2 |
neuropsychological function girls | #2 |
ncrl | #2 |
manic switches | #2 |
relatives add | #2 |
cpt oih | #2 |
adhd lifespan | #2 |
health organization asrs | #2 |
proinflammatory expansion | #2 |
n‐acetylcysteine treatment | #2 |
n11221 | #2 |
pilot adult | #2 |
adhd comparison | #2 |
oral prescription | #2 |
serum neuroleptic activity | #2 |
disorders suds | #2 |
association data | #2 |
adhd surface area | #2 |
iii adhd | #2 |
derived diagnosis | #2 |
expanded versions | #2 |
parent rating | #2 |
age onset distribution | #2 |
antisocial disorders | #2 |
adhd method | #2 |
bmi adhd symptoms | #2 |
child comorbidity illness | #2 |
comorbid conduct problems | #2 |
rates bpd | #2 |
chromosomes 6 14 | #2 |
relatives simplex families | #2 |
diagnosis attention | #2 |
odd girls | #2 |
adhd suds | #2 |
small literature | #2 |
consecutively referred | #2 |
conners adult adhd | #2 |
n1934 | #2 |
rs6938431 | #2 |
disorder adults | #2 |
morbidity dysfunction | #2 |
variance adult | #2 |
6p243 | #2 |
multicenter adhd | #2 |
parents disorder | #2 |
deficits efds | #2 |
key cognitive phenotypes | #2 |
dsmjbd | #2 |
stimulant therapy | #2 |
adhdliability | #2 |
adhd ldx | #2 |
ermph children | #2 |
cnvs copy variants | #2 |
immune disorder | #2 |
sud bpd | #2 |
juvenile bipolar phenotype | #2 |
familial association | #2 |
blind raters | #2 |
effects paternal smoking | #2 |
addicted | #2 |
n2455 | #2 |
unipolar relatives | #2 |
bias child child | #2 |
lgi regions | #2 |
adhd odd | #2 |
schizophrenia interactions | #2 |
checklist scales | #2 |
attention‐deficit hyperactivity | #2 |
adra2a polymorphism | #2 |
subjects conduct disorder | #2 |
modest evidence | #2 |
adhd psychiatric disorders | #2 |
evidence adhd | #2 |
bpd adhd | #2 |
rs3746544 | #2 |
schizophrenia pedigrees | #2 |
wwwhapmaporg | #2 |
infancy complications | #2 |
rs1801028 | #2 |
adhdprss | #2 |
wky ncrl | #2 |
large controlled | #2 |
opioid induced hyperalgesia | #2 |
adhd combined | #2 |
actively reducing severity | #2 |
ldsc heritability | #2 |
current adult adhd | #2 |
siblings youth | #2 |
control subjects adhd | #2 |
structured diagnostic interviews | #2 |
snp12snp2ctgn | #2 |
scales sex | #2 |
bipolar disorder sud | #2 |
disorder findings | #2 |
relatives | #2 |
n2246 | #2 |
ldsc genetic correlations | #2 |
risk panic disorder | #2 |
treatment childhood adhd | #2 |
case subjects adhd | #2 |
derived phenotypes | #2 |
association mtbi | #2 |
adhd comorbid problems | #2 |
life social adjustment | #2 |
cbcl profile | #2 |
6‐year longitudinal study | #2 |
problems adhd | #2 |
aklt01 | #2 |
disorder impact | #2 |
adhd families | #2 |
disease humans inhibition | #2 |
hyperactivity diagnostic | #2 |
bidirectional overlap | #2 |
manic children | #2 |
stin2vntr | #2 |
disorder adolescent | #2 |
dimesylate treatment | #2 |
adhd african americans | #2 |
postcleavage | #2 |
masxr | #2 |
adhd bipolar | #2 |
adult samples | #2 |
hyperactivity impulsiveness | #2 |
families schizophrenia patients | #2 |
familial trait | #2 |
galantamine hbr | #2 |
comparison probands | #2 |
acpts | #2 |
spectrum phenotypes | #2 |
adhd assessed | #2 |
deficits adults | #2 |
≥210 | #2 |
trauma adhd | #2 |
schizotypy handedness | #2 |
nonpsychotic relatives | #2 |
assessed structured | #2 |
candidate genetic pathways | #2 |
probands | #2 |
adhd case subjects | #2 |
genome‐wide association scan | #2 |
add probands | #2 |
child comorbidity | #2 |
deficits executive | #2 |
unweighted screener asrs | #2 |
female probands | #2 |
expert clinician | #2 |
lallele homozygotes | #2 |
clinically referred children | #2 |
adhd emotional symptoms | #2 |
comorbid conduct | #2 |
models adhd | #2 |
comorbidity panic disorder | #3 |
impulsivity errors | #3 |
desr | #3 |
networks adhd | #3 |
n2323 | #3 |
pdd adhd | #3 |
9rcarriers | #3 |
experienced pain | #3 |
temperamental correlates | #3 |
vcfsadhd | #3 |
atomoxetine response | #3 |
anxiety behavioral inhibition | #3 |
md females | #3 |
dmi addh | #3 |
reln promoter | #3 |
abstraction verbal memory | #3 |
common disorders brain | #3 |
bipolar disease | #3 |
adhd mtbi | #3 |
substance disorders adhd | #3 |
prenatal adversities | #3 |
cigarette smoking children | #3 |
n5827 | #3 |
dsmiiir diagnosis | #3 |
sirolimus 12 months | #3 |
sibling trait | #3 |
candidate gene studies | #3 |
deficits height | #3 |
studies square | #3 |
zakzanis | #3 |
substances symptoms | #3 |
ocd groups asd | #3 |
disabilities male | #3 |
subjects sud | #3 |
longitudinal follow | #3 |
z280 | #3 |
checklist cbcl | #3 |
model adhd | #3 |
hyperactivity central | #3 |
brain methylation | #3 |
mania children | #3 |
simulated workplace laboratory | #3 |
drd4 7 | #3 |
amphetamines attention | #3 |
adhd presence | #3 |
similarities genetic etiology | #3 |
27 risk loci | #3 |
methylphenidate studies | #3 |
cpt deficits | #3 |
interactions schizophrenia | #3 |
adhd ptsd | #3 |
children vcfsadhd | #3 |
emotional dysregulation adhd | #3 |
disproportionate impairment | #3 |
gsprs | #3 |
global neuroscience decade | #3 |
enuresis adhd | #3 |
probands parental | #3 |
disease humans interviews | #3 |
adhdpi | #3 |
parents panic | #3 |
schizoaffective bipolar disorder | #3 |
adhd systematic review | #3 |
adhd implications | #3 |
impairment adhd | #3 |
genetics initiative | #3 |
weight effects | #3 |
genetic receptors serotonin | #3 |
enigma neuroimaging genetics | #3 |
comorbidities adhd | #3 |
clinically referred adults | #3 |
teacher reports | #3 |
7 repeat | #3 |
adhd metaanalysis | #3 |
relatives proband groups | #3 |
smds scz | #3 |
sexdifferentiated effects | #3 |
adhd psychiatric comorbidity | #3 |
schizophrenia neurocognitive performance | #3 |
psychiatric comorbidity adhd | #3 |
hyperactivity bipolar | #3 |
controls 6 disorders | #3 |
sud youths | #3 |
disorder conduct | #3 |
conduct disorder adhd | #3 |
asrs v11 | #3 |
deficient emotional | #3 |
sud offspring | #3 |
cgsq | #3 |
excess transmission | #3 |
inattentive subtype | #3 |
schizophrenia genotype | #3 |
european‐american | #3 |
smoking probands | #3 |
nicotine disorders | #3 |
bipolar psychoses | #3 |
anxiety disorders authors | #3 |
learning disabilities adhd | #3 |
vulnerability indicators | #3 |
npl scores | #3 |
risk factors sud | #3 |
nervous stimulants | #3 |
mania disorders | #3 |
children adhd | #3 |
morbidity risk | #3 |
qtl linkage | #3 |
potential gene | #3 |
relatives persons | #3 |
large battery | #3 |
adhd emotional | #3 |
“negativity | #3 |
disorders conclusions | #3 |
non500 | #3 |
variance severity | #3 |
neurological polymorphism | #3 |
adhd common | #3 |
n2271 | #3 |
parents panic disorder | #3 |
adhd mania | #3 |
international adhd | #3 |
morning school | #3 |
rs6565113 | #3 |
nonpsychotic relatives persons | #3 |
enigma global neuroscience | #3 |
psychopathologic conditions | #3 |
drd5 marker | #3 |
association confounders | #3 |
schizophrenia schizotaxia | #3 |
intra‐individual variability | #3 |
intron13 | #3 |
oprm1 variants | #3 |
adhd bipolar disorder | #3 |
anxiety disorders parents | #3 |
adhd wm deficits | #3 |
sud children | #3 |
snps haplotype | #3 |
ldx amphetamine | #3 |
firstdegree relatives | #3 |
faraone reply | #3 |
social perception skills | #3 |
schizophrenia allele | #3 |
chromosome 10q22 | #3 |
mtbi studies | #3 |
lambdasib | #3 |
schizotaxia | #3 |
metadoxine extended release | #3 |
alcohol adhd | #3 |
adolescents mania | #3 |
n1777 | #3 |
resilience score | #3 |
major depression comorbidity | #3 |
comt adhd | #3 |
cbcl scales | #3 |
htr1e | #3 |
adhd stimulant medication | #3 |
children mania | #3 |
predisposition schizophrenia | #3 |
adhd control | #3 |
observed age | #3 |
comt promoter | #3 |
defined adhd | #3 |
impact adhd | #3 |
67e07 | #3 |
dose response effects | #3 |
familial nature | #3 |
highly heritable disorder | #3 |
neuropsychiatric disorders similarities | #3 |
topic adolescent | #3 |
parental substance disorders | #3 |
adhd data | #3 |
adhd rare cnvs | #3 |
girls attention | #3 |
psychotic behaviour | #3 |
relationship adhd | #3 |
nmu prescription stimulants | #3 |
adhd mdd | #3 |
tic disorders adhd | #3 |
lbw adhd | #3 |
manic symptoms youth | #3 |
structural imaging findings | #3 |
youths ocd | #3 |
educational deficits | #3 |
hyperactivity attention | #3 |
comorbidity diagnosis | #3 |
508e7 | #3 |
siblings young | #3 |
adhd pairwise correlations | #3 |
familial risk factors | #3 |
adult psychiatric outcomes | #3 |
adhd mental disorders | #3 |
disorder comorbid | #3 |
adhd polygenic | #3 |
ptsd adhd | #3 |
notch4 schizophrenia | #3 |
remittent | #3 |
wonderlic personnel test | #3 |
cortical thickness cases | #3 |
asthma adhd | #3 |
bpd rates | #3 |
evidence genetic association | #3 |
children adhd diagnosis | #3 |
adhd combined type | #3 |
stimulants treatment | #3 |
dat1 | #3 |
enigma wgs wgs | #3 |
cognition comorbidity | #3 |
md adhd | #3 |
childhood attention‐deficit | #3 |
caarsss | #3 |
adhd risk | #3 |
adhd comorbid conditions | #3 |
ermph | #3 |
relatives bipolar disorder | #3 |
manic symptoms children | #3 |
drug nicotine | #3 |
petronis | #3 |
schizophrenic outpatients | #3 |
asd ocd groups | #3 |
adhd psud | #3 |
persistence psychiatric disorders | #3 |
adolescent adhd | #3 |
naltrexone methylphenidate | #3 |
13q222 | #3 |
pairwise correlations disorders | #3 |
7repeat allele | #3 |
control probands relatives | #3 |
tsuang | #3 |
growth deficits | #3 |
response methylphenidate | #3 |
syndromatic | #3 |
risk panic | #3 |
psc35 | #4 |
schizophrenia genetic factors | #4 |
health female | #4 |
lgi age | #4 |
presence adhd | #4 |
neuropsychological performance schizophrenia | #4 |
4th international meeting | #4 |
motor coordination problems | #4 |
rates psychiatric | #4 |
cbcljbd phenotype | #4 |
independent transmission | #4 |
remittent adhd | #4 |
offspring sud | #4 |
distinct disorder | #4 |
bpd sud bpd | #4 |
lifetime dimensions | #4 |
d4s1644 | #4 |
mhlod | #4 |
achievement goal orientation | #4 |
rs1079727 | #4 |
adhd md | #4 |
rate switching | #4 |
selenbp1 schizophrenia | #4 |
findings risk | #4 |
adhd adulthood | #4 |
functioning adhd | #4 |
enrichment adhd | #4 |
adhd participants | #4 |
hemmings | #4 |
expected height | #4 |
relatives controls | #4 |
openlabel studies | #4 |
risk factors bpd | #4 |
adhd association | #4 |
odd adhd | #4 |
sd133 | #4 |
addictive drug | #4 |
panic disorder pregnancy | #4 |
poor motor performance | #4 |
4year followup | #4 |
reported adhd | #4 |
differences adults | #4 |
d4s2361 | #4 |
quantitative phenotype | #4 |
cbclaps | #4 |
rutters indicators | #4 |
substance disorders suds | #4 |
growing literature | #4 |
comorbid psychiatric | #4 |
adhd substance abuse | #4 |
onset adhd | #4 |
global neuroscience | #4 |
psychiatrically referred youth | #4 |
inhibition anxiety | #4 |
adhd status | #4 |
safren | #4 |
md individuals | #4 |
objective studies | #4 |
genetic heterogeneity schizophrenia | #4 |
handedness schizotypy | #4 |
jbd | #4 |
comorbid attention | #4 |
behavior checklist | #4 |
height deficits | #4 |
adhd pdd | #4 |
enigmaadhd | #4 |
reward dysfunction | #4 |
46222 | #4 |
stimulantnaïve | #4 |
vcfs adhd | #4 |
fmri replication | #4 |
adults | #4 |
snps intelligence | #4 |
female probands relatives | #4 |
suds adolescents | #4 |
nonoral routes administration | #4 |
reported findings | #4 |
support mechanism | #4 |
scores adhd | #4 |
subsequent substance disorders | #4 |
adhd based | #4 |
disorders comorbidity | #4 |
gxr adhd | #4 |
vulnerability schizophrenia | #4 |
rs3916968 | #4 |
relatives normal controls | #4 |
receiver operator characteristic | #4 |
disorders attention | #4 |
homogeneous subtypes | #4 |
pord05 | #4 |
adolescent outcome | #4 |
notch4 locus | #4 |
gender children | #4 |
anxiety disorders offspring | #4 |
comorbidity humans | #4 |
boys higher prevalence | #4 |
executive function deficits | #4 |
secondary psychotic symptoms | #4 |
risk factors adhd | #4 |
treatment adult adhd | #4 |
asd mood disorders | #4 |
intelligence snps | #4 |
treatment seeking patients | #4 |
primary substance abuse | #4 |
maoa | #4 |
adderall methylphenidate | #4 |
anxiety disorders mdd | #4 |
impaired intellect | #4 |
metadoxine placebo | #4 |
comorbid aggression adhd | #4 |
preterm sample | #4 |
rs140700 | #4 |
children comorbid adhd | #4 |
mts growth | #4 |
adhd symptom | #4 |
strattera | #4 |
risk variants adhd | #4 |
deficits executive functioning | #4 |
adhd youth | #4 |
child behavior checklist | #4 |
total score week | #4 |
developmental improvement | #4 |
attention adhd | #4 |
rs3916971 | #4 |
adhd pharmacogenetic studies | #4 |
adolescent years | #4 |
time reproduction | #4 |
acting formulations | #4 |
aggregation adhd | #4 |
sud bpd sud | #4 |
rels | #4 |
adhd control children | #4 |
bipolar disorder linkage | #4 |
adhd brain regions | #4 |
maternal smoking alcohol | #4 |
hypescheme | #4 |
factors substance | #4 |
adhd children mph | #4 |
disorders panic | #4 |
controls basal ganglia | #4 |
choice adhd | #4 |
pavgrnk000417 | #4 |
shr ncrl | #4 |
quantitative models | #4 |
disorders neuropsychological | #4 |
increased neural responses | #4 |
depression parental depression | #4 |
transporter genotypes | #4 |
adhd reported | #4 |
risk gene schizophrenia | #4 |
phenotypes adhd | #4 |
adhd pharmacotherapy | #4 |
subjects schizotaxia | #4 |
adhd etiology | #4 |
adhd controls | #4 |
coordination problems | #4 |
treatment adhd | #4 |
families girls | #4 |
adhd neuropsychological performance | #4 |
familial vulnerability | #4 |
pediatric mania | #4 |
chinese sample | #4 |
psychiatrically referred | #4 |
psychiatric comorbidity risk | #4 |
rs3785143 | #4 |
report scale | #4 |
image sample | #4 |
disorder objective | #4 |
psud | #4 |
disease genome humans | #4 |
metaanalyzes | #4 |
roh risk | #4 |
vcfs sample | #4 |
cbcl | #4 |
treatment stimulant medication | #4 |
inattentive adhd | #4 |
rutter | #4 |
psychiatric gene discoveries | #4 |
adhd impairments | #4 |
neuropsychoanalytic | #4 |
parents bpd | #4 |
adhd individuals | #4 |
angerirritability | #4 |
snpbased | #4 |
bpd sud patients | #4 |
tests psychiatric | #4 |
adhd subgroups | #4 |
17q111q12 | #4 |
parental panic | #4 |
subthreshold | #4 |
humans lisdexamfetamine | #4 |
ascertainment source | #5 |
female individuals | #5 |
grubb | #5 |
referred children | #5 |
xr adults | #5 |
checklist child | #5 |
disorder sud | #5 |
3 probands | #5 |
pleiotropic effects disorders | #5 |
oppositional defiant disorder | #5 |
growth dysregulation | #5 |
diagnosis mania | #5 |
severe scores | #5 |
adhd inattentive type | #5 |
organization adult | #5 |
adhdlike symptoms | #5 |
clinical obesity | #5 |
familial risk adhd | #5 |
screener | #5 |
disorder genetic | #5 |
elevated rates | #5 |
disorder rating | #5 |
dsm age | #5 |
ncrl rats | #5 |
kiddieschedule | #5 |
methylphenidate adults | #5 |
impairment baseline | #5 |
bipolar disorder pedigrees | #5 |
adhd nonaffected siblings | #5 |
disorder anxiety | #5 |
disorders follow | #5 |
hyperactivity clinical trials | #5 |
height weight | #5 |
intellectually capable adults | #5 |
adults adult | #5 |
nt5dc1 | #5 |
multivariate endophenotypes | #5 |
adult probands | #5 |
nonaffected siblings | #5 |
risk relatives | #5 |
shared haplotypes | #5 |
children ldx | #5 |
depression panic disorder | #5 |
behavioral inhibition children | #5 |
adhd youths | #5 |
sud | #5 |
d22s683 | #5 |
serum neuroleptic | #5 |
bipolar disorder bpd | #5 |
sms intervention | #5 |
risk anxiety | #5 |
disorders psychiatric | #5 |
child child behavior | #5 |
initial responsiveness | #5 |
ppp3cc schizophrenia | #5 |
conventional medications | #5 |
adhd comorbid anxiety | #5 |
iiv adhd | #5 |
cbcl data | #5 |
adhd tic disorders | #5 |
referred youths | #5 |
onset criterion | #5 |
inattentive symptoms | #5 |
nonmedical nmu | #5 |
psychosis scale | #5 |
adhd adult | #5 |
unipolar mdd | #5 |
impaired parents humans | #5 |
hechtman | #5 |
dopamine risk | #5 |
children dbds | #5 |
psychiatric disorders study | #5 |
wcst scores | #5 |
asrs screener | #5 |
social disability | #5 |
neuropsychiatric comorbidity | #5 |
desipramine placebo | #5 |
familial distribution | #5 |
criteria schizotaxia | #5 |
maternal reports | #5 |
disorder parents | #5 |
etiopathologies | #5 |
pathways association | #5 |
hyperactivity caregivers | #5 |
referred sample | #5 |
risk factors schizophrenia | #5 |
adhd treated | #5 |
panic disorder parents | #5 |
youth vcfs | #5 |
impairment survey | #5 |
adult attention | #5 |
anxiety disorders anx | #5 |
parental sud | #5 |
2nd cohort | #5 |
kuntsi | #5 |
schizophrenia palau | #5 |
mood disorders asd | #5 |
parents psychiatric | #5 |
adhd bupropion | #5 |
relatives female probands | #5 |
effects adhd | #5 |
prembr | #5 |
pdd subjects | #5 |
palauan | #5 |
psychiatric correlates | #5 |
comorbid disorders | #5 |
function adhd | #5 |
study genetic factors | #5 |
major depression parents | #5 |
psychosis velocardiofacial syndrome | #5 |
oosterlaan | #5 |
adhd cases | #5 |
highly heritable | #5 |
puwma | #5 |
cardinal symptom | #5 |
sex adhd | #5 |
lifetime impact | #5 |
adolescence adhd | #5 |
aagc | #5 |
desistent | #5 |
interview psychological | #5 |
adhd ld | #5 |
memantine hydrochloride | #5 |
zmynd17 | #5 |
resilience project | #5 |
year prospective | #5 |
large collaborative study | #5 |
parental adhd | #5 |
tass | #5 |
torture review | #5 |
symptoms hyperactivity | #5 |
scale adhd | #5 |
mania adhd | #5 |
mothers anxiety disorders | #5 |
adhd response | #5 |
pdmd | #5 |
boys attention | #5 |
neuropsychological risk | #5 |
proband risk | #5 |
combined subtype | #5 |
humans interview | #5 |
auditory vigilance | #5 |
adolescent alleles | #5 |
3q13 | #5 |
rs1799836 | #5 |
report screening | #5 |
genetic linkage schizophrenia | #5 |
inhibited children | #5 |
familial subtypes | #5 |
prevalence adult adhd | #6 |
scales psychometrics | #6 |
irmph | #6 |
disorders adolescent | #6 |
combined condition | #6 |
depression panic | #6 |
environmental adversity | #6 |
hyperactivity child chromosomes | #6 |
seidman | #6 |
bpd comorbid | #6 |
specific predictor | #6 |
bpd controls | #6 |
facial memory | #6 |
risk sud | #6 |
behavioral inhibition | #6 |
paternal age schizophrenia | #6 |
psychopathology children | #6 |
stimulant treatment children | #6 |
symptoms adhd | #6 |
risk attention | #6 |
followup studies | #6 |
chromosome 15 locus | #6 |
oppositional defiant | #6 |
males adhd | #6 |
prior stimulant treatment | #6 |
t515 | #6 |
literature efficacy | #6 |
teenage parenthood | #6 |
adults disorder | #6 |
altered neural connectivity | #6 |
hierarchical factor model | #6 |
oceanic palau | #6 |
familial loadings | #6 |
pediatric bpd | #6 |
parents major | #6 |
premorbid cognitive ability | #6 |
driving simulation | #6 |
disorder combined | #6 |
t518 | #6 |
adhd children adults | #6 |
cognition adults | #6 |
ppp3cb | #6 |
cognitive impairments adhd | #6 |
individual alleles | #6 |
niacin schizophrenia | #6 |
genetic linkage genome | #6 |
pavgrnk | #6 |
4634 | #6 |
groups adults | #6 |
adhd variability | #6 |
unfamiliar situations | #6 |
p1e04 | #6 |
male odds | #6 |
tmcq | #6 |
psychiatric disorders prss | #6 |
adhd tic | #6 |
year recall | #6 |
total gray matter | #6 |
symptoms disorder | #6 |
referred adults | #6 |
psychoactive substance | #6 |
maniclike symptoms | #6 |
cpg sites methylation | #6 |
liability schizophrenia | #6 |
neuroleptic activity | #6 |
objective marker | #6 |
genome‐wide | #6 |
enigma wgs | #6 |
adhd life | #6 |
parental major depression | #6 |
value09 | #6 |
schizophrenic probands | #6 |
differences cortical thickness | #6 |
adhd mood disorders | #6 |
benefitrisk ratio | #6 |
adhd genetic factors | #6 |
dopamine transporter gene | #6 |
schizophrenia spectrum schizophrenia | #6 |
nonparanoid schizophrenia | #6 |
bpdsud | #6 |
normal sexual dimorphism | #6 |
large heterogeneous | #6 |
clinical features children | #6 |
relatives probands | #6 |
pseudocontrols | #6 |
nhe inhibitors | #6 |
association studies schizophrenia | #6 |
downward extension | #6 |
loci autism | #6 |
schizophrenia premorbid | #6 |
druggable genome | #6 |
adhdia | #6 |
placebo response response | #6 |
schizophrenia deficit | #6 |
dnajc9 | #6 |
clinical scales | #6 |
wm performance patients | #6 |
dsm iii | #6 |
nmu | #6 |
stimulant prescription | #6 |
psychiatric | #6 |
adhd compared | #6 |
140 children | #6 |
pediatric bipolar | #6 |
criteria adhd | #6 |
adhd increased risk | #6 |
vulnerability indicator | #6 |
pediatric mood disorders | #6 |
mixed amphetamine | #6 |
adhd firstdegree relatives | #6 |
hyperactivity disease models | #6 |
referred children adolescents | #6 |
life adults | #6 |
fspd | #6 |
adhd women | #6 |
neuropsychological functioning | #6 |
anxiety disorder relatives | #6 |
children relatives | #6 |
gxr efficacy | #6 |
females adhd | #6 |
xp114p113 | #6 |
cbcljbd | #6 |
concurrent validation | #6 |
ascertained | #6 |
taan | #6 |
child delayed | #6 |
interpreting estimates | #6 |
disorders relatives | #6 |
schizophrenia g72 | #6 |
genetic child | #6 |
combined subtypes | #6 |
adhd mental retardation | #6 |
nmu prescription | #7 |
pdqr | #7 |
myosin5b | #7 |
asd youth | #7 |
controls probands | #7 |
relatives risk | #7 |
dimensional measures | #7 |
hyperactivity brain | #7 |
adhd symptoms | #7 |
teachers boys | #7 |
exon15 | #7 |
genome‐wide association | #7 |
palauans | #7 |
kgas | #7 |
velo‐cardio‐facial | #7 |
methylomics | #7 |
outpatient child | #7 |
asd asd youth | #7 |
adhd substance disorders | #7 |
long repeats | #7 |
adhd authors | #7 |
adhd sud sud | #7 |
attention task | #7 |
saica | #7 |
tomoxetine | #7 |
adhd criteria | #7 |
hraff | #7 |
parents prevalence | #7 |
methylphenidate therapy | #7 |
members schizophrenia | #7 |
odd | #7 |
combined type adhd | #7 |
persistence anxiety disorders | #7 |
mdd pdag | #7 |
adhd boys girls | #7 |
adhd symptoms association | #7 |
markov chain analysis | #7 |
spn812 | #7 |
pmee | #7 |
idir | #7 |
children learning disorders | #7 |
qlesqsf | #7 |
n1031 | #7 |
development adhd | #7 |
implicating | #7 |
snap25 adhd | #7 |
haplotype schizophrenia | #7 |
nalysis | #7 |
authors goal | #7 |
ancestry attention | #7 |
polygenic scores adhd | #7 |
ldx treatment | #7 |
measures adhd | #7 |
parent reports | #7 |
locus haplotypes | #7 |
parents psychiatric disorders | #7 |
exome chip analyses | #7 |
disorders probands | #7 |
adhd overweight obesity | #7 |
candidate gene schizophrenia | #7 |
coming years | #7 |
skin flush response | #7 |
prevention schizophrenia | #7 |
children bpd | #7 |
pdag mdd | #7 |
statistical measure | #7 |
flush response | #7 |
adhdct | #7 |
mph adhd | #7 |
6 psychiatric disorders | #7 |
relatives schizophrenic patients | #7 |
highrisk siblings | #7 |
association cdh13 | #7 |
adhd improvement | #7 |
childhood disorder | #7 |
adhd asrs | #7 |
studies dopamine | #7 |
sensorimotor timing | #7 |
mph adhd adults | #7 |
dependence rates | #7 |
conduct disorder girls | #7 |
nrp104 | #7 |
neurocognitive performances | #7 |
swedish registry data | #7 |
confusability | #7 |
chromosome workshop | #7 |
seeking substance | #7 |
adhd persistence | #7 |
children tourettes syndrome | #7 |
disorder substance | #7 |
child impaired | #7 |
bipolar unipolar disorders | #7 |
drd5 | #7 |
boys adhd | #7 |
pediatric major depression | #7 |
adhdrs | #7 |
neuroimage study | #7 |
adhd emotional dysregulation | #7 |
wonderlic | #7 |
systematic chart review | #7 |
adhd stimulant | #8 |
adhd manic symptoms | #8 |
probands risk | #8 |
therapeutic dilemmas | #8 |
polygenic associations | #8 |
biological relatives | #8 |
crossover comparison | #8 |
control adhd | #8 |
adhd rtv | #8 |
negative symptoms scale | #8 |
pempirical | #8 |
prescription stimulant | #8 |
childhood mania | #8 |
volumetric reductions | #8 |
attention deficit adhd | #8 |
onset bpd | #8 |
gender effects | #8 |
ordered subsets | #8 |
symptoms behaviors | #8 |
offspring trios | #8 |
controls relatives | #8 |
adhd associations | #8 |
euphoria | #8 |
avoidant disorder | #8 |
biederman | #8 |
pliszka | #8 |
subjects children | #8 |
mwq | #8 |
sample youth | #8 |
n1314 | #8 |
adhd inattentive | #8 |
rs3916965 | #8 |
adhd adolescence | #8 |
child diagnostic | #8 |
analysis association | #8 |
adhd boys | #8 |
behavioral inhibition risk | #8 |
aversion adhd | #8 |
autistic traits children | #8 |
behavior attention | #8 |
diagnosed adhd | #8 |
shared familial effects | #8 |
adhd symptom scores | #8 |
chromosome schizophrenia | #8 |
disorders families | #8 |
male multifactorial inheritance | #8 |
treatment lead | #8 |
multigenerational pedigree | #8 |
studies provide | #8 |
adhd dat1 | #8 |
promising directions | #8 |
human aggression | #8 |
disease humans polymorphism | #8 |
dimesylate ldx | #8 |
schizophrenia polymorphisms | #8 |
familybased association study | #8 |
schizophrenia members | #8 |
attention | #8 |
behavioral inhibition anxiety | #8 |
affairs cooperative | #8 |
cadhd | #8 |
adhd unaffected | #8 |
nonpsychotic | #8 |
impaired motor performance | #8 |
treatment sirolimus | #8 |
indicators schizophrenia | #8 |
bpd disorders | #8 |
10q223 | #8 |
substantial evidence | #8 |
diagnosis major depression | #8 |
presence autistic traits | #8 |
participants adhd | #8 |
agreement measures | #8 |
notch4 | #8 |
familial aggregation adhd | #8 |
unaffected siblings adhd | #8 |
metaanalysis schizophrenia | #8 |
link adhd | #8 |
hemideletion | #8 |
rs3916966 | #8 |
abbreviated questionnaire | #8 |
disorder probands | #8 |
adhdcd | #8 |
nonverbal social | #8 |
disorders baseline | #8 |
mph adults | #8 |
adhd remission | #8 |
impulsivity adhd | #8 |
adhdhi | #8 |
stimulanttreated | #8 |
psychiatric genomics | #8 |
symptoms impairment | #8 |
pvalues005 | #8 |
differential utility | #8 |
gwas psychiatric disorders | #9 |
schizophrenia resilience | #9 |
rasd2 | #9 |
deficit disruptive | #9 |
dao gene | #9 |
endophenotypic | #9 |
rpdr | #9 |
haplotype snps | #9 |
adhd article | #9 |
orosmph irmph | #9 |
hhrr | #9 |
adult report | #9 |
25e07 | #9 |
serotonin gene polymorphisms | #9 |
genes risk factors | #9 |
nonparanoids | #9 |
schizotaxic | #9 |
disorders sex interaction | #9 |
n41 | #9 |
moderate sensitivity | #9 |
addh | #9 |
adhd loci | #9 |
alzheimer disease schizophrenia | #9 |
blindly | #9 |
serotonin genes | #9 |
inattentive | #9 |
comparison girls | #9 |
ldps | #9 |
proband groups | #9 |
rs685012 | #9 |
pregnancy depression | #9 |
symptoms mania | #9 |
extendedrelease methylphenidate | #9 |
substantial risk | #9 |
aisrs | #9 |
sud bipolar disorder | #9 |
hum genet | #9 |
mdd youth | #9 |
adhdi | #9 |
hyperactivity humans | #9 |
adult symptoms | #9 |
adhd healthy | #9 |
etiologically | #9 |
lag sequential analysis | #9 |
neuropsychologic function | #9 |
nonreplications | #9 |
depression offspring | #9 |
diagnostic efficiency | #9 |
stimulant medication | #9 |
childhood psychosis | #9 |
taiwanese families | #9 |
hyperactivity automobile | #9 |
male nuclear | #9 |
nuremberg code | #9 |
snp7 | #9 |
adderall | #9 |
netherlands twin registry | #9 |
comorbidity female | #9 |
ecpbhs | #9 |
ads individuals | #9 |
39 datasets | #9 |
children assessed | #9 |
subtypes adhd | #9 |
festschrift | #9 |
adhd enuresis | #9 |
disruptive behavior disorders | #9 |
g×s interaction disorders | #9 |
sustained attention schizophrenia | #9 |
genetics network | #10 |
bipolar disorder probands | #10 |
parent‐of‐origin effects | #10 |
diminished risk | #10 |
rorb | #10 |
disorder age | #10 |
evidence genetic | #10 |
panic depression | #10 |
comorbid bpd | #10 |
sexual dimorphisms | #10 |
stimulants humans | #10 |
d4 receptor gene | #10 |
aged attention | #10 |
slod | #10 |
shared neurobiology | #10 |
image project | #10 |
adhd sud | #10 |
adhd difficulties | #10 |
rates abuse | #10 |
stimulants child | #10 |
noninhibited | #10 |
reassessed | #10 |
sleep problems adhd | #10 |
cbclap | #10 |
dms1 | #10 |
comorbidity depressive | #10 |
asd tourette syndrome | #10 |
conduct disorder | #10 |
linkage analyses | #10 |
caadid | #10 |
normal sexual | #10 |
irmph orosmph | #10 |
systematic qualitative review | #10 |
nonpharmacologic treatments | #10 |
comorbidity | #10 |
adult years | #10 |
psychiatric clinic | #10 |
groups boys | #10 |
preteen | #10 |
new specialty | #10 |
ascertainment methods | #10 |
nephews | #10 |
deficits adhd | #10 |
adhd substance disorder | #10 |
amphetamine salts | #10 |
adulthood association | #10 |
association dat1 | #10 |
4th | #10 |
small effects | #10 |
adhd quality | #10 |
drd4 | #10 |
childhood adhd symptoms | #10 |
risk md | #10 |
genetic vulnerability schizophrenia | #10 |
gwas adhd | #10 |
comorbid odd | #10 |
case identification | #10 |
psychiatric genetic studies | #10 |
untreated adhd | #10 |
genes disorders | #10 |
adhd unaffected siblings | #10 |
young adult outcome | #10 |
kruglyak | #10 |
severity adhd | #10 |
probands bpd | #10 |
anxiety disorders children | #10 |
association death | #10 |
preschool depressive | #10 |
pthreshold | #10 |
adhd childhood | #10 |
female relatives | #11 |
offspring bipolar parents | #11 |
panic disorder comorbidity | #11 |
disorders mothers | #11 |
effects genes | #11 |
n136 | #11 |
disorder pedigrees | #11 |
juvenile mania | #11 |
adhd time | #11 |
differentiated genetic | #11 |
4372 | #11 |
polymorphism 5 | #11 |
adhd female humans | #11 |
studies mtbi | #11 |
inhibition adhd | #11 |
attention deficit disorder | #11 |
adhd onset | #11 |
paternal smoking | #11 |
dimesylate | #11 |
release methylphenidate | #11 |
ldx placebo | #11 |
children bipolar | #11 |
achievement adolescent | #11 |
shared familial | #11 |
prodromal psychosis | #11 |
agoraphobia anxiety | #11 |
fbatpc | #11 |
hyperactivity child cross | #11 |
remission adhd | #11 |
real progress | #11 |
growth delays | #11 |
neuropsychological test scores | #11 |
familybased association test | #11 |
ppp3cc | #11 |
maternal antenatal anxiety | #11 |
adhd substance | #11 |
lisdexamfetamine ldx | #11 |
diagnosis adults | #11 |
defiant disorder | #11 |
adult relatives | #11 |
vcfs | #11 |
differences adhd | #11 |
markers adhd | #11 |
adolescents adhd | #11 |
hydrochloride attention | #11 |
comorbidity patterns | #11 |
inattentive type | #11 |
etiology pathophysiology | #11 |
serotonin genetic receptor | #11 |
rs1137070 | #11 |
gene adhd | #11 |
informativeness | #11 |
cardinal symptoms | #11 |
symptom subtype | #11 |
adhd psychopathology | #11 |
deficits schizophrenia patients | #11 |
psychiatric disorders youth | #11 |
rora rorb | #11 |
major depression adhd | #11 |
study perspective | #11 |
adhd intellectual disability | #11 |
youth bpd | #11 |
cutraits | #11 |
nonadhd controls | #11 |
sample adults | #11 |
children addh | #11 |
preschool depressive disorder | #11 |
differences parents | #11 |
multiple domains | #11 |
nosologists | #11 |
disorders | #11 |
disease humans schizophrenia | #11 |
pediatric bipolar disorder | #11 |
shr model | #11 |
dopamine d5 receptors | #11 |
psychotic behavior | #12 |
symptom rating | #12 |
genes methylation | #12 |
treatment attention | #12 |
disorder adult | #12 |
psychiatric clinics | #12 |
comorbidity diagnostic | #12 |
nhe9 | #12 |
unaffected sibs | #12 |
perceived motor competence | #12 |
psychiatric genetics | #12 |
adhd dopamine | #12 |
girls relationship | #12 |
adhd age | #12 |
sec23ip | #12 |
systematized | #12 |
unaffected siblings individuals | #12 |
ksadse | #12 |
epilepsy mothers | #12 |
test wcst | #12 |
probands siblings | #12 |
rs778293 | #12 |
juvenile bipolar | #12 |
adhd core symptoms | #12 |
response atomoxetine | #12 |
kappa coefficients | #12 |
cbcl children | #12 |
striatal sensitivity | #12 |
sexually dimorphic effects | #12 |
functional impairments | #12 |
obesity risk alleles | #12 |
hawi | #12 |
n1397 | #12 |
lossavoidance | #12 |
twins humans models | #12 |
digital treatment | #12 |
convergent functional | #12 |
sample consisted | #12 |
impaired parents | #12 |
impulsivity children | #12 |
impaired parents child | #12 |
rs947267 | #12 |
adhd symptoms adults | #12 |
youths bpd | #12 |
common disorders | #12 |
variable age | #12 |
comorbid disorder | #12 |
pleiotropic mechanisms | #12 |
40–48 | #12 |
disorder subjects | #12 |
treatment paliperidone | #12 |
cnvs risk | #12 |
covid19 restrictions children | #12 |
assessment adhd | #12 |
dat1 polymorphism | #12 |
stimulant medication children | #12 |
amfetamine | #12 |
neurocognitive measures | #12 |
obesity adhd | #12 |
studies relatives | #12 |
scales treatment | #12 |
metan | #12 |
effects time | #12 |
thalamic activation | #12 |
onelevel | #12 |
psychotic mood disorders | #12 |
adult outcome | #12 |
salts extended | #12 |
deficits attention | #12 |
early psychosis study | #12 |
nonoral | #12 |
multiplex schizophrenia | #12 |
defiant | #12 |
adhd offspring | #12 |
sud patients adhd | #12 |
sud adhd | #12 |
adolescent adult age | #12 |
common psychiatric | #12 |
adhd alterations | #13 |
disorder childhood | #13 |
methods subjects | #13 |
nonoral routes | #13 |
chi12 | #13 |
necrotic death | #13 |
ravg | #13 |
colorado springs | #13 |
psychiatric risk | #13 |
iiv | #13 |
studies bipolar | #13 |
diagnostic concepts | #13 |
male samples | #13 |
response inhibition adolescents | #13 |
label studies | #13 |
familial risk schizophrenia | #13 |
disorders child | #13 |
risk parents | #13 |
overanxious | #13 |
longallele | #13 |
adhdodd | #13 |
risk mood | #13 |
robust effects | #13 |
psychometrics reproducibility | #13 |
taiwanese sample | #13 |
genomewide significance | #13 |
velocardiofacial syndrome vcfs | #13 |
girls | #13 |
bpd offspring | #13 |
persistence remission | #13 |
humans methylphenidate | #13 |
disorder youth | #13 |
adhd diagnosis | #13 |
adhd alcohol | #13 |
specific hypotheses | #13 |
pkcm | #13 |
disorders sud | #13 |
rates comorbidity | #13 |
114 years | #13 |
transdermal methylphenidate | #13 |
environment adolescent | #13 |
permutation testing | #13 |
psychometric measure | #13 |
cognitive impulsivity | #13 |
adhd cognitive | #13 |
scale studies | #13 |
adderall mph | #13 |
diagnostic threshold | #13 |
convergent functional genomics | #13 |
pair 6 chromosomes | #13 |
late onset | #13 |
adverseevents | #13 |
weight bmi | #13 |
symptoms attention | #13 |
psychotic mood | #13 |
morbidity risks | #13 |
aadhd | #14 |
subcortical brain volume | #14 |
siblings cases | #14 |
comorbid condition | #14 |
attention executive | #14 |
lisdexamfetamine dimesylate ldx | #14 |
teachers reports | #14 |
genes schizophrenia | #14 |
bipolar probands | #14 |
nimh genetics | #14 |
disorder odd | #14 |
adhd phenotype | #14 |
early precursors | #14 |
n643 | #14 |
familial disorder | #14 |
differential heritability | #14 |
relatives male probands | #14 |
hillside | #14 |
children criteria | #14 |
associations adhd | #14 |
common disorder | #14 |
cautiously | #14 |
suds | #14 |
prss mdd | #14 |
older adults adhd | #14 |
factors schizophrenia | #14 |
mph adderall | #14 |
sud patients | #14 |
stimulant abuse | #14 |
symptoms psychiatric disorders | #14 |
worldwide prevalence | #14 |
cnvs park2 | #14 |
economic psychology | #14 |
adhd symptoms adulthood | #14 |
emotional impulsivity | #14 |
diagnosis mdd | #14 |
geschwind | #14 |
lphn3 adhd | #14 |
mixed amphetamine salts | #14 |
children bipolar disorder | #14 |
genetic studies schizophrenia | #14 |
children stimulants | #14 |
disorder child | #14 |
wraadds | #14 |
quetiapine bipolar disorder | #14 |
ocd scz | #14 |
unaffected siblings controls | #14 |
studies adults | #14 |
selfcontained | #14 |
social school | #14 |
siblings probands | #14 |
disorders comorbid | #14 |
adhd brain | #14 |
rs2652511 | #15 |
mphmlr | #15 |
tests psychomotor | #15 |
sackett | #15 |
risk substance | #15 |
adults substance disorders | #15 |
poor perception | #15 |
4669 | #15 |
adhd diagnostic | #15 |
healthy comparison subjects | #15 |
disord | #15 |
adhd functional connectivity | #15 |
disorder evidence | #15 |
psychiatric interviews | #15 |
cbclpbd | #15 |
interaction genotype | #15 |
nhsd | #15 |
behavior disorders | #15 |
male relatives | #15 |
executive function theory | #15 |
daily living administration | #15 |
snps methylation | #15 |
treatment xr | #15 |
seconddegree relatives | #15 |
paediatric bipolar disorder | #15 |
genderdifferences | #15 |
pregnancy risk factor | #15 |
association schizophrenia | #15 |
symptoms adulthood | #15 |
gxr children | #15 |
adhd treatment | #15 |
agents attention | #15 |
persons schizophrenia | #15 |
prodromal symptoms psychosis | #15 |
symptom count | #15 |
adhd disorders | #15 |
bipolar schizoaffective disorder | #15 |
metabolic syndrome obesity | #15 |
substance disorder patients | #15 |
male mood | #15 |
chi2 | #15 |
adhd study | #15 |
ocd comorbid adhd | #15 |
schizophrenia families | #15 |
card sorting | #15 |
zranb2 | #15 |
adhd performance | #15 |
diagnostic interviews | #15 |
asd mdd | #15 |
study design features | #15 |
wfirsp | #15 |
velocardiofacial | #15 |
49 children | #15 |
methylation gene expression | #15 |
d10s1423 | #15 |
hyperkinetic disorders | #16 |
multiple test | #16 |
scz risk | #16 |
dexedrine | #16 |
risk psychotic disorders | #16 |
informant assessment | #16 |
adhd diagnoses | #16 |
n424 | #16 |
linkage findings | #16 |
drug disorder | #16 |
adhd anxiety symptoms | #16 |
control participants participants | #16 |
cprsr | #16 |
pervasive developmental disorder | #16 |
longitudinal assessments | #16 |
onset anticipation | #16 |
ntac | #16 |
adhd symptom severity | #16 |
factual factor analysis | #16 |
dbds | #16 |
“difficulty | #16 |
brainbody | #16 |
parents anxiety disorders | #16 |
familial relationship | #16 |
delayed action | #16 |
regional cortical thickness | #16 |
growth children | #16 |
special classes | #16 |
rdoc framework | #16 |
geneenvironment interaction | #16 |
adhd obesity | #16 |
youths adhd | #16 |
resultsfirst | #17 |
multiple anxiety disorders | #17 |
5071 | #17 |
considerable overlap | #17 |
parents adhd | #17 |
ldx children | #17 |
persistent adhd | #17 |
young offspring | #17 |
substance disorders sud | #17 |
association markers | #17 |
samples children | #17 |
hyperactivity attitude | #17 |
asd ocd | #17 |
childhood predictors | #17 |
neuropsychiatric evaluation | #17 |
method participants | #17 |
relation adhd | #17 |
mania | #17 |
nonparametric linkage | #17 |
depression md | #17 |
schizophrenia psychosis | #17 |
a161t | #17 |
prevalence adhd | #17 |
bipolar disorder subjects | #17 |
condfdr | #17 |
assessment positive symptoms | #17 |
pediatric disorder | #17 |
study adhd | #17 |
rbfox1 | #17 |
pediatric samples | #17 |
driving behaviors | #17 |
psychology schizotypal | #17 |
disability adhd | #17 |
diagnostic statistical | #17 |
ocd age | #17 |
response inhibition network | #17 |
random forest regression | #17 |
medication type | #17 |
combined type | #17 |
adulthood adhd | #17 |
association scan | #17 |
accn2 | #17 |
studies psychiatric | #17 |
larger sample | #17 |
factors siblings | #17 |
prospective follow | #17 |
bipolar choice trial | #18 |
stimulant | #18 |
illness twins | #18 |
conduct disorder children | #18 |
minisatellite repeats | #18 |
dcdq | #18 |
depression genetic risk | #18 |
schizophrenia patients relatives | #18 |
adhd sud patients | #18 |
schizophrenia dtnbp1 | #18 |
linkage regions | #18 |
lisdexamfetamine dimesylate | #18 |
childhood traumas | #18 |
meet criteria | #18 |
4286 | #18 |
children vcfs | #18 |
hrr 95 | #18 |
primary substance | #18 |
symptom overlap | #18 |
adhd severity | #18 |
fullsiblings | #18 |
marijuana age | #18 |
prolonged therapy | #18 |
unaffected siblings | #18 |
adhd groups | #18 |
anxiety mdd | #18 |
relatives control subjects | #18 |
kcnj4 | #18 |
unemotionality | #18 |
neuropsychologic | #18 |
operationalized | #18 |
transporter gene | #18 |
single nucleotide severity | #18 |
potential contributor | #18 |
behavior scale | #18 |
risk disorders | #18 |
poor tolerability | #18 |
low dose naltrexone | #18 |
bipolar major | #18 |
adhd cannabis | #18 |
preschool diagnostic | #18 |
psuds | #18 |
nature nurture | #19 |
improvement symptoms | #19 |
addicted patients | #19 |
rs3918342 | #19 |
medication trials | #19 |
scz ocd | #19 |
hyperconnectivity | #19 |
candidate loci | #19 |
familial transmission | #19 |
mental health human | #19 |
casecontrol sample | #19 |
symptoms adolescent | #19 |
lod1 | #19 |
assessing outcome | #19 |
comorbidity rates | #19 |
adolescent age | #19 |
verbal memory task | #19 |
euphoric effects | #19 |
mcgue | #19 |
disorders adults | #19 |
substance adhd | #19 |
adolescent age onset | #19 |
action preparations | #19 |
adhd neurodevelopmental | #19 |
disconfirmations | #19 |
psychosocial features | #19 |
adhd young adults | #19 |
response curve | #20 |
parents risk | #20 |
illness female humans | #20 |
human ortholog | #20 |
neuropsychologically | #20 |
biological families | #20 |
inhibition children | #20 |
dicap | #20 |
linkage scans | #20 |
transmission ratio distortion | #20 |
kiddie | #20 |
controlled pilot study | #20 |
rbfox1 gene | #20 |
disorders polymorphism | #20 |
adolescent | #20 |
prenatal exposure nicotine | #20 |
humanhap550v3 | #20 |
slc6a2 | #20 |
ratings adhd | #20 |
notch4 gene | #20 |
outcome attention | #20 |
depression adhd | #20 |
manual mental | #20 |
gsma | #20 |
pedigree selection | #20 |
mflynn | #20 |
schizophrenia attention | #20 |
nonpsychotic siblings | #20 |
parent origin | #20 |
neuroleptic dose | #20 |
sibpair | #20 |
neuropsychological function | #20 |
deficits children | #20 |
sodium hydrogen exchanger | #21 |
methods age | #21 |
schizotypals | #21 |
life enjoyment | #21 |
agler | #21 |
genehunterplus | #21 |
schizophrenia disease humans | #21 |
motor problems | #21 |
humans linkage | #21 |
children pdd | #21 |
childhood conduct disorder | #21 |
comorbid adhd | #21 |
rat shr | #21 |
linkage chromosomes | #21 |
palau | #21 |
prenatal exposure alcohol | #21 |
schizophrenia taiwan | #21 |
chronic tics | #21 |
male probands | #21 |
schizophrenia united | #21 |
prospective longitudinal | #21 |
rs778294 | #21 |
prescription stimulants | #21 |
treatment growth | #21 |
monoamine oxidase maoa | #21 |
risk offspring | #21 |
bipolar pedigrees | #21 |
gender comparisons | #21 |
cacng2 | #21 |
children comorbid | #21 |
psychiatric symptoms patients | #21 |
prevalent cases | #21 |
11year followup | #21 |
familiality | #22 |
ldx | #22 |
syndrome vcfs | #22 |
10p | #22 |
study methodology | #22 |
disruptive | #22 |
pre‐school | #22 |
adderall xr | #22 |
association prs | #22 |
youth mdd | #22 |
partial replication | #22 |
polygenic overlap | #22 |
niacin skin | #22 |
genetic phenotype | #22 |
disorders major | #22 |
rg022 | #22 |
depression treatment patients | #22 |
adhd anxiety | #22 |
neuropsychological profiles | #22 |
neurocognitive performance schizophrenia | #22 |
adhd stimulants | #22 |
children attention | #22 |
adhd susceptibility | #22 |
overtransmission | #22 |
schizophrenia pgc | #22 |
youth bipolar | #22 |
bpd subjects | #22 |
controls | #22 |
6 disorders | #22 |
stimulants children | #22 |
amygdala structure | #22 |
amphetamine methylphenidate | #22 |
adhd impulsivity | #22 |
adhd rating scale | #22 |
diagnostic interview | #22 |
preliminary reliability | #22 |
phenotype definition | #23 |
mdd anxiety disorders | #23 |
kotkin | #23 |
scq asd | #23 |
wechsler scales | #23 |
notch4 receptors | #23 |
serotonin receptor gene | #23 |
comprehensively | #23 |
adolescents bpd | #23 |
adhd symptoms childhood | #23 |
neuroleptic withdrawal | #23 |
metadoxine | #23 |
asd scq | #23 |
male individuals | #23 |
syp | #23 |
executive functions efs | #23 |
anxious mothers | #23 |
interview dsm | #23 |
disequilibrium male | #23 |
n449 | #23 |
twins genetic predisposition | #23 |
propylamines | #23 |
siblings | #23 |
diagnostician | #23 |
intrinsic curvature | #23 |
genetic investigation | #23 |
handful | #23 |
wide linkage | #23 |
interacting molecules | #23 |
rs464049 | #23 |
snapiv | #23 |
risk studies | #23 |
oppositional | #23 |
heterogeneity genetic | #23 |
intelligence schizophrenia | #24 |
genome‐wide linkage scans | #24 |
stroop task performance | #24 |
stress exposure | #24 |
female humans illness | #24 |
symptoms psychosis | #24 |
ocd asd | #24 |
snorting | #24 |
neural activation patterns | #24 |
lithium bipolar disorder | #24 |
aggression anxiety | #24 |
child female humans | #24 |
amrs | #24 |
adhd comorbidities | #24 |
conduct problems adhd | #24 |
sassr | #24 |
age regions | #24 |
adra2a | #24 |
0535 | #24 |
nonstimulant | #24 |
actigraphy studies | #24 |
statistical manual | #24 |
children meeting | #24 |
guanfacine extended release | #24 |
mental control | #24 |
adhd characteristics | #24 |
chromosomes 6 | #24 |
expected growth | #24 |
quantitative phenotypes | #24 |
receptor d4 | #24 |
deficits | #24 |
refilled | #24 |
15q13 | #24 |
dsmiiir criteria | #24 |
nieces | #24 |
conners parent | #25 |
baseline assessment | #25 |
decreased volume | #25 |
–environment interactions | #25 |
d22s283 | #25 |
wkht | #25 |
symptom subtypes | #25 |
slc6a3 gene | #25 |
maternal criticism | #25 |
unique profile | #25 |
bipolar choice | #25 |
copy variants schizophrenia | #25 |
psychiatric disorders children | #25 |
anticipation schizophrenia | #25 |
dapple | #25 |
understanding adhd | #25 |
splicing regulator | #25 |
task patients | #25 |
screening scale | #25 |
biased transmission | #25 |
psychometrically | #25 |
or194 | #25 |
association snps | #25 |
efficacy atomoxetine | #25 |
psychiatric nosology | #25 |
clinical interviews | #25 |
nudt3 | #25 |
neurocognitive predictors | #25 |
dyscalculia | #25 |
school failure | #25 |
behavioral disinhibition | #25 |
young relatives | #25 |
major affective disorders | #25 |
liker | #25 |
exposure adhd | #25 |
vietnam twin registry | #25 |
social impairment | #26 |
htr1d | #26 |
twins humans | #26 |
agreement raters | #26 |
adults symptoms | #26 |
affair | #26 |
orosmethylphenidate | #26 |
structured interviews | #26 |
efpc | #26 |
bipolar phenotype | #26 |
neurodevelopmental genes | #26 |
controls adhd | #26 |
prenatal health | #26 |
association allele | #26 |
selfmonitor | #26 |
major depression md | #26 |
screening diagnosis | #26 |
nonmedical prescription stimulants | #26 |
add | #26 |
n81 | #26 |
inrich | #26 |
voxel based morphometry | #26 |
label study | #26 |
gender risk | #26 |
behavioral disorder | #26 |
wm microstructure | #26 |
psychometric measures | #26 |
core symptoms adhd | #26 |
rs3730358 | #26 |
alcohol drug abuse | #26 |
maob gene | #26 |
adhd mothers | #26 |
adrenergic uptake | #26 |
asherson | #27 |
mdd asd | #27 |
offspring risk | #27 |
association signals | #27 |
disorders executive | #27 |
cnvs adhd | #27 |
schizophrenia genetic | #27 |
consecutively | #27 |
rate remission | #27 |
ptsd adults | #27 |
hyperactivity disorder adhd | #27 |
childreniv | #27 |
d22s278 | #27 |
t102c polymorphism | #27 |
potential confounds | #27 |
international meeting | #27 |
bipolar disorder comorbidity | #27 |
treatment atomoxetine | #27 |
aff | #27 |
genetic susceptibility schizophrenia | #27 |
intelligence male | #27 |
osterrieth | #27 |
weaker effects | #27 |
greater severity | #27 |
based association | #27 |
symptom reports | #28 |
maternal adhd | #28 |
disorder compared | #28 |
persons bipolar disorder | #28 |
families schizophrenia | #28 |
subjects bpd | #28 |
schizophrenia onset | #28 |
parent teacher | #28 |
assessment negative symptoms | #28 |
image study | #28 |
ocd disorders | #28 |
new genetics | #28 |
dopamine receptor d4 | #28 |
vigilance performance | #28 |
genomewide studies | #28 |
dopamine transporter binding | #28 |
child clinical | #28 |
rest task | #28 |
adhd differences | #28 |
6179 | #28 |
cortical gyrification | #28 |
adults study | #28 |
clinical correlates | #28 |
adhd autism | #28 |
snp18 | #28 |
symptoms inattention | #28 |
raters | #28 |
sustained attention deficits | #28 |
genetic etiology | #28 |
emotional dysregulation | #28 |
male methylphenidate | #28 |
guze | #28 |
polysomnography actigraphy | #28 |
metaalgorithm | #28 |
slc6a3 | #28 |
preliminary findings | #28 |
inattention hyperactivity impulsivity | #29 |
comorbidity ptsd | #29 |
dsmiiir | #29 |
bipolar disorder youth | #29 |
disorders offspring | #29 |
adhd patients controls | #29 |
etiological heterogeneity | #29 |
disorder bipolar | #29 |
african‐american | #29 |
male polymorphism | #29 |
infants weight | #29 |
medication misuse | #29 |
studies genes | #29 |
parents bipolar disorder | #29 |
psychosocial dysfunction | #29 |
offspring parents | #29 |
medication usage | #29 |
childhood antecedents | #29 |
misuse diversion | #29 |
hyperactivity impulsivity | #29 |
attention‐deficit | #29 |
kcnn3 | #29 |
childhood diagnosis | #29 |
shared genetic basis | #29 |
robust statistical methods | #30 |
growth childhood | #30 |
parental predictors | #30 |
nicotine pregnancy | #30 |
individual studies | #30 |
diagnosticians | #30 |
relatives age | #30 |
genetic perspective | #30 |
nonaffected | #30 |
hyperactive symptoms | #30 |
specific psychopathology | #30 |
problems attention | #30 |
nimh | #30 |
treatment adolescents | #30 |
antisocial behavior asb | #30 |
association paternal age | #30 |
juvenile bipolar disorder | #30 |
caarsinv | #30 |
structural brain features | #30 |
adhd child | #30 |
bmi growth | #30 |
comorbid | #30 |
sex effects | #31 |
potential endophenotypes | #31 |
95 adhd | #31 |
n305 | #31 |
kif16b | #31 |
lodscore | #31 |
extant literature | #31 |
smoking substance | #31 |
variable tandem | #31 |
neuropsychologic deficits | #31 |
depression genetic | #31 |
neuroimage | #31 |
reanalyzed | #31 |
bpd risk | #31 |
discriminates | #31 |
nonadhd | #31 |
prs adhd | #31 |
genotype haplotypes | #31 |
methylphenidate | #31 |
twin concordance | #31 |
rgs4 schizophrenia | #31 |
charles river | #31 |
impulsivity inattention | #31 |
bipolar disorder bpi | #32 |
wiscr | #32 |
subfields hippocampus | #32 |
anxiety disorders | #32 |
impulsecontrol | #32 |
kremen | #32 |
gender | #32 |
anterior insular | #32 |
psychosis youth | #32 |
adhd adolescents | #32 |
10p13 | #32 |
child psychiatric | #32 |
asd symptoms children | #32 |
attentiondeficit | #32 |
slc6a4 | #32 |
psychiatric genetic | #32 |
rs206936 | #32 |
psychiatric disorders | #32 |
psdq | #32 |
schizophrenia affective psychosis | #32 |
aggression attention | #32 |
repeat length | #32 |
randomized crossover study | #32 |
parents child | #32 |
studies adolescent | #32 |
70–80 | #32 |
studies schizophrenia | #32 |
prior findings | #33 |
twins factor analysis | #33 |
psychiatric status | #33 |
original study | #33 |
rs1130214 | #33 |
neuropsychiatric sle | #33 |
disorder symptom | #33 |
mood anxiety | #33 |
pharmacotherapy trials | #33 |
comorbidity cross | #33 |
single snps | #33 |
rhobtb3 | #33 |
youth bipolar disorder | #33 |
frontopolar | #33 |
children risk | #33 |
adhd evidence | #33 |
aspd bpd | #33 |
association genes | #33 |
maternal smoking pregnancy | #33 |
autism symptoms | #33 |
animal model adhd | #33 |
neural reward processing | #33 |
wfirs | #33 |
ld adhd | #33 |
adhd patients | #33 |
quetiapine monotherapy | #33 |
val allele | #33 |
qsf | #33 |
psychiatric sample | #33 |
neuropsychological deficits | #33 |
10repeat allele | #33 |
briefa | #33 |
subcortical brain | #33 |
current adhd | #33 |
emerging consensus | #34 |
structural brain asymmetries | #34 |
snp4 | #34 |
social anxiety children | #34 |
candidate gene polymorphisms | #34 |
psychological tests | #34 |
linkage studies | #34 |
disorders diagnostic | #34 |
dsm5 dsmiv | #34 |
inattention | #34 |
treatment memantine | #34 |
harvard | #34 |
treatment sud | #34 |
disorder traits | #34 |
young adults adhd | #34 |
cognition interaction | #34 |
grm5 | #34 |
md risk | #34 |
risk psychiatric disorders | #34 |
disorders mood | #34 |
pharmacotherapy adhd | #34 |
gxr | #34 |
risk females | #35 |
catechol‐o‐methyltransferase | #35 |
htr1b | #35 |
adhd rating | #35 |
lithium quetiapine | #35 |
recall patients | #35 |
n265 | #35 |
choice impulsivity | #35 |
participants bpd | #35 |
schizophrenia gene | #35 |
familial risk | #35 |
adhd sleep problems | #35 |
#35 | |
complex figure | #35 |
schizophrenia schizotypy | #35 |
sample description | #35 |
n64 | #35 |
humans intelligence | #35 |
plink | #35 |
schizophrenia relatives | #35 |
bipolar disorder offspring | #35 |
bipolar spectrum disorders | #35 |
hyperactive disorder | #35 |
lifetime rates | #35 |
gypc | #36 |
adhd control groups | #36 |
overanxious disorder | #36 |
term neuropsychological | #36 |
stimulant medications | #36 |
schizophrenia genes | #36 |
suny | #36 |
structure psychopathology | #36 |
orosmph | #36 |
adhd drug | #36 |
n185 | #36 |
infant gender | #36 |
groups adhd | #36 |
neurocognitive markers | #36 |
adult antisocial | #36 |
intracranial volume icv | #36 |
d6s274 | #36 |
retrospective recall | #36 |
comorbidity children | #36 |
95 siblings | #36 |
young adult females | #36 |
neurotransmissions | #36 |
disorder bpd | #36 |
annett | #36 |
siblings controls | #36 |
nocebo response | #36 |
genetics | #37 |
tests schizophrenia | #37 |
disorder severity | #37 |
functioning adults | #37 |
delayedaction preparations | #37 |
odd dimensions | #37 |
rs5 | #37 |
offspring association | #37 |
slc22a16 | #37 |
combined sample | #37 |
studies comorbidity | #37 |
child behavioral | #37 |
n278 | #37 |
dat1 gene | #37 |
mapping genomic loci | #37 |
lisdexamfetamine | #37 |
adhd asd | #37 |
parents adhd children | #37 |
predictive utility | #37 |
symptom criteria | #37 |
genetic risk schizophrenia | #38 |
school age children | #38 |
16 genes | #38 |
methylphenidate treatment | #38 |
family‐based | #38 |
kiddie schedule | #38 |
dsm criteria | #38 |
boys | #38 |
pik4ca | #38 |
polymorphism gene | #38 |
pediatric adhd | #38 |
unfamiliar | #38 |
familial risk depression | #38 |
genome‐wide search | #38 |
adhd problems | #38 |
height children | #38 |
rs2391191 | #38 |
d15s1360 | #38 |
nonparanoid | #39 |
behavioral traits | #39 |
antisocial traits | #39 |
onset children | #39 |
increased risk adhd | #39 |
washu | #39 |
git1 | #39 |
test association | #39 |
structural brain abnormalities | #39 |
female cases | #39 |
pharmacologic treatment | #39 |
wisconsin card | #39 |
markers genetic | #39 |
asthma systematic review | #39 |
mood stabilization | #39 |
suggestive | #39 |
dsm5 criteria | #39 |
adhd behavior | #39 |
ocd adhd | #39 |
manic symptoms | #39 |
mlod | #39 |
mdd ocd | #39 |
iii personality | #39 |
onset | #40 |
heinrichs | #40 |
dsmiv criteria | #40 |
bipolars | #40 |
rare copy variants | #40 |
chromosome 10p | #40 |
familial effects | #40 |
genetics schizophrenia | #40 |
brainspan | #40 |
gxe | #40 |
rs2283265 | #40 |
genome scan | #40 |
genetic studies | #40 |
diagnosis bipolar disorder | #40 |
reln gene | #40 |
cardiovascular adverse effects | #40 |
anx | #40 |
sibpairs | #41 |
neuropsychiatr | #41 |
methodological advances | #41 |
pediatric subjects | #41 |
normal comparison subjects | #41 |
chromosomes 6q | #41 |
psychosocial adversity | #41 |
fhrs | #41 |
schizophrenia severity illness | #41 |
effects growth | #41 |
sirolimus patients | #41 |
male parents | #41 |
bdnf adhd | #41 |
parent‐of‐origin | #41 |
methylphenidate response | #41 |
male panic | #42 |
disorder social | #42 |
serotonergic pathway | #42 |
gwas meta | #42 |
diagnostic comorbidity | #42 |
schizophrenia | #42 |
tic disorders | #42 |
individual items | #42 |
fiveyear followup | #42 |
adhd deficits | #42 |
sorting test | #42 |
n262 | #42 |
child female | #42 |
dtnbp1 schizophrenia | #42 |
schizophrenia disorders | #42 |
n232 | #43 |
n176 | #43 |
digs | #43 |
p023 | #43 |
practitioner review | #43 |
children enuresis | #43 |
p094 | #43 |
adhd depression | #43 |
brain scans | #43 |
neuropsychological differences | #43 |
youngadult | #43 |
n242 | #43 |
simplex families | #43 |
neuropsychological tasks | #43 |
adhd prs | #43 |
snp1 | #43 |
disorder prevalence | #43 |
candidate endophenotype | #43 |
massachusetts general | #43 |
mri study | #43 |
mental disorders diseases | #44 |
nosologic | #44 |
immediaterelease | #44 |
secondborns | #44 |
adolescents attention | #44 |
odds ratio association | #44 |
multidimensionality | #44 |
n140 | #44 |
sidp | #44 |
prior studies | #44 |
treatment adult | #44 |
asd adults | #44 |
dopamine d5 | #44 |
prevalence psychiatric | #45 |
controls subjects | #45 |
wnl | #45 |
adhd parents | #45 |
pooled size | #45 |
institute mental | #45 |
risk schizophrenia | #45 |
offspring adhd | #45 |
substance disorder | #45 |
pharmacogenetic studies | #45 |
uncaring | #45 |
inflation rate | #45 |
snpbased heritability | #45 |
schizophrenia genome | #45 |
genetic underpinnings | #45 |
cep85l | #45 |
altered brain activation | #45 |
tcerg1l | #45 |
risk reduction strategies | #45 |
volume reductions | #45 |
illness stress | #45 |
genetic loading | #45 |
suggestive associations | #45 |
baseline adhd | #45 |
behavior rating | #45 |
converging evidence | #46 |
neuropsychological performance | #46 |
nat genet | #46 |
n164 | #46 |
machine learning study | #46 |
previous findings | #46 |
familial coaggregation | #46 |
referral bias | #46 |
gender influences | #46 |
cbt intervention | #46 |
sex bias | #46 |
adhd effects | #46 |
natural reward | #46 |
12 months treatment | #46 |
stronger connectivity | #46 |
response mph | #46 |
lyons | #46 |
10year followup | #46 |
shared polygenic risk | #47 |
oppositional symptoms | #47 |
desipramine dmi | #47 |
abstract objective | #47 |
trauma risk | #47 |
childhood disorders | #47 |
velocardiofacial syndrome | #47 |
n280 | #47 |
pooled odds ratio | #47 |
association bipolar disorder | #47 |
schizophrenia alleles | #47 |
parents depression | #47 |
compromised | #47 |
loci chromosomes | #47 |
comt | #47 |
genetic study | #47 |
psychiatric status rating | #47 |
or125 | #47 |
meehl | #47 |
ocd mdd | #47 |
disorders studies | #47 |
baiap2 | #47 |
scientific foundation | #48 |
effects gender | #48 |
revised | #48 |
n27 | #48 |
adhd prevalence | #48 |
adhd dyslexia | #48 |
disorder case | #48 |
shared heritability | #48 |
rtv | #48 |
1711 | #48 |
nullhypothesis | #48 |
n103 | #48 |
association test | #48 |
mpp3 | #48 |
inbred wky rats | #49 |
mental disorders children | #49 |
volume differences | #49 |
hyperactivity autism | #49 |
drug holidays | #49 |
anxa7 | #49 |
disorder cognitive | #49 |
familial loading | #49 |
serotonin plasma | #49 |
schizophrenia cognition | #49 |
rs2494732 | #49 |
nurture | #49 |
weak evidence | #49 |
snap‐25 | #49 |
negative schizotypy | #49 |
studies biomarkers | #50 |
wiat | #50 |
geneenvironment interactions | #50 |
intergenerational effects | #50 |
vdm | #50 |
proteins polymorphism | #50 |
caseness | #50 |
genomic relationships | #50 |
n168 | #50 |
parent teacher ratings | #50 |
impulsivity symptoms | #50 |
wais | #50 |
dsmiv dsm5 | #50 |
pair 6 | #50 |
life outcomes | #50 |
maoauvntr | #50 |
rocf | #50 |
extended pedigrees | #50 |
early onset schizophrenia | #50 |
gender association | #51 |
substantial role | #51 |
adhd knowledge | #51 |
male personality | #51 |
manovas | #51 |
peer affiliation | #51 |
adults ocd | #51 |
common psychiatric disorders | #51 |
psychology adult | #51 |
epilepsy adhd | #51 |
bpd | #51 |
disorders children | #51 |
1542 | #51 |
compelling | #51 |
asdadhd | #52 |
bipolar disorder children | #52 |
intracranial volume | #52 |
schizophrenia controls | #52 |
growth height | #52 |
gray matter alterations | #52 |
oros methylphenidate | #52 |
adra1a | #52 |
combined adhd | #52 |
metaanalysis association | #52 |
chronic schizophrenia patients | #52 |
schizophrenia sex | #52 |
youth asd | #52 |
major depression | #52 |
selenbp1 | #52 |
a218c | #52 |
dopamine plasma | #53 |
tourettes disorder | #53 |
smoking schizophrenia | #53 |
mania depression | #53 |
adhdc | #53 |
adoption study | #53 |
risk analysis | #53 |
parahippocampal gyrus | #53 |
risktaking behavior | #53 |
placebo children | #53 |
ppm1h | #53 |
schizophrenia adolescent | #53 |
extended‐release | #53 |
psychopathology | #53 |
scales schizophrenia | #53 |
snps candidate genes | #53 |
n138 | #53 |
onset bipolar | #54 |
psychlit | #54 |
ablim1 | #54 |
genetic reproducibility | #54 |
risk study | #54 |
alcohol drug | #54 |
bpd children | #54 |
pregnancy time | #54 |
dnms | #54 |
unphased | #54 |
schizophrenia psychotic disorders | #54 |
jackknife | #54 |
chromosome 6p | #54 |
tova | #55 |
emotional lability | #55 |
gene interaction | #55 |
endophenotype | #55 |
neuropsychological studies | #55 |
flat affect | #55 |
longitudinal case | #55 |
children diagnosis | #55 |
mid adolescence | #55 |
child behavior | #55 |
sample children | #55 |
1252 | #55 |
childhood trauma exposure | #55 |
viloxazine | #55 |
disorders prevalence | #55 |
disorders risk | #55 |
pair chromosomes | #56 |
schizophrenia offspring | #56 |
entry points | #56 |
alcohol substance | #56 |
extendedrelease | #56 |
children siblings | #56 |
hyperactive | #56 |
disorder agoraphobia | #56 |
n43 | #56 |
degree relatives | #56 |
subfield | #56 |
cotwin | #56 |
tics children | #56 |
interregional profiles differences | #57 |
rating inventory | #57 |
apol | #57 |
shared genetic etiology | #57 |
zdhhc8 | #57 |
barkley | #57 |
oddsratio | #57 |
methylphenidate hydrochloride | #57 |
etdt | #57 |
model attention | #57 |
atomoxetine hydrochloride | #57 |
brain structure function | #57 |
tests attention | #58 |
adhd atomoxetine | #58 |
100 children | #58 |
conners | #58 |
single snp | #58 |
children | #58 |
compelling evidence | #58 |
controls children | #58 |
vntr polymorphisms | #58 |
association comt | #58 |
repeat alleles | #58 |
function schizophrenia | #58 |
comorbid psychiatric disorders | #58 |
controlled study | #58 |
childhood young adulthood | #58 |
dbq | #58 |
heritable receptors | #58 |
analysis schizophrenia | #58 |
schizophrenia smoking | #59 |
rtn4r | #59 |
mdd children | #59 |
neuroleptic | #59 |
risk psychiatric | #59 |
mdd adhd | #59 |
risk siblings | #59 |
comt schizophrenia | #59 |
3 domains | #60 |
abuse dependence | #60 |
generalize | #60 |
disorders including | #60 |
reported associations | #60 |
disruptive behavior disorder | #60 |
executive functioning | #60 |
inattention hyperactivity | #60 |
functional remission | #60 |
duval | #60 |
lphn3 | #60 |
unipolars | #61 |
oih | #61 |
13q32 | #61 |
study adults | #61 |
cronbachs alpha | #61 |
uninhibited | #61 |
disruptive behavior | #61 |
study adherence | #61 |
disorders asd | #61 |
wide scan | #61 |
uncles | #61 |
dysregulation profile | #61 |
comparison subjects | #61 |
homogeneous subgroups | #61 |
tdts | #62 |
bipolar youth | #62 |
factors anxiety | #62 |
inhibition memory | #62 |
substantial heritability | #62 |
schizophrenia human | #62 |
symptoms | #62 |
1537 | #62 |
maternal psychopathology | #62 |
polygenic risk schizophrenia | #62 |
mph treatment | #62 |
4 year | #62 |
relatives schizophrenia | #62 |
ksads | #63 |
behavioral dysregulation | #63 |
disorders bipolar | #63 |
structured interview | #63 |
treatments adhd | #63 |
neurocognitive | #63 |
schizophrenia schizophrenic | #63 |
accounted | #63 |
n179 | #63 |
stability time | #63 |
risk severity | #63 |
endosomal | #64 |
diagnostic utility | #64 |
linkage | #64 |
europeanamerican | #64 |
methylphenidate mph | #64 |
phacking | #64 |
40 countries | #64 |
methylation cpg sites | #64 |
qlesq | #64 |
prefrontal dysfunction | #64 |
rating scales | #64 |
treatment desipramine | #64 |
child | #64 |
methylphenidate adhd | #64 |
childhood onset | #64 |
risk trauma | #64 |
adhd 95 | #64 |
males association | #64 |
children mph | #64 |
adhd epilepsy | #65 |
net gene | #65 |
temperamental | #65 |
emo | #65 |
small sample size | #65 |
controls siblings | #65 |
neuropsychological impairments | #65 |
emotional regulation | #65 |
schizophrenic | #65 |
occurrence adhd | #65 |
prior work | #65 |
disorders genetic | #65 |
male siblings | #65 |
etiology schizophrenia | #65 |
comorbid diagnosis | #65 |
oxidase gene | #65 |
zcchc4 | #65 |
function female | #65 |
marry | #65 |
ci105 | #66 |
cbcldp | #66 |
disorder chromosome | #66 |
attention hyperactivity | #66 |
tic disorder | #66 |
neuropsychological profile | #66 |
children mental retardation | #66 |
vswm | #66 |
simple phobia | #66 |
adhd dcd | #66 |
extended release | #66 |
tourettes syndrome | #66 |
behavioral genetic | #66 |
afternoons | #66 |
study studies | #66 |
global ratings | #66 |
nonrighthandedness | #67 |
patients bipolar disorders | #67 |
grade retention | #67 |
parents teachers | #67 |
variance attention | #67 |
treatment quetiapine | #67 |
mental diseases | #67 |
findings association | #67 |
subjects | #67 |
risk bipolar | #67 |
substance disorder sud | #67 |
label trial | #67 |
n217 | #67 |
entire sample | #67 |
chronic tic disorder | #67 |
questionnaires treatment | #67 |
conceptual issues | #68 |
offspring | #68 |
naturalistic | #68 |
hypofrontality | #68 |
snparray | #68 |
qms | #68 |
delay aversion | #68 |
brain gene | #68 |
physical anhedonia | #69 |
stress response genes | #69 |
people adhd | #69 |
ctgn | #69 |
low adherence | #69 |
impulsivity hyperactivity | #69 |
regulatory enzymes | #69 |
symptom checklist | #69 |
chronological age | #69 |
clarifying | #69 |
polymorphism schizophrenia | #69 |
scale assessment | #69 |
illicit substances | #69 |
panic disorder | #69 |
humans schizophrenia | #69 |
latrophilin | #70 |
new diagnoses | #70 |
a2bp1 | #70 |
smoking children | #70 |
interactions genes | #70 |
neuropsychological consequences | #70 |
npl | #70 |
linkage scan | #70 |
oros mph | #70 |
core adhd symptoms | #70 |
subsequent diagnosis | #70 |
nonrandom mating | #70 |
vergence | #71 |
treated children | #71 |
objective examine | #71 |
neuroimaging genetics | #71 |
adhd anxiety disorders | #71 |
genetic | #71 |
adhd behaviors | #71 |
mspi polymorphism | #71 |
genes role | #71 |
school functioning | #72 |
digital health intervention | #72 |
boys age | #72 |
methodological issues | #72 |
genetic receptors | #72 |
ocd subjects | #72 |
digital intervention | #72 |
learning disorders | #72 |
molecular genetic | #72 |
adhd subtype | #73 |
adhd medications | #73 |
3372 | #73 |
cortical abnormalities | #73 |
relapse depression | #73 |
schizophrenia genetics | #73 |
etiological | #73 |
anxiety adhd | #73 |
logodds | #73 |
youth | #73 |
poison control centers | #73 |
kagan | #73 |
patients rest | #73 |
cellular models | #73 |
candidate endophenotypes | #73 |
adult | #73 |
disorders childhood | #73 |
age schizophrenia | #74 |
reaction time variability | #74 |
desipramine | #74 |
based diagnosis | #74 |
transmission disequilibrium | #74 |
allele association | #74 |
preferential transmission | #74 |
pfkfb2 | #74 |
weight body mass | #75 |
neale | #75 |
risk sample | #75 |
referred | #75 |
impairment children | #75 |
hyperactivity adhd | #75 |
adhd traits | #75 |
antisocial | #75 |
efficacy outcome | #75 |
drd4 gene | #75 |
linkage schizophrenia | #75 |
akl | #75 |
mind wandering | #75 |
onset anxiety | #75 |
slc1a1 | #75 |
child china | #75 |
schizophrenia young | #76 |
child humans | #76 |
yates | #76 |
centers disease control | #76 |
nondeficit | #76 |
chronic tic | #76 |
disorders brain | #76 |
child depressive | #76 |
adhd total | #76 |
positive schizotypy | #76 |
depression pregnancy | #76 |
atomoxetine children | #77 |
wcst performance | #77 |
performance adhd | #77 |
lod score | #77 |
childhood adhd | #77 |
psychological male | #77 |
performance schizophrenia | #77 |
cortex schizophrenia | #77 |
local gyrification | #78 |
pharmacologic treatments | #78 |
adhd impairment | #78 |
predixcan | #78 |
bpi | #78 |
bipolar disorder adhd | #78 |
rare copy | #78 |
disorders female | #78 |
women antidepressants | #78 |
age adhd | #79 |
retrospective assessment | #79 |
studies relationship | #79 |
schizophrenic patients | #79 |
n46 | #79 |
pregnancy mothers | #79 |
anxiety separation | #79 |
disorder panic | #79 |
obesity metabolic syndrome | #79 |
nosological | #79 |
patients adhd | #79 |
student athletes | #79 |
additive effects | #79 |
genetic linkage studies | #79 |
cardinal | #79 |
adhd drugs | #80 |
adhd rats | #80 |
siblings schizophrenia | #80 |
linkage chromosome | #80 |
total brain | #80 |
maternal smoking | #80 |
clinical interview | #80 |
hacking | #81 |
body mass diabetes | #81 |
pathophysiology adhd | #81 |
treatment adults | #81 |
disliking | #81 |
endophenotypes | #81 |
interregional profiles | #81 |
children parents | #81 |
major diagnostic | #81 |
bipolar disorder | #81 |
differences age | #81 |
oral routes | #81 |
eyhs | #81 |
subcortical brain volumes | #81 |
symptoms diagnosis | #82 |
square distribution | #82 |
genes pathways | #82 |
impaired quality life | #82 |
association maternal smoking | #82 |
comorbidity survey | #82 |
frontopolar cortex | #82 |
auditory verbal | #82 |
gene schizophrenia | #82 |
cumulative evidence | #82 |
comorbidity disorders | #82 |
behavior assessment | #82 |
adults asd | #82 |
neurocognitive functioning | #83 |
unreliability | #83 |
illness | #83 |
oros | #83 |
paterson | #83 |
multifactorial inheritance | #83 |
disorders anxiety | #83 |
tests risk | #83 |
substance disorders | #83 |
management adhd | #83 |
adult form | #83 |
adhd adhd symptoms | #84 |
15q133 | #84 |
complex disorder | #84 |
21 months | #84 |
women adhd | #84 |
adhd assessment | #85 |
brain asymmetry | #85 |
linkage loci | #85 |
adhd subtypes | #85 |
buprenorphine maintenance | #85 |
wide significance | #85 |
monitoring response | #85 |
recycling endosome | #85 |
humans risk | #85 |
hyperkinetic disorder | #85 |
adhdrsiv | #85 |
9r | #85 |
european samples | #85 |
genomics consortium | #85 |
atomoxetine | #85 |
pord | #86 |
siblings children | #86 |
humans inhibition | #86 |
paranoid | #86 |
parents | #86 |
findings implications | #86 |
affective psychosis | #86 |
child conduct | #86 |
bipolar spectrum disorder | #87 |
bipolar | #87 |
putamen volume | #87 |
risk alleles | #87 |
synaptosomal protein | #87 |
ptsd trauma | #87 |
n203 | #87 |
3utr | #87 |
comparison children | #87 |
drug effects | #88 |
bonferroni correction | #88 |
common risk | #88 |
druggable | #88 |
comorbid psychopathology | #88 |
hyperkinetic | #88 |
empirically | #89 |
chrna2 | #89 |
2455 | #89 |
prenatal nicotine exposure | #89 |
machine learning analysis | #89 |
auditory attention | #89 |
metaanalytic review | #89 |
22 studies | #89 |
nucleotide schizophrenia | #89 |
euphoric | #89 |
comprehensive identification | #89 |
caars | #89 |
242 | #90 |
pervasive | #90 |
male neuropsychological | #90 |
snps haplotypes | #90 |
association metaanalysis | #90 |
attention deficit hyperactivity | #90 |
antidepressants pregnancy | #90 |
watt | #90 |
linkage genome | #90 |
1month | #90 |
verbal ability | #90 |
adhd treatments | #91 |
adhd males | #91 |
callousness | #91 |
naturalistic study | #91 |
assertion | #91 |
parental socioeconomic status | #91 |
identified studies | #91 |
cortical brain | #91 |
complicates | #91 |
adhd efficacy | #91 |
wcst | #91 |
studies association | #92 |
documenting | #92 |
treatment mania | #92 |
candidate gene | #92 |
h2snp | #92 |
adults schizophrenia | #92 |
studies sex | #92 |
raise | #92 |
lifetime cannabis | #93 |
referral consultation | #93 |
standardized differences | #93 |
controls participants | #93 |
ymrs | #93 |
narrowly | #93 |
rate adult | #93 |
growing body | #94 |
social development | #94 |
underachievement | #94 |
hyperactivity autistic | #94 |
gottman | #94 |
hfasd | #94 |
performance variability | #94 |
cdh13 | #94 |
gprc5b | #94 |
adhd measures | #94 |
aldh1l1 | #94 |
sustained attention | #94 |
brain case | #94 |
studies differences | #95 |
cadps2 | #95 |
asd study | #95 |
total brain volume | #95 |
minisatellite | #95 |
executive | #95 |
adolescents bipolar | #95 |
infa | #95 |
mdd bip | #95 |
chromosome 9q34 | #96 |
behavior rating inventory | #96 |
uvntr | #96 |
phenotype polymorphism | #96 |
nxph1 | #96 |
scq | #96 |
nominally | #96 |
hcadherin | #97 |
7q36 | #97 |
adolescent onset | #97 |
low cardiorespiratory fitness | #97 |
children tics | #97 |
studies asthma | #97 |
genome‐wide association study | #97 |
massachusetts general hospital | #98 |
syn2 | #98 |
oppositionality | #98 |
linkage study | #98 |
induced hyperalgesia | #98 |
hyperactivity brazil | #98 |
single nucleotide receptor | #98 |
wdpcp | #98 |
driving behavior | #98 |
nonfamilial | #98 |
identically | #98 |
bipolar disorder risk | #98 |
concerta | #98 |
abuse potential | #99 |
metaanalysis trials | #99 |
adhd role | #99 |
neurodevelopmental processes | #99 |
methodssubjects | #99 |
xp114 | #99 |
motor timing | #99 |
nonspecificity | #99 |
medication effects | #99 |
psychoactive | #99 |
substrains | #99 |
disease genetics | #99 |
chd6 | #99 |
disorder diagnosis | #99 |
clinical effects | #100 |
adhd methylphenidate | #100 |
pelham | #100 |
reticence | #100 |
hippocampal subfield volumes | #100 |
terror | #100 |
obesity abdominal obesity | #100 |
12year | #100 |
diagnostic boundaries | #101 |
genetic risk scores | #101 |
torture | #101 |
advanced paternal age | #101 |
upsit | #101 |
roh | #101 |
cosegregation | #101 |
addictive drugs | #101 |
neurocognitive impairments | #101 |
genomewide | #101 |
harlan | #101 |
depression pregnant women | #101 |
schizophrenia psychotic | #101 |
tsls | #101 |
empirical test | #101 |
slc6a4 gene | #101 |
klf13 | #102 |
treatment seeking | #102 |
inhibition psychological | #102 |
sob | #102 |
male neuropsychological tests | #102 |
functional pathways | #102 |
individuals aud | #102 |
parents offspring | #102 |
disorder psychiatric | #102 |
genome wide association | #103 |
pgc | #103 |
patients 12 months | #103 |
symptom profile | #103 |
ocd children | #103 |
clinical picture | #103 |
genetic pedigree polymorphism | #103 |
touchstone | #103 |
schizophrenia mood disorders | #103 |
genetic mechanism | #104 |
controlled studies | #104 |
individual sites | #104 |
schizophrenia metaanalysis | #104 |
genomic region | #104 |
motor competence | #104 |
1934 | #104 |
tourette disorder | #104 |
dsmiv diagnosis | #105 |
schizophrenia probands | #105 |
current article | #105 |
adhd review | #105 |
drug dyskinesia | #105 |
school dropout | #105 |
neuropsychological dysfunction | #105 |
academic problems | #105 |
children odd | #106 |
humans lod | #106 |
children methylphenidate | #106 |
cogs | #106 |
functional correlates | #107 |
consecutive sample | #107 |
chronic tic disorders | #107 |
λs | #107 |
ldn | #107 |
daao | #107 |
adolescents bipolar disorder | #107 |
lenticular | #107 |
oral methylphenidate | #107 |
disorder female | #107 |
sequential analysis | #107 |
matter volumes | #107 |
mothers adhd | #107 |
growth outcomes | #107 |
aged psychiatric | #108 |
n197 | #108 |
nesarc | #108 |
proband | #108 |
symptoms childhood | #108 |
pediatric psychopharmacology | #108 |
maternal warmth | #108 |
afni | #108 |
pervasive developmental | #108 |
918 | #108 |
site differences | #108 |
antimanic agents | #108 |
origin effects | #108 |
association cigarette smoking | #108 |
psychosis proneness | #109 |
adhd medication | #109 |
longitudinal trajectories | #109 |
gabra6 | #109 |
neuroleptic medication | #109 |
risk bipolar disorder | #109 |
worthy | #109 |
irrespective | #109 |
total scores | #109 |
depression bipolar | #109 |
adhd parent | #110 |
linkage association | #110 |
adult adhd symptoms | #110 |
enlistment | #110 |
markers genome | #110 |
rat models | #110 |
dimorphisms | #111 |
affective psychoses | #111 |
5httlpr genotype | #111 |
symptom ratings | #111 |
selective reporting | #111 |
affective symptoms | #111 |
dao | #111 |
n107 | #111 |
pediatric obsessive | #112 |
substantial proportion | #112 |
childhood risk factors | #112 |
independent studies | #112 |
factors social | #112 |
impact exposure | #112 |
brain gene expression | #112 |
unmedicated | #112 |
bipolar parents | #112 |
dopamine d4 receptors | #112 |
xr | #113 |
neuropsychological functions | #113 |
cronbach | #113 |
male prevalence | #113 |
omim | #114 |
comorbid anxiety | #114 |
functional neuroanatomy | #114 |
analysis statistical | #114 |
genet | #115 |
schizophrenia severity | #115 |
liability | #115 |
n34 | #115 |
nuclear families | #115 |
–r | #115 |
endorsed | #115 |
diseases twins | #116 |
schizophrenic psychology | #116 |
formulating | #116 |
neuropsychological | #116 |
wm abnormalities | #116 |
unipolar | #117 |
coordinated analysis | #117 |
prenatal smoking | #117 |
quality life outcomes | #117 |
trait impulsivity | #117 |
current symptoms | #117 |
polygenic association | #117 |
neurocognitive endophenotypes | #117 |
z29 | #117 |
major female | #118 |
academic functioning | #118 |
definitively | #118 |
satisfaction questionnaire | #118 |
large study | #118 |
grandfathers | #118 |
prevention science | #118 |
spm2 | #118 |
grandiosity | #118 |
genetic receptor serotonin | #118 |
dopaminergic genes | #119 |
naa ratio | #119 |
midadolescence | #119 |
method data | #119 |
schizophrenia linkage | #119 |
efd | #119 |
misunderstandings | #120 |
t01 | #120 |
differences children | #120 |
subfield volumes | #121 |
n108 | #121 |
remittance | #121 |
new avenues | #121 |
aunts | #121 |
disorder autism | #121 |
cgibp | #121 |
neurocognitive deficits | #121 |
refute | #122 |
schizoaffective | #122 |
anxious | #122 |
urvs | #122 |
psychopathology symptoms | #122 |
msit | #122 |
v11 | #122 |
pabs | #122 |
neuropsychiatric disorders | #122 |
levels adhd | #122 |
structural brain alterations | #122 |
male risk | #122 |
disregard | #122 |
brain alterations | #122 |
adhd comorbidity | #122 |
disorder depressive | #122 |
clinical status | #123 |
wechsler | #123 |
chr psychosis | #123 |
adcy2 | #123 |
age initiation | #123 |
adhd ocd | #123 |
attention regulation | #124 |
9q34 | #124 |
g×s interaction | #124 |
wechsler intelligence scale | #124 |
treatment subjects | #124 |
drug placebo | #124 |
twothirds | #124 |
maximum lod score | #124 |
laboratory observations | #124 |
longitudinal sample | #124 |
trios | #124 |
p097 | #124 |
disorder risk | #125 |
caregiver strain | #125 |
patients chronic schizophrenia | #125 |
anxiety problems | #125 |
segregation analysis | #125 |
psychosis individuals | #125 |
machine learning prediction | #125 |
positive negative symptoms | #126 |
odd conduct disorder | #126 |
familial influences | #126 |
biological parents | #126 |
memory adhd | #126 |
developmental aspects | #126 |
drug disorders | #126 |
complex genetics | #126 |
parent version | #126 |
adult alleles | #127 |
disinhibited | #127 |
genes | #127 |
taiwanese population | #127 |
psychiatric diagnoses | #127 |
drd2 | #127 |
attention child | #127 |
stevenson | #127 |
aged 6 | #128 |
neuropsychological measures | #128 |
opiate antagonists | #129 |
behavioral outcome | #129 |
personality assessment | #129 |
implicate | #129 |
familial | #129 |
intactness | #129 |
n102 | #129 |
retrospective data analysis | #130 |
1990a | #130 |
families | #130 |
adhd inattention | #130 |
moderating effects | #131 |
snps | #131 |
kinesthesia | #131 |
strong evidence | #131 |
adolescents ocd | #131 |
incapacitation | #131 |
differed | #131 |
bip mdd | #131 |
register study | #131 |
pair 15 chromosomes | #131 |
animals attention | #131 |
mood anxiety disorders | #131 |
linkage humans | #132 |
p074 | #132 |
large european cohort | #132 |
entire brain | #132 |
child cognition | #132 |
sodas | #132 |
hkd | #132 |
n79 | #132 |
learning disabilities | #132 |
childhood anxiety disorders | #132 |
male prospective | #132 |
late adolescents | #132 |
mph | #133 |
heroin dependence | #133 |
onset bipolar disorder | #133 |
preliminary examination | #134 |
vntr | #134 |
disorders social | #134 |
children adults | #134 |
male massachusetts | #135 |
social deficits | #135 |
association analyses | #135 |
risk factors smoking | #136 |
firstborns | #136 |
relied | #136 |
adolescents young | #136 |
social environments | #136 |
olfactory identification | #136 |
tspan8 | #136 |
sorcs3 | #136 |
adolescent bipolar | #137 |
memantine treatment | #137 |
gaming | #137 |
longitudinal evidence | #137 |
expressed emotion | #137 |
psychological male memory | #137 |
studies examined | #137 |
schizophrenia affective disorders | #137 |
association asthma | #137 |
control individuals | #138 |
mtor activation | #138 |
asds | #138 |
biomarkers diagnosis | #138 |
6q | #138 |
evidence association | #138 |
n129 | #139 |
symptoms disorders | #139 |
meet | #139 |
mgh | #139 |
schizophrenia studies | #139 |
neuropsychiatric | #139 |
fhr | #139 |
parental anxiety | #140 |
intriguing | #140 |
schizotypal traits | #140 |
n115 | #140 |
disorder comorbidity | #141 |
haplotype block | #141 |
emotional symptoms | #141 |
genetic vulnerability | #141 |
prss | #141 |
disorders psychotic | #142 |
covid19 restrictions | #142 |
disorders personality | #142 |
22q112 deletion syndrome | #142 |
neurotrophic | #142 |
5ht1b receptors | #142 |
conduct | #143 |
risk factors obesity | #143 |
peripheral biomarkers | #143 |
molecular genetics | #143 |
fetal movement | #143 |
hydrogen exchangers | #143 |
child psychopathology | #144 |
g72 | #144 |
elston | #144 |
agents tricyclic | #144 |
rfg | #144 |
humans linear | #144 |
blind study | #144 |
statistical female humans | #144 |
diagnosed attention | #144 |
diagnostic procedure | #144 |
common genetic variants | #145 |
pcb exposure | #145 |
n105 | #145 |
major psychoses | #145 |
affs | #145 |
p00018 | #145 |
early initiation | #145 |
individual symptoms | #145 |
genetic heterogeneity | #145 |
studies depressive | #145 |
genome‐wide association studies | #145 |
drug alcohol | #145 |
adult psychopathology | #146 |
warranted | #146 |
atypicality | #146 |
oppositional behavior | #146 |
twin studies | #146 |
intelligence quotient | #146 |
genders | #146 |
prenatal nicotine | #146 |
histrionic | #147 |
p0016 | #147 |
intraindividual variability | #147 |
lras | #147 |
comprising | #147 |
abbreviated | #147 |
cognitive variables | #148 |
basc | #148 |
sabp | #148 |
single locus | #148 |
adolescent young | #148 |
schizotypy | #149 |
adhd symptoms children | #149 |
cdrsr | #149 |
risk mdd | #149 |
parental substance | #149 |
brain correlates | #149 |
adhd relationship | #150 |
impulsive | #150 |
chrnb2 | #150 |
highlighting | #150 |
categorical | #150 |
nonmedical | #150 |
sud treatment | #150 |
synaptic biology | #151 |
consisted | #151 |
higher burden | #151 |
linkage disequilibrium mapping | #152 |
undegraded | #152 |
copy variants cnvs | #152 |
diagnostic systems | #152 |
large sample | #152 |
autistic traits | #152 |
xq21 | #152 |
functional impairment | #152 |
schizophrenia diagnosis | #152 |
atxn1 | #152 |
metaanalytic | #152 |
placebo subjects | #152 |
increases risk | #152 |
httlpr | #152 |
parent report | #152 |
implicates | #152 |
genomewide linkage | #153 |
caucasian children | #153 |
5 httlpr | #153 |
schizophrenia bipolar disorder | #153 |
editions | #153 |
schizophrenia deficits | #153 |
demoralization | #153 |
marginally | #153 |
alcohol conditions | #153 |
humans learning | #153 |
wisc | #154 |
dsm | #154 |
exposure maternal | #154 |
disorder phenotype | #154 |
atomoxetine placebo | #154 |
emphasizing | #154 |
schizophrenia magnetic resonance | #154 |
year follow | #155 |
genomewide scan | #155 |
ncsr | #155 |
humans polymorphism | #155 |
clarification | #155 |
snpheritability | #155 |
n84 | #156 |
interpersonal functioning | #156 |
600000 | #156 |
tests male | #156 |
genetic risk | #156 |
prospective controlled study | #156 |
enigma consortium | #157 |
dopamine d4 | #157 |
new knowledge | #157 |
panic disorder agoraphobia | #157 |
adolescents | #158 |
clinical diagnostic | #158 |
ppp2r2b | #158 |
oprm1 | #158 |
sledai | #158 |
greatest | #158 |
htr2c | #158 |
myo5b | #158 |
drd4 genotype | #158 |
genetic linkage | #158 |
primary setting | #158 |
cognitive tempo | #158 |
teachers parents | #159 |
adult human brain | #159 |
dav | #159 |
nonpersistent | #159 |
patients substance | #159 |
selfratings | #159 |
quetiapine treatment | #159 |
smds | #160 |
age onset | #160 |
separation anxiety disorder | #160 |
humans impulsive | #160 |
medial temporal | #160 |
tic symptoms | #161 |
genetic component | #161 |
hyperactivity disorders | #161 |
population samples | #161 |
adult adhd patients | #161 |
behavioral difficulties | #161 |
schizophrenia bipolar | #161 |
disorder clinical | #162 |
rats wky | #162 |
140 | #162 |
ksadspl | #162 |
cooccurring disorders | #162 |
disorder depression | #162 |
empirical tests | #162 |
dn cells | #163 |
5htt | #163 |
dsmiv | #163 |
neuropsychological tests | #163 |
sample | #163 |
neurobiology | #163 |
paternal age | #163 |
familial liability | #164 |
complex phenotype | #164 |
impairments | #164 |
anxiety attention | #164 |
diagnostic status | #164 |
illness schizophrenia | #164 |
boys girls | #165 |
washington university | #165 |
neurocognitive performance | #165 |
years children | #165 |
risk subsequent | #165 |
12–14 | #166 |
receptor gene | #166 |
cotwins | #166 |
shared environment | #166 |
genetic influence | #166 |
linkage genetic | #166 |
earlyonset schizophrenia | #166 |
alcohol disorders aud | #166 |
symptom reduction | #166 |
domain criteria | #166 |
antidepressant therapy | #166 |
ipsych | #167 |
moderates | #167 |
association obesity | #167 |
leonard | #168 |
neurocognitive functions | #168 |
wisciii | #168 |
polygenic architecture | #168 |
children 6 years | #168 |
perseverations | #169 |
n111 | #169 |
multifactorial | #169 |
matter microstructure | #169 |
genetic association analysis | #169 |
duration illness | #169 |
international congress | #169 |
pharmacodynamic properties | #170 |
conditional probability | #170 |
cfg | #170 |
disorders young | #170 |
anxiety child | #170 |
lgi | #170 |
arrb2 | #170 |
risk gene | #170 |
single nucleotide schizophrenia | #170 |
traumas | #170 |
n91 | #171 |
child psychiatry | #171 |
genesets | #171 |
functional laterality humans | #171 |
immune disorders | #172 |
inattention impulsivity | #172 |
treatment studies | #172 |
enuresis | #173 |
interpersonal sensitivity | #173 |
disorders study | #173 |
male mental | #174 |
gabbr1 | #174 |
subsyndromal | #175 |
tics | #175 |
large samples | #175 |
mph placebo | #176 |
confounds | #176 |
development schizophrenia | #176 |
confounded | #177 |
independent datasets | #177 |
ascertainment | #177 |
patients opioid | #177 |
suicide death | #177 |
hyperactive children | #177 |
disorders sex | #177 |
kraepelin | #177 |
strong genetic component | #178 |
parent rated | #178 |
cortical surface | #178 |
n78 | #178 |
underpinnings | #179 |
atomoxetine atx | #179 |
genetic confounding | #179 |
gene interactions | #179 |
pregnancy children | #179 |
strongest evidence | #179 |
behaviorally | #179 |
nagelkerke | #180 |
cvlt | #180 |
copy variants | #180 |
connectivity networks | #180 |
mothers pregnancy | #181 |
perceptual disorders | #181 |
combinatory | #181 |
unemotional traits | #181 |
control participants | #182 |
phenocopies | #182 |
scz bip | #182 |
htr4 | #182 |
271 | #182 |
structured | #182 |
rating | #183 |
studies gwas | #183 |
mechanistic target | #183 |
genotype humans | #183 |
psychometric testing | #183 |
effects atomoxetine | #184 |
reading difficulties | #184 |
wei | #184 |
based morphometry | #184 |
genome human | #185 |
long acting | #185 |
phenocopy | #185 |
n‐acetylcysteine | #185 |
reward sensitivity | #185 |
allison | #185 |
pdd | #185 |
biomarker studies | #186 |
predominately | #186 |
218 | #186 |
hyperactivity symptoms | #186 |
statistical female | #186 |
schizophrenia major depression | #187 |
schizophrenia evidence | #187 |
risperidone placebo | #187 |
stratifying | #187 |
3 untranslated region | #188 |
enigma | #188 |
autocorrelation | #188 |
blood biomarkers | #188 |
parahippocampus | #188 |
depression treatment | #188 |
genetic correlations | #189 |
undertreatment | #189 |
bna | #189 |
differential association | #189 |
scwt | #190 |
functioning children | #190 |
childhood | #190 |
medication adhd | #190 |
linkage evidence | #190 |
mood disorder | #191 |
psychiatric phenotypes | #191 |
schedule female | #191 |
implicated | #191 |
mph children | #191 |
greater activation | #191 |
dopamine genes | #191 |
clarify | #191 |
social dysfunction | #191 |
fsiq | #191 |
iasp | #192 |
612 years | #192 |
association response | #192 |
freedman | #194 |
joseph | #194 |
inconsistent findings | #194 |
clinical global | #195 |
polymorphisms snps | #195 |
cognitive endophenotypes | #195 |
sza | #195 |
placebo p001 | #195 |
overactivity | #197 |
dependence symptoms | #197 |
wm performance | #197 |
neural substrates | #197 |
arhgef9 | #197 |
perinatal complications | #197 |
g×s | #198 |
mdd scz | #198 |
developmentally | #198 |
lifetime diagnosis | #198 |
snps schizophrenia | #198 |
ptk2b | #198 |
specific genes | #199 |
raises | #199 |
childhood symptoms | #199 |
asic1a | #199 |
male | #199 |
bsd | #199 |
male phenotype | #199 |
asd adhd | #200 |
small samples | #200 |
childhood attention | #200 |
disruptive disorders | #200 |
mri data | #200 |
neuropsychological battery | #200 |
disorder humans | #201 |
functional genomics | #201 |
parents schizophrenia | #201 |
catecholomethyltransferase | #201 |
cognitive flexibility | #202 |
pain tolerance | #202 |
genetic liability | #203 |
unaffected | #203 |
pdq | #203 |
neuropsychological correlates | #203 |
childhood adulthood | #203 |
stopsignal task | #203 |
control association | #203 |
attentional control | #204 |
respond | #204 |
extend | #204 |
schizophreniform | #204 |
adolescent psychiatry | #204 |
concurrent validity | #204 |
microsatellite marker | #204 |
uptodate | #206 |
nonshared | #206 |
selfdirectedness | #206 |
genes risk | #206 |
sluggish cognitive tempo | #207 |
method drug | #207 |
prolactin levels | #208 |
parental alcohol | #208 |
prkg1 | #208 |
susceptibility schizophrenia | #208 |
baseline follow | #209 |
variable expression | #209 |
clinical benefits | #209 |
maudsley | #210 |
acds | #210 |
n96 | #210 |
60mg | #210 |
park2 | #210 |
5year followup | #210 |
correspondence | #210 |
vntr polymorphism | #211 |
greater risk | #211 |
predisposition disease | #211 |
ps005 | #212 |
dimensional models | #212 |
hkdc1 | #212 |
adult patients adhd | #212 |
apoe4 allele | #212 |
grm7 | #212 |
stroop task | #212 |
trauma ptsd | #213 |
sampling strategy | #213 |
replication studies | #213 |
sought | #213 |
negative outcomes | #213 |
cvltii | #214 |
continuous performance test | #214 |
humans neuropsychological | #214 |
disorders models | #214 |
rare cnvs | #214 |
suggestive evidence | #214 |
schizophrenia chinese | #214 |
lifetime version | #215 |
adult cognition | #215 |
bilag | #215 |
male mental disorders | #215 |
vivo correlation | #216 |
functional mri study | #216 |
chromosome 15 | #217 |
male schizophrenia | #217 |
glr | #217 |
antisocial personality | #217 |
parental | #218 |
gene based | #218 |
panic | #218 |
trim31 | #218 |
hippocampal subfield | #218 |
misunderstood | #219 |
polygenic | #219 |
study selection | #219 |
normal controls | #220 |
drug double | #220 |
snpa | #220 |
triangularis | #221 |
symptoms adults | #221 |
parental psychopathology | #221 |
irritable mood | #221 |
studies cognition | #221 |
telephone interview | #221 |
n76 | #222 |
childhoodonset | #222 |
score male | #222 |
patient engagement | #222 |
methyltransferase comt | #222 |
diagnoses | #222 |
learning disability | #223 |
revisited | #223 |
study findings | #223 |
axis disorders | #224 |
adhd sleep | #224 |
abnormalities schizophrenia | #224 |
sensing ion | #224 |
gria2 | #224 |
effective treatments | #224 |
default network | #225 |
coordination disorder | #225 |
bipolar spectrum | #225 |
hk3 | #226 |
inattentiveness | #226 |
subfields | #226 |
children placebo | #226 |
individual variability | #227 |
criteria diagnosis | #227 |
subcortical regions | #227 |
scales psychotic | #227 |
dependent variables | #227 |
unemotional | #227 |
disorder study | #227 |
atomoxetine treatment | #228 |
age subjects | #228 |
comorbid anxiety disorders | #228 |
control based | #228 |
male twins | #228 |
equally | #229 |
birth complications | #229 |
structural abnormalities | #229 |
overlapped | #229 |
psychiatric outcomes | #230 |
4years | #231 |
risk indicators | #231 |
commission errors | #231 |
heritable | #231 |
international multicenter | #231 |
differences prevalence | #232 |
serotonin transporter gene | #232 |
hyperactivity behavior | #232 |
candidate genes | #234 |
study sample | #234 |
worse performance | #234 |
discriminating | #235 |
disorder medication | #235 |
probabilistic forecasts | #235 |
shr wky rats | #236 |
fifty years | #238 |
placebo response | #238 |
reliably | #238 |
route administration | #238 |
agoraphobia | #238 |
allelic heterogeneity | #239 |
scientific data | #240 |
patients siblings | #240 |
pdag | #240 |
nosology | #240 |
healthy siblings | #240 |
acid oxidase | #240 |
adequately | #241 |
adolescent offspring | #241 |
doubleblind | #241 |
disorder asd | #241 |
symptoms quality | #241 |
sodium hydrogen | #242 |
joint analysis | #242 |
psychiatric comorbidities | #242 |
neurodevelopmental model | #242 |
reward processing | #242 |
impulsive choice | #242 |
onset obsessive | #243 |
aggressive behaviors | #243 |
female | #243 |
valid | #243 |
patients relatives | #243 |
giftedness | #244 |
n74 | #244 |
population differences | #245 |
disorder ptsd | #245 |
paliperidone | #245 |
adversity | #245 |
interregional | #245 |
5ht2a receptor | #245 |
cadm2 | #246 |
community controls | #246 |
expression genetic | #246 |
dsmivtr | #246 |
motor performance | #247 |
812 | #247 |
studies associations | #248 |
chinese families | #248 |
epigenetic studies | #248 |
cigarette smoking | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
german patients | #252 |
hypoactivation | #252 |
intellect | #253 |
iqs | #253 |
female subjects | #253 |
genomewide association | #253 |
tourette | #253 |
benzodiazepine | #254 |
studies metaanalysis | #254 |
study schizophrenia | #254 |
kappas | #254 |
cpt performance | #254 |
schizophrenia adult | #254 |
conduct problems | #255 |
larsson | #256 |
cacna1c gene | #256 |
biochemical studies | #256 |
shared genetic | #256 |
carlson | #257 |
children adhd symptoms | #257 |
year study | #259 |
endorsement | #259 |
parental depression | #259 |
piq | #260 |
n61 | #260 |
diagnosis | #261 |
anxiety depressive disorders | #261 |
dexamphetamine | #261 |
pharmacotherapy | #261 |
sex factors | #263 |
genomewide linkage scan | #263 |
obsessive compulsive disorder | #263 |
selfreports | #263 |
22q11ds | #263 |
fluid intelligence | #263 |
disorder personality | #264 |
attention problems | #264 |
conceptualized | #264 |
distinct subtypes | #264 |
adverse health | #264 |
confirm | #264 |
long term outcomes | #265 |
new models | #266 |
diagnostic validity | #266 |
ptsd risk | #266 |
5090 | #266 |
schizophrenia cases | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
strong support | #268 |
genetic approaches | #268 |
neuropsychological impairment | #268 |
diagnosis schizophrenia | #268 |
test scores | #269 |
diagnostic process | #269 |
years baseline | #269 |
largest | #270 |
phlda1 | #270 |
age effects | #270 |
withdrawn | #270 |
segregate | #270 |
circadian genes | #271 |
adult psychiatric | #271 |
genetic overlap | #271 |
social adversity | #271 |
sibling pairs | #271 |
symptoms assessed | #271 |
structural brain | #272 |
diagnostic issues | #272 |
statistics topic | #273 |
age | #273 |
4year | #273 |
rora | #273 |
alcohol smoking | #273 |
szs | #273 |
search terms | #273 |
444 | #273 |
schizophrenia siblings | #273 |
sleep behavior | #274 |
22 years | #274 |
surgency | #275 |
maf1 | #275 |
reading disability | #275 |
underlie | #275 |
familial schizophrenia | #276 |
t102c | #276 |
2q | #276 |
missingness | #276 |
adhd healthy controls | #277 |
adolescent risk | #277 |
nicotinic schizophrenia | #277 |
growing evidence | #277 |
mania symptoms | #277 |
manual | #278 |
synaptosomal | #278 |
nr3c1 | #278 |
clinical setting | #278 |
early psychosis | #278 |
ocd | #279 |
silico approach | #279 |
nicotine dependence | #279 |
intelligence scale | #279 |
brain volumes | #280 |
rating scale | #280 |
child parent | #280 |
polygenic risk | #280 |
remitted | #280 |
acting | #280 |
n47 | #280 |
abuser | #280 |
cognition female | #280 |
premature death | #281 |
individuals | #281 |
phenotyped | #281 |
disorders adult | #281 |
psychotic bipolar | #281 |
response inhibition | #282 |
5ht1b | #282 |
reading problems | #282 |
collaborative analysis | #282 |
onset ocd | #282 |
titrated | #283 |
continue | #283 |
velo | #283 |
antisocial behaviors | #283 |
aspd | #284 |
quantitative traits | #285 |
gria3 | #285 |
normal variation | #285 |
3untranslated region | #285 |
neuroanatomical | #285 |
neoffi | #285 |
clues | #286 |
siblings patients | #286 |
swanson | #286 |
quantitative analyses | #286 |
scale children | #286 |
explication | #286 |
effects age | #287 |
deficit schizophrenia | #288 |
schizophrenia abnormalities | #288 |
bmisds | #289 |
postmortem brain | #289 |
psychiatric traits | #290 |
disease haplotypes | #290 |
22q112 | #290 |
pediatric ocd | #290 |
publication bias | #291 |
low serum levels | #291 |
subcortical volumes | #291 |
substrain | #292 |
modest | #293 |
groups children | #293 |
cognition disorders | #294 |
hypertensive rat | #294 |
subjective responses | #294 |
salary | #294 |
psychosis schizophrenia | #295 |
european populations | #295 |
interference control | #295 |
adverse impact | #295 |
dtnbp1 | #295 |
post‐traumatic stress disorder | #295 |
risk factors children | #295 |
executive functions | #296 |
ldsc | #296 |
continuous performance | #296 |
asd traits | #297 |
anxiety disorder | #297 |
early onset | #297 |
obesity overweight | #297 |
diagnostic approach | #298 |
discriminated | #298 |
reanalysis | #298 |
predisposition | #299 |
negative symptom | #299 |
effects stress | #300 |
qvalues | #300 |
cortical thickness | #300 |
roc analysis | #301 |
psychiatric hospitalization | #301 |
cognitive measures | #301 |
states adolescent | #302 |
emotional problems | #302 |
prefrontal function | #302 |
published literature | #302 |
intrasubject variability | #302 |
psychometrics | #303 |
height body | #303 |
permuted | #303 |
psychiatric conditions | #304 |
795 | #304 |
ats | #305 |
case subjects | #305 |
aggressive behavior | #305 |
interviewers | #305 |
manifest | #305 |
affective disorders | #305 |
dsm5 | #305 |
dopamine transporter | #306 |
early morning | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
membrane transport | #309 |
perseveration | #309 |
documented | #309 |
gene environment | #309 |
omission errors | #309 |
myh9 | #309 |
spencer | #309 |
genetic schizophrenia | #310 |
motor domain | #310 |
efficacy treatment | #310 |
life social support | #310 |
memory wm | #310 |
adolescent aggression | #310 |
rdoc | #311 |
stroop test | #312 |
gender age | #312 |
mainstays | #312 |
childhood adolescence | #312 |
mapping female | #313 |
npsr1 | #313 |
underscore | #314 |
genetic analyses | #314 |
risk estimation | #315 |
bedtimes | #315 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
asb | #317 |
demonstrable | #318 |
schizophrenia review | #318 |
5ht2c | #319 |
n55 | #319 |
individual genes | #319 |
adolescent adrenergic | #320 |
shared genetic influences | #321 |
gene | #321 |
intelligence tests | #321 |
addictive disorders | #321 |
risperidone treatment | #322 |
bipolar type | #322 |
robins | #322 |
humans longitudinal | #322 |
127 | #322 |
time variability | #323 |
abusers | #323 |
conceptual models | #324 |
guanfacine | #324 |
nolan | #324 |
manic | #325 |
neonatal abstinence syndrome | #326 |
sex characteristics | #326 |
yielded | #326 |
status female | #327 |
impaired | #327 |
spurious | #327 |
xq26 | #327 |
etiologic | #328 |
comprised | #328 |
disorders pervasive | #329 |
8q | #329 |
metaanalyses | #330 |
overrepresented | #330 |
sexdifferences | #330 |
scores patients | #331 |
htr2a | #331 |
drug response | #331 |
women schizophrenia | #332 |
expression brain | #333 |
naltrexone | #333 |
txndc5 | #333 |
familial factors | #333 |
cognitive dysfunctions | #334 |
multiple comparisons | #334 |
obesity diabetes | #334 |
mood disorders | #335 |
24weeks | #335 |
forthcoming | #335 |
adler | #335 |
methylphenidate placebo | #336 |
persist | #336 |
inferior parietal lobule | #336 |
humans mental | #336 |
rey | #336 |
mobp | #337 |
777 | #337 |
tph2 | #337 |
neuropsychological test | #337 |
asd individuals | #337 |
disentangle | #338 |
patients attention | #339 |
evening | #339 |
replications | #339 |
psychopathological | #339 |
disorder ocd | #340 |
consistently | #340 |
pnmt | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
placebo effects | #341 |
encompassing | #341 |
treatment bipolar | #341 |
intelligence | #341 |
maoa genotype | #342 |
bipolarity | #342 |
multicenter analysis | #342 |
phobic | #342 |
neuroimaging studies | #342 |
visual memory | #342 |
integrated analysis | #344 |
schizoaffective disorder | #344 |
tbv | #344 |
frontal pole | #344 |
mood problems | #344 |
comorbid diagnoses | #344 |
catechol methyltransferase | #345 |
casecontrol studies | #345 |
systematically | #345 |
864 | #346 |
gifts | #346 |
study genotype | #347 |
mdd bpd | #347 |
confused | #347 |
converging | #348 |
tic severity | #348 |
psychotic | #348 |
collaborative study | #349 |
schizotypal personality disorder | #349 |
temporal processing | #349 |
adolescent anxiety | #350 |
aetiological | #350 |
methylphenidate atomoxetine | #350 |
suspiciousness | #351 |
distractibility | #352 |
disequilibrium | #352 |
receptor genes | #352 |
adults children | #352 |
disease genome | #353 |
impairing | #353 |
disorders middle | #354 |
maob | #354 |
substantial | #354 |
genetic environmental | #354 |
child attention | #354 |
brain atlas | #354 |
reln | #354 |
executive attention | #354 |
gabra1 | #354 |
dsmiii | #355 |
prodh | #355 |
male adolescent | #355 |
rgs4 | #355 |
phobic disorders | #356 |
schizophrenia data | #356 |
heterogeneous disorder | #356 |
measures attention | #357 |
chrna7 | #357 |
children anxiety disorders | #357 |
gottesman | #358 |
maternal cigarette smoking | #359 |
persists | #359 |
psychiatric symptoms | #359 |
disorder patients | #359 |
deviant | #359 |
linkage analysis | #360 |
symptom scores | #360 |
n54 | #361 |
neuroleptic treatment | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
elevated risk | #366 |
core symptoms | #366 |
confirmation | #366 |
memory load | #367 |
pediatric populations | #367 |
771 | #367 |
comparison groups | #368 |
risk psychopathology | #368 |
bpd mdd | #368 |
study entry | #368 |
young adulthood | #369 |
702 | #369 |
hyperactivityimpulsivity | #369 |
differential involvement | #369 |
nervousness | #370 |
differential susceptibility | #370 |
representativeness | #370 |
schizophrenia risk | #371 |
current concepts | #371 |
damphetamine | #371 |
comt gene | #372 |
replicate | #372 |
endorse | #372 |
prevention strategies | #372 |
executive function | #373 |
5httlpr | #373 |
genomewide association studies | #373 |
snp heritability | #374 |
small sample | #374 |
driving performance | #374 |
916 | #375 |
dozens | #375 |
wide analysis | #375 |
scz | #375 |
teenage | #376 |
emphases | #376 |
medication children | #376 |
sas | #377 |
data studies | #377 |
memory short | #377 |
genetic architecture | #377 |
children medication | #377 |
child adolescent | #377 |
schizotypal personality | #378 |
children adolescents | #378 |
impression | #378 |
control adults | #379 |
marriages | #379 |
pearson | #380 |
converged | #380 |
opd | #380 |
ht1b | #380 |
youths | #380 |
invaluable | #381 |
overlap | #381 |
culmination | #381 |
general cognitive ability | #381 |
receptors dopamine | #381 |
disorder diagnostic | #381 |
methylphenidate children | #381 |
relevant articles | #381 |
chisquare | #382 |
adolescent patients | #382 |
psychopharmacological treatment | #383 |
carefully | #383 |
antimanic | #383 |
psychopathologies | #383 |
researched | #384 |
summary statistics | #384 |
7r | #385 |
gad2 | #385 |
multigenerational | #386 |
treatment children | #386 |
18p | #386 |
neural activation | #387 |
chinese subjects | #387 |
contrasted | #388 |
evenings | #388 |
versa | #388 |
npas2 | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
brain circuits | #390 |
studies children | #390 |
disorder symptoms | #390 |
handedness | #390 |
lefthandedness | #390 |
perinatal morbidity | #390 |
genetic predisposition | #391 |
interaction genetic | #391 |
schizophrenia susceptibility | #392 |
lambert | #392 |
comorbid substance | #392 |
p54 | #393 |
genes expression | #394 |
substance users | #394 |
dopamine norepinephrine | #395 |
function humans | #395 |
hippocampal subfields | #395 |
adolescents adults | #396 |
3methoxy4hydroxyphenylglycol | #397 |
mental health children | #397 |
schizophrenia disorder | #397 |
psychometric | #397 |
disorders schizophrenia | #397 |
fbat | #397 |
spm8 | #398 |
wandering | #398 |
earlier onset | #398 |
clinical risk psychosis | #398 |
neuropsychological testing | #400 |
control sample | #401 |
suffocation | #402 |
inattention symptoms | #402 |
core symptom | #402 |
academic outcomes | #402 |
relations male | #403 |
inconsistencies | #403 |
implications findings | #403 |
psychostimulants | #405 |
hyperparameter | #405 |
neuropsychiatric conditions | #406 |
n52 | #406 |
vntrs | #406 |
diagnosis children | #406 |
parahippocampal | #406 |
attending | #407 |
childhood risk | #408 |
cognitive inhibition | #408 |
0038 | #409 |
communitybased | #409 |
behavior genetics | #409 |
distinct subsets | #410 |
substance | #410 |
children studies | #411 |
twin study | #411 |
reading comprehension | #411 |
impulsive behavior | #411 |
dextroamphetamine | #411 |
psychotic disorders | #412 |
childhood anxiety | #412 |
apoe4 | #412 |
tourette syndrome | #412 |
neanderthal | #412 |
consistent evidence | #412 |
interview | #412 |
systematic literature search | #413 |
anticipation | #413 |
moderated | #413 |
performance tests | #414 |
151 | #414 |
reviewing | #414 |
volition | #415 |
polymorphism snp | #415 |
genetic receptor | #416 |
elucidating | #416 |
schizotypal | #416 |
functional effects | #417 |
effects brain | #417 |
conferred | #418 |
adolescent psychiatric | #418 |
adult intelligence | #418 |
genetic association | #419 |
srsa | #419 |
deletion syndrome | #419 |
questionnaires adolescent | #419 |
dopamine d4 receptor | #420 |
antidepressive agents | #420 |
kdm4a | #420 |
daily doses | #420 |
sexes | #421 |
adult subjects | #421 |
modestly | #421 |
iccs | #422 |
cdis | #422 |
drug dependence | #422 |
operating characteristic | #422 |
tricyclic | #423 |
reliability validity | #423 |
medicated | #423 |
characteristic curve | #424 |
gcta | #424 |
transport proteins | #425 |
discovery sample | #425 |
subtests | #425 |
cardiff | #426 |
parent ratings | #426 |
attain | #427 |
hum | #427 |
spectrum disorders | #428 |
diversion | #428 |
brain volume | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
disentangling | #431 |
personality development | #431 |
operating characteristics | #432 |
teacher | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
perceptual organization | #436 |
frequency genotype | #436 |
cprs | #436 |
1433 | #436 |
12q | #436 |
lower scores | #437 |
relatives patients | #437 |
grin2a | #437 |
disorder brain | #437 |
correlation coefficients | #438 |
adolescent psychopathology | #438 |
srs2 | #438 |
impulsiveness | #438 |
toddlerhood | #438 |
visual learning | #438 |
22q112ds | #439 |
digit span | #439 |
risk psychosis | #439 |
nominal | #439 |
genetic genetic predisposition | #439 |
method female | #440 |
aged neuropsychological | #440 |
major risk factor | #440 |
snps association | #440 |
post hoc analysis | #441 |
trex | #441 |
white matter microstructure | #441 |
meaningful | #441 |
gmo | #441 |
allelic association | #441 |
corroborated | #441 |
virtual histology | #442 |
female functional | #442 |
disorders autism | #442 |
planum temporale | #442 |
adult analysis | #442 |
logistic regression model | #442 |
n80 | #443 |
differential female | #444 |
disorders surveys | #444 |
conferring | #444 |
10 year | #444 |
emphasize | #444 |
pcdh10 | #445 |
statistic | #446 |
ntrk3 | #446 |
nucleotide receptors | #446 |
534 | #446 |
862 | #446 |
holland | #447 |
motor coordination | #448 |
originally | #448 |
genome wide | #448 |
behavior child | #448 |
earlier age | #449 |
expressiveness | #449 |
early response | #450 |
wistar kyoto | #450 |
risk variants | #450 |
exceptions | #451 |
sex | #451 |
prevalence correlates | #452 |
subsequent risk | #452 |
clinical expression | #452 |
brain abnormalities | #452 |
chat | #456 |
children adolescent | #456 |
zscores | #457 |
psychiatry | #457 |
79 | #457 |
masse | #458 |
structural magnetic | #458 |
independently | #458 |
preliminary study | #458 |
22q112 deletion | #460 |
522 | #460 |
lander | #460 |
genetic correlation | #460 |
polygenic risk score | #460 |
psychotic disorders schizophrenia | #460 |
hyperkinesis | #461 |
smoking pregnancy | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
pregnancy complications | #465 |
decrements | #465 |
life treatment | #465 |
affection | #465 |
runs | #466 |
gene sets | #466 |
control rates | #466 |
anxiety depressive | #467 |
inbred wky | #467 |
mini | #467 |
bpad | #468 |
subjects patients | #469 |
genetic effects | #470 |
patient adherence | #470 |
disorders treatment | #470 |
cacna1c | #470 |
remission relapse | #471 |
receiver operating | #471 |
psychology adolescent | #472 |
risk allele | #472 |
response remission | #473 |
chrna4 | #473 |
plp1 | #474 |
norepinephrine transporter | #474 |
environmental risk factors | #474 |
developmental coordination | #476 |
cautious | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
5th | #479 |
multiplex families | #479 |
dysthymia | #479 |
humans | #480 |
symptom | #480 |
adds | #480 |
genetic risk variants | #480 |
cortex child | #481 |
semistructured | #481 |
diagnostic categories | #481 |
genotyped | #482 |
maternal anxiety | #482 |
data extraction | #482 |
etiology | #483 |
arithmetic | #483 |
sml | #484 |
nfil3 | #484 |
conception | #484 |
verbal learning | #484 |
treatment methylphenidate | #484 |
agents bipolar | #485 |
756 | #485 |
adulthood | #485 |
baseline age | #486 |
epidemiologically | #486 |
outcome variables | #486 |
symptom dimensions | #487 |
evaluates | #487 |
adult anxiety | #487 |
123 | #487 |
spontaneity | #488 |
female adolescents | #489 |
genetic disorders | #489 |
unpublished | #489 |
longterm effects | #489 |
neuropsychiatric disorder | #490 |
schizophrenia autism | #490 |
administration schedule | #490 |
shared environmental | #490 |
smoking prevention | #492 |
common variant | #492 |
schizophrenia age | #492 |
pnds | #493 |
overlapping | #493 |
late adolescence | #495 |
antisocial personality disorder | #495 |
frequency genetic | #495 |
separation anxiety | #497 |
psychobiology | #497 |
anxiety | #497 |
schizophrenia patients | #497 |
pair human | #497 |
restlessness | #497 |
longitudinal studies | #498 |
bonferroni | #498 |
daoa | #499 |
placebos | #499 |
addressed | #499 |
candidate | #499 |
genetic mechanisms | #499 |
case reports | #500 |
comt val158met polymorphism | #500 |
identifying | #500 |
d4 receptors | #501 |
rat strains | #501 |
nocebo | #501 |
verbal memory | #503 |
additional evidence | #503 |
865 | #503 |
child executive | #505 |
circadian clock genes | #505 |
n26 | #506 |
subscale | #506 |
fallacy | #506 |
cooperativeness | #507 |
continued | #507 |
tobacco disorder | #508 |
reflecting | #508 |
developing schizophrenia | #509 |
delay discounting | #509 |
agg | #510 |
educational status | #511 |
shared | #511 |
dichotomous | #511 |
p80 | #512 |
obsessive compulsive | #512 |
identifiable | #512 |
95 death | #512 |
risk haplotype | #513 |
lod | #513 |
disproportionate | #514 |
coaggregation | #514 |
morning | #515 |
assessments | #515 |
phis | #515 |
disorders depression | #515 |
total sample | #516 |
normal control | #516 |
cognitive traits | #517 |
n39 | #517 |
contributing | #517 |
15q | #518 |
missing link | #519 |
environmental influences | #520 |
fn1 | #520 |
pbat | #520 |
specificity ppv | #521 |
gyrus cinguli | #521 |
dichotic | #521 |
social class | #522 |
disorder obsessive | #522 |
selfreport | #522 |
polymorphism single | #522 |
attention memory | #523 |
dibenzothiazepines | #523 |
dmi | #524 |
phg | #524 |
assortative | #524 |
adult bipolar | #524 |
dedication | #524 |
disorder treatment | #525 |
clinical diagnoses | #525 |
sciencedirect | #525 |
covariates | #525 |
pacific island | #525 |
affiliations | #526 |
persistence | #527 |
criminality | #527 |
functioning | #527 |
design study | #528 |
symptomatic remission | #528 |
adolescent children | #528 |
adverse life events | #528 |
depression anxiety disorders | #528 |
community samples | #529 |
flnc | #529 |
abrupt | #529 |
ruled | #529 |
parental reports | #529 |
compulsive disorder | #529 |
tagsnps | #530 |
control children | #530 |
medications | #531 |
strongest | #531 |
increased burden | #531 |
autism schizophrenia | #532 |
n40 | #532 |
existing studies | #532 |
subjects age | #533 |
clinical sample | #533 |
analyses conducted | #534 |
temperament character | #534 |
selective review | #535 |
intercorrelations | #535 |
asd | #535 |
global impression | #537 |
parsing | #537 |
autistic symptoms | #538 |
child adhd | #538 |
models genetic | #538 |
d4 receptor | #539 |
milder | #541 |
personality factors | #541 |
lobe humans | #542 |
taiwanese | #543 |
disease genotype | #543 |
single nucleotide | #543 |
independent samples | #544 |
complexities | #544 |
severe symptoms | #544 |
population sample | #545 |
ld | #545 |
choice behavior | #546 |
cognitive impairments | #546 |
genetic influences | #547 |
computer program | #548 |
healthy control subjects | #548 |
functional variant | #548 |
risk children | #549 |
clash | #549 |
patients schizophrenia | #549 |
behavior male | #549 |
nonclinical sample | #549 |
schizophrenia study | #549 |
oral route | #549 |
dichotomized | #549 |
765 | #550 |
fam | #550 |
genetic pathways | #550 |
define | #551 |
case control | #551 |
ideally | #551 |
motor inhibition | #551 |
major diagnosis | #552 |
performance test | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
viewed | #555 |
suggests | #555 |
release oral | #555 |
prs schizophrenia | #555 |
phenotypic features | #556 |
spectrum disorder | #556 |
child anxiety | #557 |
neuropsychiatric diseases | #557 |
nogo task | #557 |
equivocal | #558 |
neurodevelopmental | #558 |
africanamerican | #558 |
justify | #559 |
gray matter volumes | #560 |
response variability | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
adolescents risk | #565 |
risk smoking | #565 |
4th edition | #566 |
patients sud | #566 |
intermediate phenotypes | #566 |
risky behaviors | #566 |
twins female | #566 |
neurocognitive impairment | #567 |
haplotype | #567 |
3050 | #567 |
unaffected relatives | #568 |
replication study | #569 |
diverging | #570 |
environment interaction | #570 |
onsets | #570 |
10−8 | #570 |
birthday | #571 |
keywords | #571 |
risk genes | #571 |
dose reduction | #573 |
white matter abnormalities | #574 |
irritability | #574 |
obesity body mass | #574 |
inbred shr | #575 |
questionnaires adult | #575 |
spaced | #576 |
gyri | #576 |
asd diagnosis | #576 |
medical genetics | #577 |
parent | #577 |
schizophrenia sample | #577 |
chromosomes human | #577 |
individually | #577 |
impulsivity | #578 |
82 | #578 |
finetuning | #578 |
symptoms children | #579 |
subsample | #579 |
5httlpr polymorphism | #580 |
development anxiety | #580 |
preschool age | #580 |
cold pressor test | #580 |
haplotype analysis | #581 |
psychiatric association | #582 |
apol1 | #582 |
rdc | #582 |
drd1 | #582 |
delinquent behavior | #583 |
3rd | #583 |
new approaches | #584 |
hk1 | #584 |
fine mapping | #585 |
separately | #585 |
data children | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
examine | #588 |
defaultmode network | #588 |
compared controls | #588 |
nback task | #588 |
138 | #589 |
haplotypes humans | #590 |
patients comorbid | #591 |
behavior adult | #591 |
estonian | #591 |
40mg | #591 |
criticism | #593 |
2005 | #594 |
concordant | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
nonpharmacologic | #597 |
snap25 | #597 |
generalizable | #597 |
discounted | #597 |
899 | #598 |
new directions | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnostic specificity | #604 |
clinical settings | #604 |
diagnosing | #604 |
disorganized | #606 |
performance children | #606 |
clinician | #606 |
cognitive outcomes | #606 |
social environment | #607 |
personality traits | #607 |
4 6 | #608 |
sizeable | #608 |
small fraction | #608 |
true | #609 |
executive dysfunctions | #609 |
gold standard | #609 |
antisocial behavior | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
pleiotropic | #612 |
complex disorders | #612 |
chromosome 6 | #613 |
grandmothers | #614 |
educational achievement | #614 |
schizophrenia brain | #614 |
behavior disorder | #615 |
curve analysis | #615 |
snp markers | #615 |
disease etiology | #615 |
memory deficits | #616 |
genetic epidemiology | #616 |
prevalence severity | #616 |
tscores | #617 |
genome scans | #617 |
african children | #618 |
differ | #618 |
genetic associations | #618 |
val158met | #618 |
correcting | #619 |
digeorge | #619 |
vigilance | #620 |
genetic markers | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
juvenile delinquency | #624 |
receptor serotonin | #624 |
executive dysfunction | #625 |
misconceptions | #625 |
executive control | #625 |
mood stabilizers | #626 |
hrr | #627 |
seeks | #627 |
attentional deficits | #627 |
treatment disorder | #629 |
child gender | #629 |
fibromyalgia | #629 |
schizophrenia findings | #630 |
reject | #631 |
deficits schizophrenia | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
icv | #638 |
generalisability | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
advertisement | #641 |
adult outcomes | #641 |
ranks | #641 |
illness duration | #642 |
inconsistent | #643 |
gateway | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
avoidant | #652 |
gene association | #652 |
treatment effects | #652 |
128 | #653 |
physical conditions | #653 |
hyperactivity inattention | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
random allocation rats | #656 |
bipolar disorder schizophrenia | #656 |
reward anticipation | #656 |
studies evidence | #657 |
groups compared | #658 |
impairment | #658 |
boldness | #658 |
psychosocial treatment | #658 |
hypomanic | #659 |
volumes | #659 |
association exposure | #660 |
core feature | #661 |
poorer performance | #661 |
peer relations | #662 |
referrals | #662 |
structural alterations | #662 |
digeorge syndrome | #665 |
permission | #665 |
lowlevel | #665 |
subcortical | #666 |
dacc | #666 |
psychiatric illnesses | #667 |
mood | #668 |
prominent | #669 |
swedish population | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
129 | #679 |
sleep difficulties | #679 |
middle childhood | #680 |
psychopathological symptoms | #680 |
mental disorders humans | #680 |
neurotic | #681 |
gene frequency | #681 |
semantic fluency | #682 |
trait | #682 |
quetiapine | #682 |
soviet union | #682 |
severe phenotype | #683 |
east asian | #685 |
remitting | #685 |
scales | #685 |
p0019 | #687 |
chromosomal region | #688 |
children groups | #688 |
17q | #688 |
younger children | #689 |
fibromyalgia patients | #689 |
postmortem brains | #689 |
tcas | #694 |
average age | #694 |
disorder schizophrenia | #694 |
testretest reliability | #695 |
cortical surface area | #696 |
participants | #696 |
parcellation | #696 |
5years | #697 |
4–5 | #697 |
pharmacokinetic profile | #697 |
drug abuse | #699 |
122 | #699 |
relevant studies | #699 |
effects methylphenidate | #700 |
nonrandom | #701 |
adult mental | #701 |
illness surveys | #701 |
quota | #701 |
treatmentnaïve | #704 |
pleiotropic effects | #704 |
gwa studies | #704 |
follow studies | #705 |
preschool years | #706 |
adaptive functioning | #706 |
pathogenesis schizophrenia | #706 |
autism spectrum | #708 |
school settings | #709 |
p009 | #709 |
children diagnosed | #710 |
informative | #713 |
chronic schizophrenia | #713 |
eric | #714 |
dysphoric | #714 |
maternal report | #714 |
misuse | #714 |
prs | #714 |
disorders substance | #715 |
ethanol consumption | #715 |
728 | #715 |
stress disorder | #715 |
641 | #716 |
3 weeks | #716 |
contradictory | #717 |
groundwork | #719 |
abstraction | #719 |
meta‐analysis | #720 |
clinical population | #721 |
multiple genes | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
gender dysphoria | #726 |
male adolescents | #726 |
lateonset | #726 |
common snps | #726 |
attention deficits | #727 |
schizophrenics | #727 |
dizygotic | #728 |
statistical | #728 |
structured clinical interview | #729 |
assortative mating | #729 |
fmri study | #730 |
786 | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
git | #733 |
voxel based | #733 |
correlates | #733 |
phenotypic heterogeneity | #734 |
finding | #734 |
wky | #735 |
health intervention | #737 |
gyrification | #737 |
life cycle | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
boston | #742 |
refill | #742 |
caudate | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
bupropion | #745 |
topic twins | #745 |
soviet | #745 |
neuropsychological status | #746 |
compulsive | #746 |
manifested | #747 |
duplications | #748 |
child interaction | #748 |
adrb1 | #749 |
examining | #750 |
934 | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
molecular genetic analysis | #754 |
347 | #754 |
post hoc | #755 |
comt val158met | #755 |
mental disorders | #756 |
recalled | #756 |
neuroleptics | #756 |
bipolar depression | #756 |
nhe | #757 |
schizophrenia scz | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
humans logistic | #765 |
likelihoods | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
comt polymorphism | #772 |
emerged | #772 |
performance patients | #774 |
birth rates | #776 |
parent reported | #776 |
depressive | #777 |
behavioral phenotypes | #777 |
human pair | #777 |
phenotypes | #778 |
deletion polymorphism | #779 |
euthymic | #779 |
weaknesses | #780 |
schizophrenia relationship | #780 |
risky behavior | #780 |
inheritance | #781 |
iowa gambling task | #782 |
wky rats | #782 |
questioning | #783 |
fourth edition | #783 |
combined analysis | #783 |
emerging roles | #784 |
mega | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
adolescence | #787 |
963 | #787 |
pbd | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
behavioral | #791 |
spelling | #791 |
cgi | #791 |
subtypes | #792 |
clinical criteria | #793 |
individuals schizophrenia | #793 |
association polymorphisms | #794 |
motivations | #794 |
symptom burden | #794 |
delinquent | #796 |
caveats | #796 |
separate | #797 |
additional studies | #800 |
363 | #800 |
genomic regions | #802 |
dopamine d1 receptors | #803 |
prenatal exposure | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
superior frontal | #805 |
clinically | #805 |
dysfunction | #805 |
male memory | #806 |
dorsolateral | #806 |
novelty seeking | #806 |
latent classes | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
ucla | #810 |
dopamine function | #810 |
phonemic | #811 |
preschool female humans | #811 |
adjusting | #811 |
dopamine serotonin | #811 |
blind | #813 |
coadministration | #815 |
declarative | #816 |
mhpg | #816 |
quantitative measures | #817 |
breakthroughs | #817 |
lasting | #817 |
cfb | #817 |
tryptophan hydroxylase | #817 |
substance dependence | #818 |
single gene | #818 |
epigenetic factors | #818 |
memory attention | #818 |
cortical development | #820 |
meeting | #820 |
rated | #821 |
patients psychotic disorders | #821 |
counties | #821 |
hme | #822 |
switches | #822 |
prefrontal regions | #824 |
parental report | #824 |
transcriptomic analysis | #824 |
rare coding variants | #825 |
common genetic | #825 |
humans models | #827 |
adolescents asd | #827 |
s100a6 | #828 |
treatment interventions | #829 |
timeframe | #830 |
multipoint | #830 |
lifetime prevalence | #831 |
multiple testing | #831 |
prevalent | #831 |
conduct disorders | #832 |
association tests | #832 |
liabilities | #833 |
college students | #834 |
n60 | #837 |
sleep disorder | #837 |
gray | #837 |
matter humans | #838 |
aversion | #838 |
inbred shr rats | #838 |
symptom profiles | #839 |
obstetric complications | #839 |
prescription | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
exception | #847 |
dnm | #847 |
dysregulated | #848 |
gwas summary | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
nonsignificant | #857 |
putative | #857 |
schizophrenia healthy | #858 |
putamen | #858 |
estimated prevalence | #858 |
heightened risk | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
glossary | #866 |
seventy | #866 |
global assessment | #866 |
crosssectional studies | #867 |
mental | #869 |
nnt | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
pediatric | #874 |
shr rats | #874 |
perseverative errors | #874 |
comorbidity depression | #875 |
existing evidence | #875 |
manova | #876 |
positive symptoms | #876 |
genetic counseling | #876 |
hypotheses | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
psychedelics | #886 |
12p | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
n95 | #893 |
obsessive | #893 |
n17 | #893 |
bonn | #894 |
decade | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
anterior cingulate | #903 |
biological psychiatry | #903 |
bipolar illness | #904 |
weight body | #904 |
reinforcer | #904 |
genetic contribution | #904 |
sibling | #904 |
aptitude | #904 |
visit | #905 |
late childhood | #906 |
826 | #906 |
psychosocial functioning | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
ggc | #911 |
symptom control | #911 |
amygdala reactivity | #912 |
psychosocial | #912 |
pedigrees | #912 |
visuospatial memory | #913 |
complications pregnancy | #913 |
underlying pathophysiology | #914 |
versions | #914 |
association age | #916 |
school performance | #917 |
disorder specific | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
screening tool | #924 |
pharmacogenetic | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
developmental trajectories | #927 |
dividing | #927 |
affective disorder | #928 |
cpg sites | #930 |
participating | #930 |
nucleotide | #930 |
194 | #933 |
heroin addiction | #933 |
permutation | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
study designs | #938 |
female genotype | #938 |
diagnostic | #938 |
irrs | #940 |
robustly | #940 |
severe form | #941 |
critics | #941 |
tdt | #943 |
brain regions | #946 |
gwas | #946 |
22q | #948 |
sles | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
personality disorder | #954 |
amphetamine | #954 |
relapsers | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
female frontal | #963 |
children epilepsy | #963 |
clinical assessment | #963 |
dopamine uptake | #965 |
tandem repeat | #965 |
scores | #965 |
cgis | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
cuneus | #968 |
splicing factor | #968 |
freesurfer | #969 |
schizophrenia association | #970 |
mtbi | #970 |
examined | #970 |
pharmacological treatment | #970 |
medication treatment | #971 |
aggression | #972 |
risky sexual behavior | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
psychosis risk | #978 |
resolve | #978 |
neurodevelopmental disorder | #980 |
2–4 | #980 |
459 | #982 |
educational | #982 |
pertaining | #982 |
seriousness | #985 |
alleles | #986 |
symptoms age | #986 |
logistic regression models | #986 |
patients sle | #987 |
difficulties | #988 |
ranked | #990 |
tci | #990 |
small proportion | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
colleagues | #996 |
temporal stability | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
keystone | #999 |
detoxification | #999 |
diathesis | #999 |
adolescent analysis | #1000 |
child child | #1001 |
stata | #1003 |
interviews | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
long‐term outcome | #1007 |
0016 | #1007 |
preschool cohort | #1007 |
confounding factors | #1007 |
allele | #1007 |
daughter | #1007 |
structural mri | #1008 |
norms | #1008 |
multiplex | #1009 |
qualifications | #1009 |
risk alcohol | #1009 |
posttraumatic stress disorder | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
maturational | #1020 |
metabotropic | #1020 |
conclusive | #1021 |
risk prediction | #1024 |
relates | #1024 |
insufficient | #1026 |
004 | #1027 |
pharmacotherapies | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
wwwclinicaltrialsgov | #1031 |
analytic | #1031 |
frontostriatal | #1031 |
symptoms child | #1032 |
patients panic disorder | #1032 |
– compulsive | #1034 |
predicted | #1034 |
preface | #1034 |
73 | #1034 |
negative symptoms | #1035 |
brain disorders | #1035 |
rodent models | #1035 |
total score | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
general intelligence | #1041 |
serotonin | #1041 |
twin | #1043 |
gaf | #1044 |
mental health treatment | #1044 |
relate | #1045 |
heightened | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
psychiatric morbidity | #1056 |
vice | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
199 | #1063 |
illicit | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
heritability | #1068 |
paranoia | #1068 |
pooled | #1068 |
awakenings | #1068 |
childhood trauma | #1068 |
emotional | #1069 |
negative impact | #1069 |
memantine | #1069 |
memory impairments | #1070 |
word reading | #1070 |
human genetics | #1070 |
controlled clinical | #1071 |
reading ability | #1071 |
social problems | #1071 |
single nucleotide receptors | #1071 |
risk scores | #1071 |
genetic model | #1071 |
4q | #1072 |
character inventory | #1072 |
validity | #1073 |
associations | #1073 |
obesity risk | #1074 |
studying | #1075 |
3′utr | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
schizophrenia social | #1082 |
adult antipsychotic | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
psds | #1086 |
onset psychosis | #1086 |
autoreceptors | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
subtype | #1090 |
distinctive | #1090 |
development disorders | #1092 |
polygenic scores | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
scientific literature | #1096 |
irritable | #1096 |
semistructured interview | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
daughters | #1103 |
external validity | #1103 |
future work | #1103 |
cnvs | #1104 |
odds | #1106 |
10 weeks | #1107 |
diagnostic groups | #1107 |
psychosis | #1107 |
bip | #1108 |
emotional behavioral | #1108 |
experimental test | #1110 |
prioritized | #1110 |
psychoses | #1110 |
10−5 | #1111 |
share | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
exchangers | #1123 |
632 | #1123 |
556 | #1124 |
mts | #1125 |
coexisting | #1125 |
projects | #1127 |
dysthymic disorder | #1128 |
quantifies | #1128 |
enriched | #1128 |
similarities | #1128 |
investigator | #1129 |
adult alcoholism | #1130 |
weighting | #1130 |
n28 | #1134 |
attention performance | #1134 |
psychiatric diagnosis | #1135 |
independent sample | #1136 |
birth outcomes | #1136 |
blood pressure response | #1138 |
laterality humans | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
prodromal | #1145 |
early adolescent | #1145 |
cognitive domains | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
measurement invariance | #1147 |
emotionality | #1147 |
refine | #1149 |
discounting | #1150 |
humans intellectual | #1150 |
children association | #1150 |
discriminability | #1150 |
developmental model | #1152 |
continents | #1152 |
quick | #1152 |
normals | #1153 |
refinements | #1153 |
generalizability | #1153 |
clinical profiles | #1154 |
alspac | #1154 |
sensory gating | #1154 |
ht2c | #1160 |
differential humans | #1160 |
uncorrected | #1160 |
phenotype | #1161 |
review findings | #1163 |
” “ | #1163 |
studies data | #1164 |
phobia | #1164 |
neurocognitive function | #1165 |
deteriorated | #1166 |
clinical groups | #1166 |
affective | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
gwas data | #1176 |
bpd patients | #1176 |
cohen | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
cinguli humans | #1182 |
childhood exposure | #1182 |
reward | #1182 |
persisting | #1182 |
nonverbal | #1183 |
addressing | #1184 |
triads | #1184 |
paradox | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
dysbindin | #1189 |
hydrochloride | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
compulsivity | #1198 |
onequarter | #1198 |
addictions | #1198 |
wm | #1199 |
placebo | #1199 |
asian continental | #1200 |
230 | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
problems children | #1209 |
externalizing symptoms | #1209 |
nationwide cohort study | #1209 |
conceptualizations | #1210 |
neuropsychology | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
lbw | #1220 |
underlying | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
partly | #1227 |
approximated | #1227 |
0011 | #1229 |
molecular alterations | #1232 |
subgroup | #1232 |
refining | #1232 |
poster | #1233 |
health organization | #1234 |
pregnancy prenatal | #1234 |
children ages | #1235 |
gprotein | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
risk asthma | #1247 |
avenues | #1247 |
enjoyment | #1247 |
kf | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
risk ratio | #1256 |
serotonin transporter | #1256 |
summarize | #1256 |
nervous | #1257 |
dysfunctions | #1257 |
goal | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
developmental pathways | #1277 |
entire | #1277 |
386 | #1277 |
n24 | #1278 |
04 | #1281 |
study evidence | #1281 |
priori | #1282 |
paternal | #1282 |
behavior adolescent | #1283 |
increased rates | #1283 |
hopes | #1283 |
neuroimaging | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
male nerve | #1288 |
somatic complaints | #1288 |
orbitofrontal | #1288 |
warmth | #1289 |
aspect | #1289 |
posttraumatic | #1291 |
dual psychiatry | #1291 |
unmyelinated | #1291 |
1hmrs | #1291 |
animal conditioning | #1292 |
clomipramine | #1292 |
quantitative trait | #1292 |
misclassification | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
prediction accuracy | #1309 |
sgas | #1309 |
vin | #1310 |
extant | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
short | #1323 |
parents adolescents | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
measures | #1334 |
polysubstance | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
genetic background | #1336 |
authors | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
longterm outcome | #1342 |
clinical phenotypes | #1342 |
542 | #1344 |
registry data | #1344 |
explaining | #1345 |
llysine | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
loci genetic | #1356 |
diagnostic tool | #1356 |
simon | #1357 |
variabilities | #1357 |
flush | #1357 |
seekers | #1358 |
gene discovery | #1359 |
antidepressive | #1359 |
broad spectrum | #1361 |
mammalian target | #1362 |
middle frontal gyrus | #1362 |
intergenerational | #1365 |
abcd | #1367 |
uptake inhibitors | #1369 |
unexplored | #1369 |
neuronal development | #1369 |
school teachers | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
thought disorder | #1386 |
new onset | #1386 |
highlighted | #1386 |
dimensional approach | #1389 |
treatment depression | #1391 |
6 years | #1391 |
familial aggregation | #1391 |
prodrome | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
thalamic | #1395 |
rats shr | #1395 |
manuscripts | #1395 |
satisfying | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
lability | #1400 |
suggesting | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
issue | #1414 |
shyness | #1414 |
independent | #1415 |
impressions | #1416 |
prepubertal children | #1416 |
332 | #1417 |
logical | #1419 |
carry | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
163 | #1431 |
taps | #1431 |
interaction effects | #1432 |
cognitive profiles | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
78 | #1453 |
height | #1453 |
square | #1453 |
ewas | #1453 |
hypermethylation | #1454 |
population stratification | #1454 |
switching | #1455 |
replicability | #1457 |
dorsal striatum | #1457 |
collaborations | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
principal | #1467 |
discordant | #1467 |
untranslated | #1468 |
valuable | #1468 |
partial remission | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
openlabel | #1474 |
statistically | #1474 |
cognition patients | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
mri studies | #1497 |
allele carriers | #1497 |
smaller | #1497 |
small sample sizes | #1499 |
lifespan | #1499 |
twins monozygotic | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
multisite | #1505 |
male mothers | #1505 |
ddc | #1505 |
examination | #1508 |
salience network | #1510 |
manifestation | #1510 |
objectivity | #1511 |
existing literature | #1511 |
reports | #1513 |
emotions female | #1513 |
attained | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
114 | #1523 |
cna | #1523 |
topic | #1523 |
bipolar patients | #1526 |
inconsistency | #1526 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
nacetylaspartate | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
default | #1541 |
nucleotide risk | #1541 |
adult life | #1542 |
dopamine receptor | #1542 |
poses | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
influenced | #1554 |
problem behaviors | #1554 |
857 | #1556 |
automobile | #1556 |
failed | #1559 |
early exposure | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
insular | #1565 |
475 | #1565 |
subscales | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
swedish | #1573 |
191 | #1573 |
consortium | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
meta | #1579 |
life quality | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
findings studies | #1582 |
single nucleotide polymorphism | #1582 |
located | #1582 |
cutoffs | #1583 |
network dmn | #1583 |
models male | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
firstepisode schizophrenia | #1588 |
rs4680 | #1588 |
major depressive | #1588 |
pain patients | #1589 |
genetic data | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
subcortical structures | #1596 |
162 | #1596 |
symptom presentation | #1598 |
tpv | #1599 |
moderators | #1599 |
statistics nonparametric | #1601 |
psychotropic medications | #1601 |
jan | #1602 |
managed | #1603 |
utr | #1604 |
suffer | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
1979 | #1610 |
proneness | #1610 |
monoamine oxidase | #1611 |
alcoholism | #1613 |
emotional faces | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
large body | #1622 |
distinguishing | #1622 |
risk mental | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
spatial organization | #1627 |
ht2a receptor | #1627 |
louis | #1628 |
dysphoria | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
study children | #1630 |
kyoto | #1630 |
ambiguous | #1631 |
memory task | #1631 |
emrs | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
social communication | #1643 |
alpha7 | #1643 |
rack1 | #1643 |
tendency | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
rea | #1653 |
controlled | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
psychotic disorder | #1659 |
require | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
presentations | #1663 |
comorbid depression | #1663 |
asm | #1664 |
510 | #1665 |
chronic patients | #1666 |
mood symptoms | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
statements | #1675 |
alcohol spectrum | #1675 |
53 | #1677 |
registers | #1678 |
calling | #1678 |
introns | #1678 |
homogeneous | #1679 |
social anxiety | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
prescribed | #1684 |
mildly | #1684 |
46 | #1684 |
ancestries | #1685 |
memory deficit | #1685 |
github | #1689 |
autistic disorder | #1689 |
mdd | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
recruited | #1698 |
motor skills | #1698 |
diagnose | #1699 |
91 | #1702 |
item | #1704 |
memory consolidation | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
neuroscience | #1712 |
personality characteristics | #1712 |
rater | #1712 |
health records | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
107 | #1731 |
inhibitory control | #1731 |
cbs | #1732 |
hindered | #1733 |
machine | #1735 |
highlight | #1735 |
stand | #1736 |
identical | #1736 |
aimed | #1739 |
predictors | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
forum | #1746 |
curated | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
326 | #1756 |
sertraline | #1756 |
120 | #1758 |
5ht2a | #1758 |
ventral striatum | #1761 |
social | #1761 |
genetic models | #1761 |
drowsiness | #1763 |
bipolar affective | #1763 |
chance | #1765 |
includes | #1765 |
adult onset | #1766 |
mystery | #1768 |
operant | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
treatment implications | #1773 |
dizygotic twins | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
commonalities | #1786 |
higher doses | #1786 |
major | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
male motor | #1791 |
frustration | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
positive association | #1797 |
causal variants | #1797 |
disabilities | #1797 |
autism spectrum disorders | #1800 |
members | #1801 |
reporters | #1801 |
aged models | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
nucleotide polymorphism | #1812 |
expanded | #1812 |
146 | #1813 |
aetiology | #1813 |
european descent | #1813 |
frequently | #1815 |
internationality | #1815 |
purchases | #1816 |
brain imaging | #1816 |
hippocampal volume | #1819 |
cohens | #1819 |
lds | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
neural activity | #1841 |
patterns | #1841 |
assessment tools | #1842 |
trauma exposure | #1842 |
twins | #1845 |
distinctions | #1845 |
initiative | #1845 |
literacy | #1846 |
pertinent | #1847 |
psychological | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
individual | #1851 |
fearful | #1851 |
vocabulary | #1851 |
nonparametric | #1852 |
differentiating | #1853 |
young | #1853 |
brainderived neurotrophic factor | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
tph | #1859 |
prevalence | #1859 |
behavioral measures | #1860 |
incentives | #1860 |
affiliation | #1861 |
cnb | #1861 |
8p | #1862 |
obstacle | #1864 |
poison | #1865 |
multilevel | #1865 |
switch | #1865 |
vocalization | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
histograms | #1879 |
roc curve | #1879 |
animal model | #1880 |
shrs | #1880 |
delusions | #1881 |
longer duration | #1882 |
afb | #1882 |
common genetic variation | #1883 |
genome | #1885 |
false | #1888 |
differs | #1888 |
substance abuse | #1890 |
metaanalysis studies | #1890 |
spanning | #1894 |
heterogeneous | #1894 |
susceptibility genes | #1896 |
maintained | #1899 |
latent class analysis | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
analyses | #1903 |
chinese | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
epidemiologic | #1909 |
majority | #1909 |
ads | #1910 |
support vector machine | #1911 |
disorders mental | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
liking | #1923 |
satisfied | #1923 |
association maternal | #1923 |
child cross | #1926 |
aggregate | #1926 |
overview | #1927 |
advertising | #1928 |
251 | #1928 |
sleep problems | #1928 |
empirical studies | #1929 |
ssri | #1930 |
asd children | #1934 |
95 cis | #1934 |
simulation study | #1937 |
borderline personality disorder | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
correctly | #1972 |
depression | #1972 |
clinical implications | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
repeats | #1977 |
child depression | #1977 |
listing | #1978 |
conflicting | #1978 |
ptsd | #1981 |
hippocampus humans | #1981 |
common mental disorders | #1984 |
chinese population | #1984 |
phase 3 trial | #1986 |
pax5 | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
formulations | #2005 |
asian continental ancestry | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
absence | #2014 |
muscle function | #2014 |
akt1 | #2014 |
noradrenergic | #2015 |
sms | #2015 |
cognitive deficits | #2016 |
possibility | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
phenomenology | #2030 |
sleep disturbances | #2030 |
memory verbal | #2031 |
brain responses | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
receptors nicotinic | #2037 |
prenatally | #2037 |
diminished | #2040 |
retest reliability | #2040 |
asperger | #2041 |
erythematosus systemic | #2041 |
nicotinic acetylcholine | #2045 |
227 | #2046 |
cognitive processing | #2046 |
informants | #2048 |
erythematosus | #2049 |
cognition | #2050 |
functional | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
common diseases | #2061 |
insula | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
overweight obesity | #2066 |
demography | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
functional mri | #2069 |
massachusetts | #2069 |
0008 | #2071 |
phenotypic | #2072 |
parental education | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
43 | #2090 |
latent class | #2090 |
factors child | #2093 |
49 | #2095 |
aud | #2096 |
wky shr | #2096 |
subsets | #2099 |
dopaminergic | #2100 |
69 | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
child relations | #2112 |
specific genetic | #2112 |
nicotinic | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
poorer | #2119 |
monoamine | #2119 |
postpartum period | #2119 |
relative age | #2119 |
84 | #2121 |
51 | #2122 |
pgs | #2122 |
career | #2122 |
sixth | #2124 |
pbls | #2126 |
identifies | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
episode schizophrenia | #2137 |
dbh | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
methods participants | #2145 |
pvs | #2145 |
behavioral disorders | #2146 |
intraclass | #2147 |
105 | #2147 |
receptors adrenergic | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
glutamatergic | #2150 |
232 | #2150 |
finemapping | #2150 |
represents | #2150 |
repositioning | #2151 |
assessing | #2151 |
rrr | #2153 |
mao | #2153 |
psychiatric patients | #2155 |
differentiated | #2164 |
abdominal obesity | #2164 |
clinical assessments | #2166 |
shr wky | #2167 |
declarative memory | #2167 |
differing | #2168 |
differential diagnostic | #2168 |
genetic association studies | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
mb | #2171 |
adversely | #2171 |
prevalences | #2171 |
tardive dyskinesia | #2172 |
severity | #2172 |
aggregated | #2177 |
irt | #2180 |
moderating | #2181 |
externalizing | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
thought | #2188 |
computerassisted imaging | #2188 |
differential expression | #2189 |
processing speed | #2189 |
scale | #2192 |
generalized anxiety disorder | #2192 |
regular | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
conceptual | #2197 |
lifecycle | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
developing brain | #2206 |
brain mapping | #2206 |
abstract background | #2207 |
169 | #2209 |
ottawa | #2209 |
remained | #2209 |
surveys questionnaires | #2210 |
accidents | #2210 |
homozygosity | #2210 |
illness severity | #2211 |
antenatal | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
biologically | #2220 |
completed | #2220 |
hippocampal formation | #2220 |
complex diseases | #2220 |
autism | #2221 |
val66met | #2222 |
cognitive task | #2225 |
visuospatial | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
cognitive deficit | #2263 |
novo mutations | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
pathways | #2266 |
bds | #2266 |
rewards | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
cognitive development | #2275 |
axis | #2275 |
gray matter volume | #2275 |
remain | #2275 |
tend | #2276 |
imaging male | #2277 |
mtl | #2277 |
random allocation | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
moderation | #2283 |
lithium | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
diverse populations | #2294 |
regions | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
biology | #2304 |
239 | #2304 |
clinic | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
lupus | #2310 |
difficult | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
questionnaires | #2332 |
organ size | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
covariate | #2335 |
disorganization | #2335 |
early risk | #2336 |
depression female | #2340 |
lesser extent | #2342 |
utility | #2342 |
functional networks | #2344 |
nature | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
concurrently | #2368 |
limited evidence | #2368 |
symptoms schizophrenia | #2369 |
smallest | #2369 |
efforts | #2376 |
social cognitive | #2377 |
antipsychotic agents | #2379 |
catecholamine | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
raising | #2395 |
convergence | #2395 |
problem solving | #2398 |
gray matter | #2401 |
essence | #2401 |
frontal | #2403 |
pubmed | #2406 |
sirolimus | #2407 |
addictive | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
statistical significance | #2418 |
alternative | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
bdnf | #2429 |
term outcome | #2429 |
confounders | #2431 |
fmri data | #2431 |
clinical trial | #2433 |
protein interactions | #2433 |
241 | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
timepoints | #2448 |
dimorphism | #2448 |
items | #2449 |
multiple studies | #2450 |
deconvolution | #2452 |
mvr | #2452 |
systemic lupus erythematosus | #2456 |
overweight children | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
anxiety symptoms | #2460 |
brain maturation | #2460 |
traumatic stress | #2461 |
logistic | #2461 |
concordance | #2461 |
autosomes | #2462 |
sex distribution | #2464 |
crossover study | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
prescriptions | #2489 |
higher scores | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
hoc analysis | #2496 |
180 | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
establish | #2504 |
original | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
21st | #2512 |
preschool diagnosis | #2512 |
heterosis | #2513 |
thresholds | #2515 |
quotient | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
risky | #2553 |
psychotic features | #2553 |
depressive disorders | #2554 |
exploratory study | #2555 |
quantitative | #2555 |
neural responses | #2555 |
bipolar affective disorder | #2557 |
memory tasks | #2557 |
income | #2560 |
chronological | #2560 |
risk loci | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
numerous | #2573 |
30 years | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
problems | #2586 |
brothers | #2586 |
pvalues | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
exist | #2595 |
disrupted | #2595 |
229 | #2596 |
internalizing externalizing | #2598 |
brain response | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
iowa | #2603 |
simplex | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
advances | #2611 |
increased activation | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
evidence role | #2624 |
multiple levels | #2624 |
kynurenine | #2625 |
psycinfo | #2625 |
mothers | #2630 |
bdnf gene | #2633 |
imaging studies | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
global functioning | #2642 |
fetal alcohol | #2642 |
genetic variants | #2644 |
preschool female | #2644 |
behavior | #2644 |
inability | #2645 |
medical conditions | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
puzzle | #2665 |
periodicals | #2665 |
n14 | #2666 |
health disorders | #2669 |
089 | #2669 |
genetic evidence | #2670 |
88 | #2670 |
chromosome | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
inconclusive | #2676 |
partially | #2676 |
mediating | #2676 |
physiotherapy | #2678 |
memory tests | #2678 |
adolescent development | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
triad | #2689 |
age range | #2689 |
conditional | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
evidenced | #2698 |
immaturity | #2698 |
extended | #2700 |
chr | #2701 |
neurite | #2702 |
attenuate | #2702 |
interrogation | #2702 |
flares | #2703 |
delinquency | #2707 |
ext | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
occurring | #2714 |
aggressive | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
curve | #2731 |
teens | #2731 |
awakening | #2732 |
thicker | #2733 |
systematic literature review | #2733 |
doubt | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
naa | #2760 |
patients bipolar disorder | #2760 |
collaboration | #2760 |
gt | #2761 |
manifestations | #2762 |
unadjusted | #2765 |
4 years | #2765 |
created | #2768 |
ccs | #2769 |
reproducibility | #2773 |
psychiatric diseases | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
25 | #2777 |
preventive measures | #2777 |
clinical heterogeneity | #2783 |
mechanisms underlying | #2783 |
bivariate | #2784 |
children symptoms | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
411 | #2791 |
dna copy | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
constellation | #2796 |
auditory perception | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
clinical experience | #2808 |
recognition visual | #2808 |
397 | #2809 |
misdiagnosis | #2809 |
monetary | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
circuitry | #2823 |
indexes | #2823 |
telephone | #2824 |
1300 | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
early recognition | #2839 |
discriminant validity | #2839 |
adoption | #2841 |
treatment study | #2843 |
reelin | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
continental ancestry | #2863 |
depression scale | #2863 |
parenting parents | #2865 |
screened | #2866 |
addresses | #2866 |
internal external | #2867 |
mothers children | #2867 |
discordance | #2868 |
cognition humans | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
citations | #2885 |
shifting | #2885 |
age differences | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
cognitive control | #2916 |
amph | #2916 |
biological mechanisms | #2919 |
institutes | #2919 |
variability | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
causal relationship | #2942 |
disorders sleep | #2942 |
distinct | #2946 |
disorders patients | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
overlaps | #2971 |
markers | #2971 |
models neurological | #2976 |
stratification | #2981 |
qtl | #2983 |
725 | #2983 |
weight height | #2988 |
investigators | #2989 |
imaging mri | #2991 |
attempts | #2991 |
tic | #2997 |
performance measures | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
centres | #3006 |
196 | #3006 |
377 | #3007 |
19th century | #3010 |
remission | #3011 |
genetic variation | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
symptoms patients | #3039 |
difficulties questionnaire | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
pilot | #3061 |
280 | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
cortical | #3078 |
driving | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
predictable | #3098 |
stressful life | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
076 | #3107 |
brain health | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
ptsd symptoms | #3127 |
383 | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
nation | #3146 |
european countries | #3146 |
exploratory | #3150 |
99 | #3150 |
ancestry | #3151 |
behavior social | #3152 |
oxford | #3157 |
pharmacokinetic | #3157 |
spd | #3165 |
explanations | #3165 |
functional consequences | #3166 |
biological processes | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
caution | #3171 |
status humans | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
imaging study | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
attempt | #3202 |
initial treatment | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
discontinuity | #3229 |
scanner | #3229 |
situation | #3229 |
65 | #3235 |
depression study | #3236 |
htt | #3237 |
mediation analysis | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
211 | #3257 |
correlated | #3257 |
publicly | #3265 |
caudate nucleus | #3265 |
17p | #3266 |
interactive effects | #3266 |
humans magnetic | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
longitudinal cohort | #3282 |
increased likelihood | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
metropolitan | #3336 |
clock gene | #3336 |
ambiguity | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
battery | #3371 |
frontal regions | #3371 |
glycolysis | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
typically developing | #3386 |
impaired performance | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
clock genes | #3390 |
multimorbidity | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
depression symptoms | #3405 |
traumatic brain | #3405 |
desirability | #3406 |
oxidase | #3411 |
pool | #3413 |
performing | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
experiencing | #3439 |
definition | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
lca | #3448 |
children mothers | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
cognitive behavioral | #3466 |
genomewide association study | #3466 |
hallucinations | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
methylation | #3477 |
remaining | #3477 |
behavioral response | #3478 |
irr | #3480 |
postmortem | #3482 |
transmission | #3482 |
slower | #3488 |
exposure pregnancy | #3489 |
lesser | #3489 |
convergent | #3489 |
epidemiological study | #3492 |
applying | #3492 |
alpha2 | #3497 |
aged polymorphism | #3497 |
short stature | #3497 |
083 | #3497 |
social behaviors | #3497 |
matched healthy | #3502 |
identifier | #3506 |
p002 | #3506 |
brain function | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
104 | #3519 |
specificity | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
pediatricians | #3527 |
basis | #3527 |
constitutes | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
preferentially | #3536 |
reliable | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
cognitive behavioral therapy | #3544 |
sleep wake | #3544 |
fact | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
neuronal function | #3558 |
ecgs | #3558 |
preventive interventions | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
collaborative | #3585 |
mse | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
major gene | #3606 |
cardio | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
methylation status | #3618 |
questions | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
prior | #3640 |
posttraumatic stress | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
neurotransmission | #3735 |
daily life | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
therapy cbt | #3744 |
international | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
neurophysiological | #3758 |
333 | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
promoter polymorphism | #3787 |
peers | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
exchanger | #3844 |
male marijuana | #3844 |
developmental disorders | #3850 |
children aged | #3850 |
disease genes | #3850 |
elevations | #3851 |
risk development | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
74 | #3876 |
influences | #3876 |
208 | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
plasma membrane | #3898 |
neurology | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
specific factors | #3937 |
frontal gyrus | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
preliminary evidence | #4000 |
factorial | #4000 |
categorization | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
common variants | #4047 |
diabetes risk | #4047 |
discussion | #4051 |
modeled | #4051 |
mathematics | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
serotonin uptake | #4068 |
cag | #4068 |
magnetic resonance | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
temporal lobe | #4098 |
lobe | #4098 |
maternal depression | #4100 |
genetic variations | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
plausible | #4121 |
comprises | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
dosing | #4145 |
german | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
route | #4216 |
helpful | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
gpcr | #4253 |
predict | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
trajectory | #4263 |
representative | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
mediate | #4378 |
intolerance | #4378 |
066 | #4382 |
psychological adolescent | #4383 |
clarity | #4383 |
docosahexaenoic | #4391 |
transcriptomic | #4391 |
solving | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
striatal dopamine | #4449 |
human studies | #4449 |
62 | #4454 |
genotypes | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
disorders cognitive | #4516 |
visits | #4516 |
valuation | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
higher level | #4553 |
employment | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
psd | #4587 |
neuronal differentiation | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
unmet | #4651 |
trouble | #4651 |
regression model | #4652 |
marriage | #4658 |
centers | #4660 |
deliveries | #4660 |
microsatellite | #4660 |
anterior cingulate cortex | #4661 |
trajectories | #4662 |
243 | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
hazards models | #4715 |
vector machine | #4715 |
estimate | #4716 |
smd | #4717 |
sed | #4719 |
mbr | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
taiwan | #4757 |
drug | #4757 |
77 | #4760 |
conflict | #4760 |
tasks | #4762 |
portions | #4763 |
heavily | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
noncarriers | #4791 |
samples | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
cognitive tests | #4825 |
modafinil | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
cigarettes | #4881 |
young age | #4881 |
subsamples | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
hemispheric | #4949 |
delays | #4949 |
pooled analysis | #4951 |
powerful | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
selective attention | #5021 |
caucasians | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
probabilistic | #5039 |
discuss | #5039 |
distinguish | #5040 |
correct | #5040 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
auc | #5047 |
sga | #5050 |
marital | #5051 |
convergent validity | #5051 |
early | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
screening | #5104 |
103 | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
single nucleotide polymorphisms | #5132 |
mediation | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
pharmacogenomics | #5147 |
involves | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
238 | #5193 |
disability | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
remains | #5215 |
molecular biology | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
billion | #5295 |
trend | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
072 | #5308 |
life events | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
predictive tests | #5345 |
individual level | #5345 |
social interactions | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
penetrance | #5380 |
higher frequency | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
label | #5403 |
37 | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
risk individuals | #5468 |
york | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
promoter regions | #5525 |
verbal fluency | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
modulate | #5547 |
155 | #5547 |
elevated | #5549 |
closely | #5549 |
prevention | #5551 |
restraint | #5552 |
flanking | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
baseline treatment | #5565 |
frontal cortex | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
predominance | #5578 |
significance | #5578 |
240 | #5579 |
mediators | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
lower risk | #5663 |
perinatal | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
40 years | #5686 |
1999 | #5686 |
gene variants | #5687 |
markov | #5688 |
vbm | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
databases | #5696 |
normal | #5696 |
systems biology | #5703 |
primary outcome measure | #5713 |
cognitive functions | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
focused | #5728 |
thirty | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
region | #5928 |
statement | #5928 |
linked | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
rois | #6005 |
moderating role | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Kjør rapport | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Kjent for Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Kjent for Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Kjent for Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Kjent for Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Kjent for Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Kjent for Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Kjent for Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Kjent for Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Kjent for Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Kjent for Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Kjent for Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Kjent for Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Kjent for Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Kjent for Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Nøkkelpersoner for Hyperactivity Disorder
Stephen V Faraone∗:Ekspertvirkning
Konsepter somStephen V Faraone∗har direkte innflytelse:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:Kol Impact
Konsepter relatert til arbeidet til andre forfattere somfor which Stephen V Faraone∗ har innflytelse:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
Er dette profilen din? Krev profilen din Kopier url Legg inn lenke til profilen din |